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ABSTRACT
Adverse drug reactions constitute a major cause of patient morbidity and mortality, and 
are important factors in drug attrition within the pharmaceutical industry. Some adverse 
drug reactions are inextricably linked to the process of drug metabolism, through the 
generation of chemically reactive intermediates. The hepatotoxicity associated with 
overdose of paracetamol is a pertinent example of an adverse drug reaction that is linked 
to the generation of an electrophilic metabolite, N-acetyl-p-benzoquinoneimine 
(NAPQI). This molecule binds covalently to specific hepatic proteins and inhibits their 
function, contributing to liver failure. Mammalian cells have evolved a multi-faceted, 
highly regulated defence system, which affords protection against chemical and 
oxidative stress. By far the most important regulator of inducible cell defence is the 
transcription factor Nrf2, which controls the expression of numerous genes involved in 
the detoxification of electrophiles and reactive oxygen species, the maintenance of 
cellular redox balance, and the degradation of damaged/misfolded proteins. In the 
absence of cellular stress, Nrf2 is restrained in the cytosol and repressed by the cysteine- 
rich protein Keapl. The main aims of the studies presented in this thesis were to further 
our understanding of the means by which the Nrf2 pathway is regulated, and to explore 
its role in the protection against drug-induced liver injury (DILI).
Previous work in this laboratory has demonstrated that the Nrf2 pathway is activated in 
mouse liver following administration of hepatotoxic and non-hepatotoxic doses of 
paracetamol. It has been proposed that the molecular trigger for activation of Nrf2 by 
electrophiles is the modification of cysteine residues within Keapl, which inhibits the 
repressive activity of Keapl towards Nrf2. In order to test the hypothesis that the 
modification of Keapl by NAPQI may play a role in the activation of Nrf2 observed in 
mouse liver following administration of paracetamol, a series of experiments were 
performed using the mouse hepatoma cell line Hepa-lclc7. RNA interference (RNAi), 
directed against Nrf2 and Keapl, was used to validate Hepa-lclc7 as a suitable model 
for studying the Nrf2 pathway. Using immunofluorescence confocal microscopy and 
luciferase reporter transgene analysis, NAPQI was shown to directly activate the Nrf2 
pathway in Hepa-lclc7 cells. Activation of the Nrf2 pathway was shown to correlate 
with the induction of cell defence, as demonstrated by a time-dependent increase in 
levels of glutathione (GSH). By using a combination of RNAi and quantitative real-time 
PCR, the increase in GSH was shown to be caused by an Nrf2-dependent induction of 
Gclc, the Nrf2-regulated rate-limiting enzyme in the synthesis of GSH. In order to 
explore the importance of cysteine reactivity in the activation of Nrf2 by NAPQI, the 
activity of the transcription factor was assessed following exposure of Hepa-lclc7 cells 
to the model cysteine-reactive electrophiles 2,4-dinitrochlorobenzene (DNCB) and 15- 
deoxy-A-(12,14)-prostaglandin J2 (15d-PGJ2), and the lysine-reactive molecule trimellitic 
anhydride (TMA). Both DNCB and 15d-PGJ2 invoked a concentration-dependent 
increase in nuclear levels of Nrf2, as measured by Western blot. In contrast, TMA had 
no effect on the nuclear level of Nrf2, indicating that cysteine reactivity is an important 
property of Nrf2-activating molecules, and that this may underlie the ability of NAPQI 
to induce Nrf2-dependent cell defence. Although Nrf2 activation was observed
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concomitantly with the depletion of GSH for NAPQI and DNCB, this was not a 
prerequisite for activation of the transcription factor, as 15d-PGJ2 stimulated the nuclear 
accumulation of Nrf2 without having any apparent effect on cellular GSH levels.
In order to further explore the possibility that NAPQI activates the Nrf2 pathway 
through direct modification of cysteine residues in Keapl, an in vitro test system was 
developed, based on the expression and purification of recombinant Keapl protein, and 
the analysis of residue-specific modification(s) by liquid chromatography electrospray 
ionization tandem mass spectrometry (LC-ESI-MS/MS). All three Nrf2-activating 
molecules, NAPQI, DNCB and 15d-PGJ2, selectively modified cysteine residues in 
Keapl in vitro. TMA, which did not activate Nrf2, modified lysines, but not cysteines, 
within Keapl. Although no single cysteine residue was found to be preferentially 
modified by NAPQI, DNCB and 15d-PGJ2, all three molecules did modify one or more 
cysteines within the central intervening region (IVR) of Keapl. A cell-based method for 
analysing Keapl modification was then developed, so as to enable the examination of 
Keapl modification, in tandem with Nrf2 activation, within a more biologically-relevant 
cellular context. Immunoprécipitation of endogenous Keapl was attempted, however the 
levels of Keapl that were purified were too low to enable reliable LC-ESI-MS/MS 
analysis. Therefore, HEK293T cells were transfected with an expression vector for 
Keapl tagged with a V5 epitope. The ectopic expression of Keapl-V5 was shown not to 
compromise the responsiveness of the Nrf2 pathway to electrophiles. By using a 
combination of immunoaffinity purification and LC-ESI-MS/MS analysis, the residue- 
selective modification of Keapl-V5 was demonstrated following exposure of HEK293T 
cells to NAPQI, DNCB and 15d-PGJ2. No single cysteine residue was universally 
modified, although, as in the in vitro experiments, all three Nrf2-activating molecules 
modified one or more cysteines within the IVR domain of Keapl-V5.
In summary, the results presented in this thesis have demonstrated that NAPQI can 
directly activate the Nrf2-ARE cell defence pathway in mouse liver cells, and selectively 
modifies cysteines residues within Keapl, both in the recombinant protein in vitro and in 
a cell-based model. This work has also identified a potential unifying mechanism by 
which Nrf2 activation is triggered; through the direct modification of one or more 
cysteines within the IVR domain of Keapl. In future studies, it will be important to 
determine whether this mechanism applies to all Nrf2-activating molecules, and to 
explain how the modification of cysteines in Keapl is translated into the activation of 
Nrf2.
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1.1 INTRODUCTION
Adverse drug reactions, i.e. any undesirable effect of a drug outside of its intended 
therapeutic action (Pirmohamed et al., 1998), constitute a major cause of patient 
morbidity and mortality, and are important factors in drug attrition within the 
pharmaceutical industry (Park et al., 2005b). It is, therefore, imperative that advances in 
our understanding of the chemical, biochemical and molecular mechanisms that underlie 
specific adverse reactions translate into the ‘designing out’ of toxicity and the 
development of safer, more effective medicines.
From a mechanistic perspective, at least, adverse drug reactions can be considered as 
pharmacological, immunological and/or chemical in nature. Although generally 
beneficial, drug metabolism, the physiological process by which a foreign chemical 
(xenobiotic) is biotransformed and eliminated from the body, can, in some cases, be 
inextricably linked to toxicity, through the generation of chemically reactive 
intermediates (for a review, see Park, 1986); the hepatotoxicity associated with overdose 
o f paracetamol being a pertinent example. Paracetamol is bioactivated to an electrophilic 
metabolite, N-acetyl-p-benzoquinoneimine (NAPQI), which binds covalently to specific 
hepatic proteins and inhibits their function, contributing to liver failure (for a review, see 
Zhou et al., 2005).
The liver, as the major site of drug metabolism, is at relatively high risk of exposure to 
toxic species generated through metabolic bioactivation, and thus is a major target for 
tissue-specific toxicity, or drug-induced liver injury (DILI) (Park et al., 1995). However, 
as with other mammalian tissues, the liver has evolved a multi-faceted, highly regulated 
cell defence system. At the forefront of this system is a group of specialised proteins, 
known as transcription factors. Through their ability to ‘sense’ cellular stress and induce 
adaptive responses, characterised by the upregulated expression of a multitude of genes 
encoding detoxification enzymes and antioxidants (Prestera et al., 1993b; Primiano et 
al., 1997), transcription factors play a major role in governing the protection against 
drug-induced toxicity. By far the most important regulator of inducible, and perhaps
4
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basal, cell defence is the transcription factor Nrf2 (for a review, see Jaiswal, 2004). 
Through a pathway that also involves the thiol-rich cytosolic repressor protein Keapl, 
Nrf2 controls the expression of numerous genes involved in the detoxification of 
electrophiles and reactive oxygen species, the maintenance of cellular redox balance, 
and the degradation of damaged/misfolded proteins (Jaiswal, 2004).
An appreciation of the molecular mechanisms that underlie the adaptive response to 
cellular stress, primarily regulated by the Nrf2 pathway, is vital to gain insights into the 
signalling events that determine the progression, and outcome, of adverse drug reactions 
such as DILI. Therefore, this thesis aims to further our understanding of the means by 
which the Nrf2 pathway is regulated, and to elucidate its role in the protection against 
DILI.
1.2 ADVERSE DRUG REACTIONS
Adverse drug reactions constitute a major cause of patient morbidity and mortality (Park 
et al., 2005a). Indeed, in a recent prospective analysis of 18,820 hospital admissions 
across two Merseyside National Health Service (NHS) Trusts, during a six month period 
between 2002 and 2003, adverse drug reactions, or related incidents, accounted for 1225 
(6.5 %) admissions, with 72 % of these incidents classified as ‘avoidable’ by clinicians 
(Pirmohamed et al., 2004). Of patients admitted with an adverse reaction during this 
study, 28 (2.3 %) died as a direct result of the reaction (Pirmohamed et al., 2004). Due 
to the time and cost associated with treating patients, adverse drug reactions place an 
estimated £466 million burden on the NHS per year (Pirmohamed et al., 2004). 
Furthermore, adverse drug reactions have been responsible for the withdrawal of 4 % of 
all drugs licensed in the United Kingdom (UK) between 1974 and 1994 (Jefferys et al., 
1998). Hence, adverse drug reactions pose a significant public health problem.
From a clinical perspective, adverse drug reactions can be grouped into five main 
categories (Table 1.1), although these are not mutually exclusive, and a particular
5
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reaction may have characteristics of more than one subtype (Park et al., 1995). From a 
chemico-pharmacological point of view, adverse drug reactions can simply be regarded 
as on-target, i.e. those that are predictable from the known primary or secondary 
pharmacology of the drug, or off-target, i.e. those that are not predictable from a 
knowledge of the basic pharmacology of the drug, often exhibiting marked inter­
individual variability in the degree of susceptibility (Liebler et al., 2005).
Type Features Example
A Augmented; predictable from the known 
pharmacology of the drug, often represent 
an exaggeration of the pharmacological 
effect, usually dose-dependent
Hypotension with anti­
hypertensives, haemorrhage with 
anti-coagulants
B Bizarre; idiosyncratic, not predictable 
from the basic pharmacology of the drug, 
no simple dose-response relationship, 
host-dependent metabolic/immunological 
factors may contribute to, and determine, 
individual susceptibility
Hepatitis with halothane, 
hypersensitivity with anti­
convulsants
C Chemical; can be predicted or rationalised 
from the chemical structure of the drug or 
metabolite
Hepatotoxicity with paracetamol
D Delayed; occur some time, even years, 
after treatment, include teratogenic effects 
seen in children following drug intake by 
the mother during pregnancy
Foetal hydantoin syndrome with 
phenytoin, phocomelia with 
thalidomide
E End-of-treatment; occur upon drug 
withdrawal, especially when treatment is 
stopped suddenly
Withdrawal syndrome upon 
stopping paroxetine, withdrawal 
seizures upon stopping phenytoin
Table 1.1 - Clinical classification of adverse drug reactions. Features and examples of 
type A-E adverse drug reactions. Adapted from Park et al. (1998).
1.3 DRUG METABOLISM
In general terms, drug metabolism is the process by which a xenobiotic undergoes 
enzymatic conversion from a non-polar, lipophilic compound that is readily absorbed via 
the gastrointestinal tract, to a polar, hydrophilic species (Hodgson et al., 2001). 
Typically, the net result of this process is the elimination of the molecule from the body
6
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in urine, and thus an eventual loss of pharmacological activity. Conventionally, drug 
metabolism is divided into two phases; functionalisation (phase I) and conjugation 
(phase II) (Williams, 1959). Typically phase I and II metabolic reactions occur 
sequentially. However, phase I metabolism is not a pre-requisite for phase II 
conjugation, providing a suitable functional group is present in the parent compound 
(Timbrell, 2002).
1.3.1 Phase I metabolism
Phase I metabolic reactions generally involve oxidation, reduction, hydrolysis or 
hydration of the parent molecule, and result in the exposure or introduction of a 
functional group (Gibson et al., 2001). The majority of oxidative phase I reactions are 
catalysed by the cytochrome P450 (CYP450) monooxygenase system, which comprises 
a superfamily of enzymes located predominantly in the smooth endoplasmic reticulum 
(Timbrell, 2002). The CYP450 enzymes evolved 400-500 million years ago, to enable 
animals to detoxify foreign chemicals ingested through plant matter (Gonzalez et al., 
1994). O f the numerous sub-families, CYP1, CYP2 and CYP3 are predominantly 
involved in xenobiotic metabolism (Gibson et al., 2001). Although CYP450-catalysed 
oxidation involves a complex biochemical cycle, the overall outcome is straightforward; 
the transfer of one atom of oxygen (from molecular oxygen, O2) to the drug to form a 
hydroxyl group (-OH), with the remaining oxygen atom converted to water (H2O) 
(Gibson et al., 2001). Other enzymes that catalyse oxidative reactions include flavin- 
containing monooxygenases, alcohol dehydrogenase and monoamine oxidase, which 
metabolise nicotine, ethanol and noradrenaline, respectively (Hodgson et al., 2001). Of 
the less common non-oxidative phase I reactions, reduction, an important route of 
metabolism for azo- and nitro-compounds, epoxides and quinones, is catalysed by 
reductases (Gibson et al., 2001). Esterases and amidases catalyse the hydrolysis of esters 
and amides, respectively, and the hydration o f epoxides is catalysed by epoxide 
hydrolase (Gibson et al., 2001). Individuals that are deficient in phase I metabolising 
capacities may be susceptible to ‘on-target’ adverse drug reaction, where diminished
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clearance of the parent drug may lead to augmentation of the intended pharmacological 
effect. For example, patients carrying polymorphisms in the gene encoding CYP2C9, 
which is responsible for the phase I hydroxylation of the ^-enantiomer of the 
anticoagulant warfarin, demonstrate a reduced ability to metabolise the parent drug, and 
thus are at high risk of haemorrhage should they receive a ‘normal’ dose (Wadelius et 
al., 2007). As a result, patients with variant genotypes require a reduction in the 
prescribed dose in order to benefit from the anti-coagulant effects of warfarin without an 
increased risk of bleeding (Wadelius et al., 2007).
1.3.2 Phase II metabolism
Phase II reactions are characterised by the conjugation of a substituent polar group onto 
a functionalised molecule. Such groups include glucuronyl, sulphate, acetyl, and 
glutathione (GSH). Glucuronylation, a major route of metabolism for alcohols, phenols, 
carboxylic acids, amines and thiols, involves the transfer of uridine diphosphate 
glucuronic acid (UDPGA) to a nucleophilic group, such as hydroxyl, carboxyl (- 
COOH), amine (-NH2) or sulphydryl (-SH) (Gibson et al., 2001). Catalysed by 
glucuronosyl transferases (UGT), the glucuronylation pathway has a relatively high 
capacity, due to the high tissue abundance of the co-factor UDPGA (Gibson et al., 
2001). Sulphation, catalysed by sulphotransferases (ST), involves the transfer of 
phosphoadenosine phosphosulphate (PAPS) to nucleophilic hydroxyl and amine groups, 
particularly in phenols and alcohols (Gibson et al., 2001). Due to the relative low 
abundance of PAPS, sulphation is a low-capacity phase II pathway (Gibson et al., 2001). 
The N-acetyl transferase family catalyses acetylation, the transfer of acetyl coenzyme A 
to amine groups (Gibson et al., 2001). Acetylation is an important metabolic pathway 
for aromatic amines, sulphonamides and hydrazines (Timbrell, 2002). Conjugation with 
GSH is an important route of metabolism for a number of xenobiotics, including 
epoxides, alkenes and aromatic nitro-compounds (Timbrell, 2002). In addition to its 
physiological role in xenobiotic metabolism, GSH, as the most abundant non-protein 
thiol, present at millimolar concentrations in most cells, also acts as a major antioxidant
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(for a review, see Kaplowitz et al., 1985). The conjugation of GSH to reactive species, 
which can proceed non-enzymatically or via a glutathione S-transferase (GST) - 
catalysed reaction, is an important means of detoxifying electrophilic molecules. The 
nucleophilic cysteine thiol of GSH attacks an electrophilic moiety, forming a thioether 
bond between the two molecules (Timbrell, 2002). The resulting polar conjugate is then 
excreted in bile (Timbrell, 2002). Section 1.5.1.2 further details the role of GSH in cell 
defence.
1.3.3 The role of drug metabolism in adverse drug reactions
In general, the functionalisation of a xenobiotic, via phase I metabolic 
biotransformation, provides a handle for phase II conjugation reactions. However, this 
process may also result in bioactivation to yield an intermediate species that is more 
reactive towards cellular macromolecules and, in turn, is more toxic than the parent 
compound (Park, 1986). The propensity of a parent drug to form a reactive intermediate 
is a function of its chemistry, with structural ‘alerts’ now well defined; examples include 
epoxides, quinones, hydroxyl amines and furans (Park et al., 2005a). The balance 
between bioactivation and detoxification is a critical determinant of the risk of reactive 
intermediate-induced toxicity (Fig. 1.1).
Phase II conjugation reactions and other intrinsic bioinactivation pathways provide a 
means of detoxifying reactive phase I products. However, saturation of these 
detoxification pathways may enable the concentration of reactive intermediates, which 
consequently may interact with, and damage, critical macromolecules, such as proteins 
and nucleic acids. In this regard, the process of drug metabolism can be inextricably 
linked to certain adverse drug reactions (Park, 1986; Zhou et al., 2005). For instance, 
compounds that inhibit the CYP450-mediated bioactivation of the non-steroidal anti­
inflammatory drug (NSAID) paracetamol to its electrophilic metabolite NAPQI prevent 
its hepatotoxicity (Brady et al., 1988; Mitchell et al., 1973; Roberts et al., 1986). 
Furthermore, CYP2E1 knockout mice are protected against (Lee et al., 1996), whereas
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Figure 1.1 - The role of drug metabolism in adverse drug reactions. The metabolic 
biotransformation of drugs can, in some instances, lead to the formation of chemically 
reactive intermediates including quinones, epoxides and thiophenes. Unless detoxified, 
these intermediates may cause toxicity, often via the process of covalent binding to 
critical macromolecules, such as DNA and proteins.
induction of CYP2E1 increases susceptibility to (Burk et al., 1990; Chien et al., 1997; 
Thummel et al., 2000), paracetamol-induced liver injury. Hence, the hepatotoxicity 
associated with overdose of paracetamol is a pertinent example of a bioactivation-related 
adverse drug reaction. A more detailed discussion of paracetamol-induced 
hepatotoxicity is presented in section 1.4.1. Phase II biotransformations, although 
typically regarded as bioinactivation reactions, may themselves yield toxic intermediates 
(Zhou et al., 2005). For example, glucuronosyl transferases catalyse the conversion of 
carboxylic acid drugs, including certain NSAIDs, to electrophilic acyl glucuronides, that 
bind covalently to plasma and hepatic proteins (Ritter, 2000). Thus, drug metabolism 
can represent a double-edged sword; although generally a favourable process 
responsible for the elimination of foreign chemicals from the body, in certain 
circumstances, metabolic biotransformations may generate reactive species that pose a 
significant threat to cellular homeostasis.
10
Chapter 1
1.4 DRUG-INDUCED LIVER INJURY (DILI)
Adverse drug reactions can have many different pathological manifestations, affecting 
any part of the body. However, as the liver is quantitatively the most important site of 
drug metabolism and, thus, bioactivation, it is a major target for tissue-specific toxicity, 
or DILI (Park et al., 1995). In fact, DILI is the most common reason for the withdrawal 
o f a drug from the market following initial regulatory approval (Temple et al., 2002), 
with more than 600 drugs having been linked to hepatotoxicity (Park et al., 2005a). 
Furthermore, DILI accounts for more than half of all cases of acute liver failure (Lee, 
2003). As DILI mimics natural disease, an increased understanding of the pathogenesis 
of DILI will enable advances in both drug safety and the treatment of natural liver 
disorders, such as cirrhosis and hepatitis (Park et al., 2005a).
1.4.1 Paracetamol hepatotoxicity
Paracetamol is a commonly-used analgesic and antipyretic, the pharmacological activity 
o f which is thought to stem from the inhibition of cyclooxygenase activity and 
consequent reduction of prostaglandin synthesis (Botting, 2000a; Botting, 2000b; 
Boutaud et al., 2002; Greco et al., 2003; Hinz et al., 2008; Sciulli et al., 2003). The 
hepatotoxicity associated with overdose of paracetamol is the single biggest cause of 
acute liver failure in both the UK (Davem et al., 2006) and United States of America 
(USA) (Larson et al., 2005). Furthermore, within the field of toxicology, paracetamol- 
induced hepatotoxicity represents one of the most widely used models of DILI (for a 
review, see Newsome et al., 2000). Three major pathways determine the metabolic fate 
o f paracetamol; glucuronylation, sulphation and oxidation (Fig. 1.2). At well-tolerated 
therapeutic doses (4 g per day) (Thomas, 1993), around 55 % and 30 % of renally- 
excreted metabolites are non-toxic glucuronide and sulphate conjugates, respectively 
(Howie et al., 1977; Tone et al., 1990). A small proportion (5-10 %) of a therapeutic 
dose of paracetamol is bioactivated, mainly via CYP2E1, and less so CYP3A4 and 
CYP1A2, -mediated oxidations, to yield the electrophilic metabolite NAPQI (Dahlin et
11
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al., 1984; Manyike et al., 2000; Raucy et al., 1989; Thummel et al., 1993). The exact 
chemistry that underlies the oxidation of paracetamol to NAPQI has yet to be fully 
elucidated. NAPQI is quenched via spontaneous or GST-mediated conjugation with 
GSH and excreted in urine as a cysteine conjugate and mercapturic acid breakdown 
products (Coles et al., 1988; Howie et al., 1977; Prescott, 1980).
Paracetamol N-acetyl-p-benzoquinoneimine (NAPQI)
OH O
Elimination Stress
Figure 1.2 - Metabolic fate of paracetamol. The majority of a therapeutic dose of 
paracetamol is eliminated via the formation of glucuronide and sulphate conjugates, 
reactions catalysed by uridine diphosphate glucuronosyl transferases (UGT) and 
sulphotransferases (ST), respectively. A small proportion of a paracetamol dose is 
bioactivated, via CYP2E1, 1A2 and 3A4 -catalysed oxidations, to the electrophilic 
metabolite N-acetyl-p-benzoquinoneimine (NAPQI). At therapeutic doses, NAPQI is 
efficiently detoxified through glutathione S-transferase (GST) -catalysed conjugation 
with glutathione (GSH). Following an overdose, the saturation of conjugation pathways 
enables the accumulation of NAPQI and subsequent depletion of GSH stores. This 
facilitates the covalent binding of NAPQI to critical macromolecules, a process that is 
thought to contribute to the hepatocellular necrosis typically observed following 
paracetamol overdose. Adapted from Zhou et al. (2005).
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Following paracetamol overdose, or the induction of specific CYP450 isoenzymes, the 
relatively low-capacity sulphation pathway becomes saturated, such that a greater 
fraction of the dose undergoes glucuronylation and oxidation, the latter resulting in the 
accumulation of NAPQI (Bessems et al., 2001). Indeed, the different sensitivities of 
laboratory animal species to paracetamol-induced hepatotoxicity (generally, mice and 
hamsters are more sensitive than rats, rabbits and guinea pigs) are thought to be 
determined by the differential rates of bioactivation and detoxification (Gregus et al., 
1988; Ioannides et al., 1983; Tee et al., 1987). Under conditions of NAPQI 
accumulation, cellular GSH stores become depleted due to a shift in the balance between 
NAPQI formation and GSH synthesis (Potter et al., 1974), and this is an obligatory step 
for paracetamol-induced hepatotoxicity (Davis et al., 1974). As such, rapid therapeutic 
intervention with N-acetyl-L-cysteine, which replenishes GSH stores (Hazelton et al., 
1986), is the current treatment of choice for patients who present following an 
intentional or accidental paracetamol overdose (Smilkstein et al., 1991).
The depletion of hepatic GSH enables NAPQI to covalently modify and inhibit at least 
17 enzymes in various hepatocellular compartments in rodents (for a review, see Park et 
al., 2005a), including y-glutamylcysteine ligase, catalytic subunit (Gclc) (Kitteringham 
et al., 2000), glyceraldehyde-3-phosphate dehydrogenase (Dietze et al., 1997), aldehyde 
dehydrogenase (Landin et al., 1996) and Ca2+/Mg2+ ATPase (Tsokos-Kuhn et al., 1988). 
Covalent modification of these proteins, and the oxidation of protein sulphydryls (Birge 
et al., 1988; Tirmenstein et al., 1990), by NAPQI has been hypothesised to contribute to 
mitochondrial dysfunction and the disruption of intracellular calcium homeostasis (for a 
review, see Jaeschke et al., 2003) and, as such, is thought to be a critical step in the 
development of the centrilobular hepatic necrosis typically observed following 
paracetamol overdose (McJunkin et al., 1976; Mitchell et al., 1973). The centrilobular 
region is a primary target for paracetamol-induced toxicity due to the relatively high 
zonal expression of bioactivating CYP450s {Oinonen, 1998 #727}. The importance of 
mitochondrial protein binding in the toxicity of paracetamol is demonstrated by the 
observation that, despite both paracetamol and its non-toxic regioisomer 3- 
hydroxyacetanilide showing a similar overall degree of covalent binding, the reactive
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metabolite of paracetamol binds to substantially more mitochondrial proteins than the 
metabolite of 3-hydroxyacetanilide (Myers et a l, 1995; Qiu et al., 2001; Tirmenstein et 
a l, 1989). Therefore, it is likely that the extent of modification to specific 
macromolecules, and not covalent binding per se, is the major factor underlying 
paracetamol-induced hepatotoxicity. Furthermore, the early signs of paracetamol- 
induced hepatocellular damage, both in vivo and in vitro, can be reversed by the 
reducing agent dithiothreitol (Albano et a l, 1985; Rafeiro et a l, 1994; Tee et a l, 1986), 
implying that the reversible oxidation of thiols to disulphides is also an important step in 
the progression of paracetamol-induced toxicity. The identification of critical protein 
targets for specific hepatotoxins, and the molecular mechanisms that underlie DILI, 
therefore, are major goals of current toxicological research.
1.4.2 Other drugs associated with hepatotoxicity
Other drugs associated with DILI, via discrete mechanisms, include; isoniazid, the first- 
line treatment for tuberculosis (Yew et al., 2006); troglitazone (Chojkier, 2005), an anti­
diabetic withdrawn from the marketplace in 2000; nevirapine and efavirenz (Rivero et 
a l, 2007), non-nucleoside reverse transcriptase inhibitors commonly used in 
combination regimens for the treatment of patients with human immunodeficiency virus 
(HIV); the anesthetic halothane (Kenna, 1997); and the NSAID diclofenac (Boelsterli, 
2003). Hence, DILI is associated with multiple dmgs and represents a significant health 
concern, both for patients and the pharmaceutical industry.
1.5 MECHANISMS OF DEFENCE AGAINST DILI
Although the liver is a rich source of enzymes capable of bioactivating xenobiotics, and 
thus is at high risk of reactive intermediate-induced toxicity, it also possesses many 
bioinactivation pathways that are, in general, tightly coupled to bioactivation, and hence 
provide an intrinsic means of detoxifying reactive species. Such protective pathways
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take various forms, and can be grouped into three ‘tiers’ of cell defence (Fig. 1.3); a) 
constitutive, relatively low levels of detoxification enzymes and antioxidants, b) the 
enhancement of these basal defences through transcription factor-mediated, upregulated 
expression of cytoprotective genes, and c) orchestrated cell suicide, in a final attempt to 
prevent the spread of damage to neighbouring cells.
High
GSH/GSSG
Ratio
Low
GSH/GSSG
Ratio
Response pathway: Normal Antioxidant
defence
Apoptosis
Signalling pathway:
Outcome:
Nrf2-ARE
Induction of 
detoxification 
enzymes
Mitochondrial
permeability
Caspases
Cell death
Figure 1.3 - The three major tiers of cell defence. Cells are equipped with three major 
‘tiers’ of defence, the relative contributions of which are primarily determined by the 
levels of chemical/oxidative stress within a given cell. The first tier encompasses 
constitutive levels of non-protein antioxidants and detoxification enzymes. Transcription 
factors regulate the transition to the second tier of defence; the upregulated expression of 
detoxification enzymes. Should these initial attempts to defend the cell prove futile, 
programmed cell death (apoptosis) may ensue, in order to limit the spread of damage to 
neighbouring cells. The major features of the three tiers are discussed in section 1.5. 
Adapted from Nel et al. (2006).
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1.5.1 Tiers of cell defence -  Basal antioxidants and detoxification enzymes
The first defensive barrier comprises constitutive levels of antioxidant compounds and 
enzymes capable of detoxifying a broad range of reactive species, particularly 
electrophiles and free radicals, the latter generated through various aerobic metabolic 
transformations (Yu, 1994).
1.5.1.1 Non-protein antioxidants
a-Tocopherol (vitamin E; Fig. 1.4) is a potent, lipid-soluble antioxidant, that has a 
primary role in breaking chain reactions involving oxygen and lipid peroxyl free radicals 
(Yu, 1994). Ascorbic acid (vitamin C; Fig. 1.4) is a hydrophilic antioxidant that directly 
scavenges reactive oxygen species (ROS), byproducts of mitochondrial aerobic 
respiration (Yu, 1994). In addition, ascorbic acid has the capacity to recycle oxidised a- 
tocopherol, restoring its antioxidant properties following radical scavenging (Yu, 1994). 
Other radical-trapping antioxidants include P-carotene (Fig. 1.4), a metabolic precursor 
of retinol (vitamin A), and bilirubin (Fig. 1.4), a breakdown product of heme catabolism 
(Yu, 1994). In general, the scavenging actions of the above-mentioned antioxidants are 
‘suicidal’ in nature; by donating an electron to a radical, and thus generating a non­
radical species, the antioxidant is inactivated, but, in doing so, provides an alternative to 
critical macromolecules as targets for reactive species (Davies, 2000).
Figure 1.4 - Chemical structures of the major non-protein antioxidants.
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1.5.1.2 Glutathione
GSH is the most abundant non-protein thiol, and is at the forefront of cell defence, 
providing a redox buffer for chemical and oxidative stress (DeLeve et al., 1991). The 
two-step synthesis of GSH involves; a) the rate-limiting conjugation of L-glutamate and 
cysteine, via y-glutamylcysteine ligase (GCL), to yield y-glutamylcysteine, and b) the 
conjugation of glycine to y-glutamylcysteine, via glutathione synthetase (GS), to yield y- 
glutamylcysteinylglycine (GSH) (Kaplowitz et al., 1985). The cysteine thiol of GSH 
endows it with a powerful nucleophilic group that facilitates the major functions of 
GSH, namely the conjugation of electrophiles, detoxification of ROS and thiol- 
disulphide exchange (DeLeve et al., 1991). The reaction of GSH with electrophilic 
species to yield thioether conjugates may proceed spontaneously, particularly with 
highly reactive ‘soft’ electrophiles, or enzymatically, the latter being catalysed by the 
GST family (DeLeve et al., 1991). GSH conjugates are cleaved by y- 
glutamyltranspeptidase, which removes the y-glutamyl moiety (DeLeve et al., 1991). 
The remaining cysteinyl-glycine conjugate is then cleaved by dipeptidase, yielding a 
cysteinyl conjugate, which in turn is acetylated to form a mercapturic acid (DeLeve et 
al., 1991). Ultimately, the various breakdown products of GSH-conjugate metabolism 
are recycled or excreted (DeLeve et al., 1991).
In contrast to its role in the detoxification of electrophiles, the antioxidant capacity of 
GSH does not stem from its ability to react with ROS directly, but from its function as a 
substrate for GSH peroxidases (GPX), which catalyse the reduction of hydrogen 
peroxide (H20 2) and lipid hydroperoxides (DeLeve et al., 1991). These reactions yield 
GSH disulphide (GSSG), which is reduced back to GSH via a nicotinamide adenine 
dinucleotide phosphate (NADPH) -dependent, GSH reductase-mediated reaction, a cycle 
that serves to maintain essential redox balance (DeLeve et al., 1991). Due to the 
relatively high acid dissociation constant (pKa 9.2) of GSH (Jung et al., 1972) and its 
cellular abundance, factors that disfavour disulphide formation, GSSG is normally 
maintained at less than 1 % of total cellular glutathione, though under conditions of 
oxidative stress, when GSSG levels may increase, GSSG can be actively transported out
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of cells, in order to protect against redox imbalance (DeLeve et ah, 1991). GSH also 
serves an important function in thiol-disulphide exchange reactions, whereby the 
favourable redox state of a given cysteine residue is maintained through bidirectional 
reaction with GSH, mediated by thiol-transferases (DeLeve et al., 1991). The 
preservation of cysteine redox state is particularly important for the function of certain 
enzymes whose catalytic activity is dependent upon the integrity of a sulphydryl or 
disulphide moiety. Examples of such enzymes include protein tyrosine phosphatases, 
and the peroxiredoxin (PRX) and thioredoxin (TRX) protein families (Dickinson et al., 
2002). The PRX and TRX families, in their own right, serve as important antioxidant 
defence proteins, as discussed in section 1.5.1.3.
1.5.1.3 Detoxification enzymes
The superoxide dismutase (SOD) family, members of which utilise the transition metals 
copper and zinc (Cu,Zn-SOD) or manganese (Mn-SOD) at their active sites, catalyse the 
dismutation of two superoxide anion radicals (0 2 ') to H20 2 and 0 2 (Nordberg et al., 
2001). The cytotoxic product of this reaction, H20 2, is detoxified via reduction to H20  
and 0 2 by GPX, catalase, and/or PRX (Nordberg et al., 2001). The heme-containing 
catalase family constitutes an important antioxidant defence found predominantly within 
peroxisomes, organelles involved in the oxidative metabolism of fatty acids (Nordberg 
et al., 2001). Catalases also function to detoxify phenols and alcohols, via a coupled 
reaction with H20 2 (Nordberg et al., 2001). Within the PRX family of peroxidases, a 
conserved cysteine residue is utilised to enable the reduction of H20 2 and other 
peroxides (Ishii et al., 2007; Wood et al., 2003). In members of the PRX family that 
contain two thiols (2-Cys), the resulting cysteine sulphenic acid (-SOH) reacts with a 
second ‘resolving’ cysteine, either in the second subunit of a homodimer, or within the 
same subunit in monomeric atypical 2-Cys enzymes, resulting in the formation of an 
intermolecular/intersubunit disulphide bond, respectively, rendering PRX inactive (Ishii 
et al., 2007; Wood et al., 2003). PRX function is reestablished through reduction of this 
disulphide by thiol-containing electron donors, including GSH and the TRX family
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(Ishii et a l, 2007; Wood et al., 2003). Oxidised TRX is reactivated by TRX reductase 
(TRX-R) (Ishii et a l, 2007; Wood et a l, 2003). Hence, numerous inter-related and 
highly regulated processes enable the maintenance of steady-state levels of chemical and 
protein -based antioxidants, providing the cell with a degree of basal protection against 
low-level chemical/oxidative stressors.
1.5.2 Tiers of cell defence -  Upregulation of antioxidants and detoxification 
enzymes
The second tier of cell defence involves the induction of cytoprotective genes, an 
adaptive response that increases the cell’s capacity to nullify reactive species, through 
the increased expression of enzymes that catalyse detoxification reactions or the 
synthesis of antioxidants (Presterà et a l, 1993b; Primiano et a l, 1997). The induction of 
cell defence genes is mediated by certain transcription factors, proteins that recognise 
specific deoxyribonucleic acid (DNA) sequences, bind to these sequences, and recruit 
the co-activators and ribonucleic acid (RNA) polymerase required to enable 
transcription and translation of target genes (Latchman, 1997). At the forefront of the 
adaptive response to cellular stress are the transcription factors nuclear factor-erythroid 2 
(NF-E2) -related factor 2 (Nrf2), nuclear factor kB (NF-kB), activator protein 1 (AP-1), 
hypoxia-inducible factor 1 (HIF-1) and members of the heat-shock factor (HSF) family. 
A detailed evaluation of the role of transcription factors in the adaptive response to 
cellular stress is presented in section 1.7.
1.5.3 Tiers of cell defence -  Programmed cell death (apoptosis)
Should initial efforts to detoxify and eliminate a cellular stressor prove futile, a last-ditch 
attempt is made to halt the spread of damage to neighbouring cells, through programmed 
cell death (apoptosis). Membrane blebbing, cell shrinkage, chromatin condensation and 
DNA fragmentation are the hallmarks of apoptotic cell death (Robertson et al., 2000).
19
Chapter 1
These orchestrated events culminate in the cell being engulfed by macrophages, thus 
preventing the insult from spreading to neighboring cells (Robertson et al., 2000). In this 
regard, apoptosis is distinct from necrosis, which can be regarded simply as a failure of 
cellular homeostasis, resulting from a sudden, lethal insult (Raffray et al., 1997). 
Necrosis promotes an inflammatory response via the uncontrollable release of cellular 
contents into the local environment, leading to the damage of nearby cells (Robertson et 
al., 2000). Although there appears to be a degree of overlap between the biochemical 
signaling mechanisms that regulate the apoptotic and necrotic pathways {for a review, 
see \Nicotera, 2004 #722}, various factors determine the balance between the two types 
o f cell death, including the nature of the toxic insult, the dose and/or time of exposure to 
the insult, and the relative thresholds for apoptosis and necrosis within a given cell type 
(Raffray et al., 1997).
1.5.3.1 Regulation of apoptosis
Apoptosis may be triggered via two distinct pathways, prompted by extrinsic or intrinsic 
signals, and involves the sequential activation of caspases, a family of cysteine proteases 
that act as both initiators and effectors of cell death (Thomberry et al., 1998). In the 
extrinsic pathway, cell surface transmembrane death receptors, such as Fas and tumour 
necrosis factor receptor (TNF-R), recognise specific extracellular ligands, such as Fas 
ligand (FasL) or TNF-a, respectively, an event that induces receptor trimerisation 
(Budihardjo et al., 1999). The subsequent formation of a death-inducing signalling 
complex between clustered receptors, intracellular ‘death-domain’ -containing proteins 
and procaspase-8 triggers the activation of downstream effector caspases (Budihardjo et 
al., 1999). Perhaps more relevant to xenobiotic-induced chemical/oxidative stress, the 
intrinsic apoptotic pathway is triggered via an increase in mitochondrial membrane 
permeability, though a consensus has yet to be reached on the molecular events that 
cause such permeation (Blank et al., 2007). A variety of intracellular stress signals can 
stimulate the intrinsic pathway, including DNA and cytoskeletal damage, oxidative and 
endoplasmic reticulum stress, and the misfolding of proteins (Blank et al., 2007;
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Chandra et al., 2000). These and other stress signals promote the leakage of proteins, 
normally resident within the mitochondrial inter-membrane space, into the cytosol 
(Hengartner, 2000). Amongst the proteins released, cytochrome c, a component of the 
electron transport chain, associates with apoptotic protease activating factor 1 (APAF-1) 
to form the ‘apoptosome’ complex, which then binds to, and activates, procaspase-9 
(Riedl et al., 2007). As with activation of procaspase-8 in the extrinsic pathway, 
activation of procaspase-9 triggers downstream effector caspases, particularly caspases - 
3 and -7 (Blank et al., 2007). Notable caspase substrates include cytoskeletal proteins 
such as actin (Mashima et al., 1999) and lamin A (Rao et al., 1996), degradation of 
which causes loss o f membrane integrity, the inhibitor of caspase-activated DNAse 
(ICAD) (Enari et al., 1998), inactivation of which promotes DNA fragmentation, the 
DNA repair enzyme poly (adenosine diphosphate-ribose) polymerase (PARP) (Lazebnik 
et al., 1994), and components of various cell division/survival signalling cascades 
(Blank et al., 2007). Apoptosis is partly regulated by the cellular redox balance, and thus 
is sensitive to oxidative stress (Chandra et al., 2000; Davis et al., 2001), which in turn is 
both a trigger and a target for the basal and inducible defence machinery discussed 
above. Hence, cells employ an integrated three-pronged defence strategy to coordinate 
protection against cytotoxic reactive species and other stressors.
1.6 REDOX REGULATION OF CELL DEFENCE
As with other cellular processes, cell defence is subject to redox regulation. The 
sulphydryl group of the amino acid cysteine represents a versatile moiety that facilitates 
the regulation of protein function, via reversible and irreversible redox reactions, i.e. 
those involving the loss (oxidation) or gain (reduction) of electrons at the sulphydryl 
group (Cooper et al., 2002). The various oxidation states of cysteine sulphydryls are 
summarised in Figure 1.5. Some cysteines are stabilised in the thiolate form (-S') via 
structural interactions with basic amino acids, namely arginine, lysine or histidine 
(Snyder et al., 1981). The deprotonated thiolate is more nucleophilic, and thus reacts 
more readily with oxidants, than the protonated thiol (-SH; a), which is relatively
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unreactive (Netto et a l, 2007). Nevertheless, the thiol is capable of partaking in various 
reactions; sequential oxidations yield sulphenic acid (-SOH; b), which is generally 
unstable and reacts further to the more stable sulphinic (-SO 2H; c) and sulphonic acids 
(-SO 3H; d) (Paget et a i,  2003). Oxidation to sulphenic acid may also lead to the 
formation of a disulphide (S-S), either within a single protein (e), between separate 
proteins (f), or with a small, non-protein thiol such as GSH (S-glutathionylation) (g) 
(Paget et a l, 2003). Other important redox reactions include thiol-disulphide exchange 
reactions between a thiol and disulphide (h), and modifications by reactive nitrogen 
species such as nitric oxide, to yield S-nitrosothiol (-SNO; i), or peroxynitrite, to yield 
S-nitrothiol (-SNO2; j) (Cooper et a l, 2002).
Figure 1.5 - Schematic overview of the various cysteine oxidations states. Letters 
representing each oxidation state refer to descriptions given in the main text. Adapted 
from Paget et al. (2003).
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The oxidation state of certain cysteines is often critical to the function of a given protein 
and, as such, changes in the cellular redox environment can affect protein activity, either 
positively or negatively. A well-characterised redox-sensitive protein is the prokaryotic 
transcription factor OxyR, a major regulator of bacterial cell defence genes including 
katG (a hydrogen peroxidase), gorZ (a GSH reductase) and oxyS (a small RNA involved 
in DNA repair) (Paget et al., 2003). OxyR ‘senses’ oxidative stress through a reactive 
cysteine (Cys-199) that, in a non-oxidative environment, is stabilised in the thiolate form 
via interaction with a basic arginine residue (Choi et al., 2001). Oxidation of this 
cysteine results in a conformational change that activates OxyR, enabling the 
transcription factor to recognise specific response elements in the promoter regions of 
target genes (Paget et al., 2003). Until recently, this conformational change was thought 
to be dependent upon the formation of an intramolecular disulphide bond (Storz et al., 
1990). However, evidence has emerged to suggest that, rather than acting as a simple 
‘on/off switch, cysteine oxidation regulates OxyR in a graded manner, dependent upon 
the specific oxidation state of Cys-199, which may be modified to yield sulphenic acid, 
S-nitrosothiol or a mixed disulphide (Kim et al., 2002).
The concept that a protein’s function may be modulated through simple chemical 
changes within a single amino acid represents an important paradigm in cellular redox 
signalling. Redox-sensitive transcription factors that have major roles in regulating the 
eukaryotic cytoprotective response include Nrf2, NF-kB and AP-1. A more detailed 
discussion of the role of these transcription factors in cell defence is presented in section 
1.7.
1.7 TRANSCRIPTIONAL REGULATION OF CELL DEFENCE
As discussed in section 1.5.2, one of the major tiers of cell defence involves the 
upregulated expression of cytoprotective genes, a process mediated by certain 
transcription factors. In working to nullify electrophiles and free radicals, these 
transcription factors play a critical role in maintaining cellular homeostasis. It is
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noteworthy that the activity of these regulatory proteins themselves is particularly 
sensitive to changes in cellular redox balance. The ability of cytoprotective pathways to 
‘sense’ and respond to chemical/oxidative stress has an important influence on the 
balance between bioactivation and detoxification, which ultimately determines the fate 
of a cell exposed to a potentially toxic species.
1.7.1 Nuclear Factor kB
NF-kB is a major regulator of the innate and adaptive immune response, cell 
proliferation and apoptosis, and thus serves an important function in the response to 
cellular stress. Under basal conditions, NF-kB is localised within the cytosol as a 
dimeric complex, usually comprising p50 and p65 subunits (Hayden et al., 2004). The 
subcellular distribution of NF-kB is regulated by members of the inhibitor of kB (IkB) 
family; the association between the two molecules masks the nuclear localisation signal 
(NLS) in the NF-kB complex, thus inhibiting its nuclear translocation (Hayden et al., 
2004). Activation of NF-kB, in response to a variety of stimuli, including bacterial and 
viral infection, oxidative and endoplasmic reticulum stress, proinflammatory cytokines, 
and certain chemical agents (Pahl, 1999), involves the stimulation of a protein kinase 
cascade that promotes activation of IkB kinase (IKK), which subsequently 
phosphorylates critical serine residues within IkB, resulting in the latter’s ubiquitination 
and proteasomal degradation (Hayden et al., 2004). Consequently, the NLS of NF-kB is 
unmasked, facilitating its nuclear translocation and the transactivation of target genes, 
through binding to specific DNA sequences, known as kB elements (Hayden et al., 
2004). Notable NF-kB targets include the stress-response genes cyclooxygenase 2 
(COX2) and inducible nitric oxide synthase (iNOS), the detoxification enzymes GST 
subunit Pl-1 (GSTP1-1), GCL and SOD, and the apoptotic regulators p53, Bcl-xL and 
FasL (Pahl, 1999). Notably, exposure of mice to hepatotoxic doses of paracetamol 
causes the NF-kB -dependent upregulation of pro-inflammatory mediators, including 
interleukin-ip (IL-ip) and TNFa, and the anti-inflammatory cytokine IL-10 (Dambach 
et al., 2006), indicating the role of NF-kB in regulating the cellular stress response.
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The activity of NF-kB is subject to direct and indirect redox modulation (Kabe e t a l., 
2005; Pantano e t a l., 2006). A rise in the levels of ROS in response to various stimuli, 
including TNF-a, IL-1 and lipopolysaccharide (LPS), augments NF-kB activation 
through induction of upstream protein kinases (Pantano e t  a l., 2006). Changes in the 
cellular GSH:GSSG balance have also been associated with repression of IkB and 
activation of NF-kB (Mihm e t a l., 1995). Based on this evidence, therefore, it would 
appear that NF-kB is stimulated under oxidising conditions. However, recent reports that 
specific chemical entities can attenuate the DNA-binding activity of NF-kB, through 
chemical modification of Cys-62 within the p50 subunit (Cemuda-Morollon e t a l., 2001; 
Lee e t  a l., 2002; Mahon e t a l., 1995; Xia e t a l., 2004), appear to conflict with this view. 
Furthermore, covalent modification of IKK at Cys-179, by electrophiles including 
cyclopentenone prostaglandins (Rossi e t a l., 2000), 4-hydroxynonenal (Ji e t a l., 2001) 
and acrolein (Valacchi e t a l., 2005), inhibits its kinase activity and thus perturbs 
transactivation of target genes by NF-kB. In addition, NAPQI, the electrophilic 
metabolite of paracetamol, perturbs NF-kB activity in Hepa 1-6 mouse hepatoma cells, 
by inhibiting the degradation of IkB (Boulares e t a l., 1999).
The balance between cytoplasmic and nuclear redox events, and their effects on NF-kB 
activity, is particularly evident in the case of TRX. Over-expression of TRX, which 
localises predominantly in the cytoplasm, represses activation of NF-kB, by reversing 
oxidation events promoted by NF-kB-stimulating ROS (Meyer e t a l., 1993). However, 
in response to phorbol 12-myristate-13-acetate (PMA), TNF-a, or ionising radiation, 
TRX translocates to the nucleus, and enhances the DNA-binding activity of NF-kB, by 
maintaining Cys-62 of p50 in a reduced state (Hirota e t a l., 1999). In a further 
demonstration of its redox regulation, NF-KB-dependent gene expression is suppressed 
by the quinone derivative E3330, but this inhibitory effect does not involve changes in 
the degradation of IkB or the nuclear translocation of NF-kB (Hiramoto e t a l., 1998). 
Indeed, E3330 modifies and inhibits redox effector factor 1 (REF-1) (Hiramoto e t a l., 
1998), a nuclear protein that mediates the redox regulation of several transcription 
factors (Evans e t a l., 2000), and can reduce the oxidised Cys-62 of p50, thus restoring 
the DNA-binding activity of NF-kB (Nishi e t a l., 2002). Thus, by perturbing the activity
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of REF-1, E3330 indirectly inhibits the binding of NF-kB to DNA (Hiramoto et al., 
1998). In summary, NF-kB is a redox-sensitive transcription factor with important 
functions in the cellular stress-response, although the redox regulation of NF-kB is 
particularly dependent on its subcellular localisation, and may involve a variety of 
signalling pathways.
1.7.2 Activator Protein 1
The transcription factor AP-1 plays an important role in various cellular processes, 
including proliferation, differentiation, survival and death (Shaulian et al., 2002). AP-1 
exists as a dimer, comprising members of the Jun, Fos and/or activating transcription 
factor (ATF) protein families (Karin et al., 1997). Jun homodimers and Jun-Fos 
heterodimers, typically c-Jun and c-Fos, bind to the 12-O-tetradecanoate-13-acetate 
(TPA) -responsive element (TRE), whereas ATF homodimers and Jun-ATF 
heterodimers bind to the cyclic adenosine monophosphate (cAMP) -responsive element 
(CRE) (Karin et al., 1997). Activation of AP-1, by stimuli including cytokines, bacterial 
and viral infection, and certain cellular and chemical stresses, is mediated predominantly 
via the mitogen-activated protein kinase (MAPK) pathway (Shaulian et al., 2002). 
Activation of AP-1 involves the upregulation of immediate early genes that encode e.g. 
c-Jun and c-Fos, with subsequent dimérisation and binding to recognition elements 
resulting in the transactivation of genes including GSTs, GCL, COX2, iNOS and various 
apoptotic regulators (Karin et al., 1997). AP-1 is known to be redox-sensitive (Schenk et 
al., 1994), to such a degree that oxidation of a single cysteine residue within c-Jun and c- 
Fos can influence their DNA-binding capacities (Abate et al., 1990). Previous work has 
demonstrated a reduction in AP-1 DNA-binding following adduction of c-Jun by 
reactive chemical species (Biswal et al., 2002; Perez-Sala et al., 2003). Furthermore, in a 
similar manner to NF-kB, the DNA binding activity of AP-1 is subject to redox 
regulation by REF-1 (Xanthoudakis et al., 1992).
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1.7.3 Hypoxia-Inducible Factor 1 and Heat Shock Factors
Other transcription factors with important roles in the adaptive response to cellular stress 
include HIF-1 and members of the HSF family. Under circumstances of low cellular 
oxygen levels (hypoxia), activation of HIF-1 enables induction of genes that facilitate 
short and long-term adaptation to hypoxia, including growth factors involved in cell 
survival and proliferation, regulators of erythropoiesis and angiogenesis, and 
components of various metabolic pathways (Semenza, 2003). In response to elevated 
temperature and other stresses, the HSF family of transcription factors mediate the 
induction of heat-shock proteins (HSP), which function to solubilise denatured protein 
aggregates, facilitate the restoration of protein function, and direct irreversibly damaged 
proteins to the cellular degradation machinery (Kiang et al., 1998). In general terms, 
therefore, the heat-shock response represents a defence against protein damage (Wu, 
1995).
1.7.4 The antioxidant response pathway
Mammalian cells have evolved an inducible line of cell defence, termed the antioxidant 
response pathway, that facilitates the enhanced bioinactivation and clearance of oxidants 
and electrophilic molecules, via the transcriptional upregulation of an array of 
detoxification and antioxidant enzymes (Primiano et al., 1997). The three regulatory 
components of the antioxidant response pathway are a) the antioxidant response element 
(ARE) DNA motif, found within the promoter regions of numerous cytoprotective 
genes, b) Nrf2, the redox-sensitive transcription factor that binds to the ARE, and c) 
Keapl, the cysteine-rich cytosolic repressor of Nrf2.
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1.7.4.1 Nuclear Factor Erythroid 2 (NF-E2) -Related Factor 2 (Nrf2)
Nrf2 was first isolated during a screen for Nuclear factor erythroid 2 (NF-E2) -regulating 
proteins in a complementary DNA (cDNA) expression library derived from hemin- 
induced erythroleukemia cells (Moi e t a l., 1994). Unlike NF-E2, which regulates globin 
gene expression in developing erythroid cells (Igarashi e t  a l., 1994), Nrf2 is expressed in 
many tissues (Moi e t  a l., 1994), particularly those associated with detoxification (liver 
and kidney) and those that are exposed to the external environment (skin, lung and 
gastrointestinal tract) (Motohashi e t  a l., 2002). As with other members of the CNC 
family of transcription factors (Itoh e t a l., 1995), so named because of structural 
similarities with the D ro so p h ila  protein cap ‘n ’ collar (CNC), Nrf2 contains a C-terminal 
basic leucine zipper (bZip) structure that facilitates dimerisation and DNA binding (Moi 
e t  a l., 1994).
Through reporter transgene (Venugopal e t a l., 1996) and electrophoretic mobility shift 
assay (Nguyen e t a l., 2000) experiments, Nrf2 was shown to bind to the ARE and 
upregulate the expression of target genes. The ARE, a cA-acting DNA enhancer motif 
with a consensus sequence defined as 5'-gagTcACaGTgAGtCggCAaaatt-3' (where 
essential nucleotides are in capitals and the core is in bold) (Nioi et al., 2003),, was 
originally identified within a 41 base-pair section from the 5’-flanking region of the rat 
GSTA2 gene that was responsive to the phenolic antioxidant (3-naphthoflavone 
(Rushmore e t  a l., 1990). Although Nrf2 is by far the most potent transcriptional 
activator of the ARE amongst members of the CNC family (Kobayashi e t a l., 1999; 
Papaiahgari e t a l., 2006), Nrfl also appears to play a role, albeit limited, in the 
regulation of ARE gene expression, at least at the basal level (Kwong e t a l., 1999; 
Myhrstad e t a l., 2001; Venugopal e t a l., 1996; Xu e t  a l., 2005). Furthermore, Nrfl is 
important for embryonic development, as Nrfl knockout (Nrfl7') embryos die within 
17-18 days of gestation (Chan et a l., 1998). Evidence also exists, however, to suggest 
that Nrfl (Wang e t a l., 2007), in addition to the remaining members of the CNC family, 
Nrf3 (Sankaranarayanan e t a l., 2004), bric-a-brac/tram-track/broad complex (BTB) and 
CNC homolog 1 (BACH1) (Dhakshinamoorthy e t a l., 2005; Reichard e t  a l., 2007; Sun
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et al., 2002) and BACH2 (Muto et al., 2002), may act as negative regulators of Nrf2- 
mediated ARE gene expression, in part by competing with Nrf2 for binding to the ARE.
Nrf2 only binds with high affinity to the ARE as a heterodimer with small Maf proteins 
(Itoh et al., 1997). Members of the small Maf family, comprising MafF, MafK and 
MafG, possess a bZip domain, facilitating their dimerisation with other bZip proteins 
(Kataoka et al., 1993). However, small Maf proteins lack transactivation domains, and 
thus the ability of the Nrf2-Maf heterodimer to promote transcription is reliant on the 
transactivation faculty o f Nrf2 (Motohashi et al., 2002). Indeed, over-expression of 
small Maf proteins represses Nrf2-mediated transactivation of cell defence genes 
(Dhakshinamoorthy et al., 2002; Dhakshinamoorthy et al., 2000; Nguyen et al., 2000), 
through binding of small Maf homodimers, which lack intrinsic transcriptional activity, 
to the ARE (Dhakshinamoorthy et al., 2000).
Structural comparison of the chicken homologue of Nrf2 (erythroid cell-derived protein 
with CNC homology; ECH) (Itoh et al. 1995) with the human and mouse proteins 
enabled the identification of six highly-conserved regions, termed Nrf2-ECH homology 
(Neh) domains (Itoh et al., 1997) (Fig. 1.6 and Table 1.2). The binding of Nrf2 to the 
ARE, which involves a highly conserved cysteine residue (Cys-506) within the Nehl 
domain of the transcription factor (Bloom et al., 2002), stimulates transcription of 
downstream genes, in part, by recruiting transcriptional co-activators (Lin et al., 2006), 
particularly cAMP responsive element binding protein (CREB) -binding protein (CBP) 
through its Neh4 and Neh5 domains (Katoh et al., 2001; Zhu et al., 2001). CBP 
promotes transcription via a) its intrinsic histone acetyltransferase (HAT) activity, b) 
interaction with other proteins possessing HAT activity, and c) bridging to components 
of the general transcriptional machinery (Bannister et al., 1996; Kalkhoven, 2004). 
Histones form the core of nucleosomes, around which DNA is wound into a condensed 
structure that represses transcription, but that can be unfolded to increase accessibility to 
general transcription factors and RNA polymerase II, and thus promote gene 
transcription (Grunstein, 1990; Kuo et al., 1998).
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Figure 1.6 - Nrf2 functional domains. Schematic overview of the six Neh functional 
domains in Nrf2, drawn to scale, with each domain labelled. The line at the top of the 
panel indicates 100 amino acid sections of the protein. See Table 1.2 for functional 
characteristics of each domain.
Domain Location (in 
mouse protein)
Function(s) and Features Reference(s)
Neh2 1-96 Contains DLG and ETGE motifs 
(points of interaction with Keapl) 
Contains lysine-rich region (target for 
ubiquitination)
Contains DIDLID element (regulation 
of Nrf2 turnover under homeostatic 
conditions)
Itoh e ta l .  (1999)
Katoh e t al. (2005) 
McMahon e t  al. (2004) 
McMahon e t  al. (2006) 
Tong e t  al. (2006a)
Neh4 111-141 Transactivation
Interaction with co-activator CBP
Katoh e t al. (2001)
Neh5 172-201 Transactivation
Interaction with co-activator CBP 
Contains nuclear export signal (#175- 
186)
Katoh e t al. (2001) 
Li e t al. (2006) 
Zhang e t al. (2007b)
Neh6 330-380 Regulation of Nrf2 turnover under 
stressed conditions
McMahon e t al. (2004)
Nehl 427-560 Contains CNC and bZip regions 
ARE binding
Dimerisation with other bZip 
proteins (small Mafs)
Contains nuclear localisation (#494- 
511) and export (#545-554) signals
Bloom e t al. (2002) 
Itoh e ta l .  (1999) 
Jain e t al. (2005)
Neh3 561-597 Transactivation
Interaction with putative co-activator 
proteins
Nioi e t  al. (2005)
Table 1.2 - Nrf2 functional domains.
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Hence, the interaction with transcriptional co-activators such as CBP enables Nrf2 to 
regulate the basal and inducible expression of numerous cytoprotective genes, as 
summarised in Table 1.3. Therefore, activation of Nrf2 promotes cell survival through 
the detoxification and/or elimination of chemical/oxidative stressors (Fig. 1.7).
Protein Function Reference(s)
Aldo-keto 
reductases (AKR)
Reduce aldehydes and ketones to yield 
primary and secondary alcohols
Lou e t al. (2006) 
Nishinaka e t  al. (2005)
Glutamate cysteine 
ligase, catalytic 
subunit (GCLC)
Catalyses the conjugation of cysteine with 
L-glutamate, to form y-glutamylcysteine
Chan e t  al. (2000b) 
Jeyapaul e t al. (2000) 
{Wild, 1999 #8 }
Glutamate cysteine 
ligase, regulatory 
subunit (GCLM)
Lowers the Km of GCLC for glutamate and 
raises the Kj for GSH
Moinova e t al. (1999) 
W ild e /al. (1999) 
Chan e t al. (2000b)
Glutathione 
peroxidases (GPX)
Catalyse the reduction of H2O2 and other 
peroxides, using GSH as a substrate
Banning e t al. (2005) 
Singh e t al. (2006b)
Glutathione 
reductase (GSR)
Catalyses the reduction of oxidized 
glutathione (GSSG) to GSH
Thimmulappa e t al. (2002)
Glutathione 
synthetase (GS)
Catalyses the conjugation of glycine with 
y-glutamylcysteine
Lee e t  al. (2005)
Glutathione
S-transferases
(GST)
Reduces pK a of GSH, catalysing its 
conjugation to electrophiles
Chanas e t  al. (2002) 
Hayes e t  al. (2000) 
McMahon e t al. (2001)
Heme-oxygenase 1 
(HO-1)
Catabolises heme to yield biliverdin, 
carbon monoxide and free iron
Alam e t al. (1999); 
Ishii e t al. (2 0 0 0 )
Microsomal 
epoxide hydrolase 
(MEH)
Hydrates simple epoxides and arene oxides 
to more polar vicinal diols and tran s-  
dihydrodiols
Ramos-Gomez e t al. 
(2001); Slitt é ta l .  (2006); 
Thimmulappa e t al. (2002)
NAD(P)H:quinone
oxidoreductases
(NQO)
Catalyse two-electron reduction and 
detoxification of quinones
Venugopal e t al. (1996) 
Wang e t al. (2006)
Peroxiredoxin 1 
(Prxl)
Reduces H2O2, peroxynitrite and other 
organic hydroperoxides
Kim e t al. (2007)
Superoxide 
dismutases (SOD)
Catalyse the dismutation of superoxide 
radicals to O2 and H20 2
Park e t al. (2002)
Thioredoxins
(TRX)
Catalyse the reversible reduction of 
disulfides to sulphydryls
Kim e t  al. (2001) 
Kim e t  al. (2003)
UDP-
Glucuronosyltransf- 
erases (UGT)
Catalyse conjugation of UDPGA to 
lipophilic substrates
Shelby e t  al. (2006) 
Yueh e t al. (2007)
Table 1.3 - Cell defence proteins encoded by Nrf2-regulated genes.
31
Chapter 1
Electrophile conjugation 
GSH homeostasis 
Production of reducing equivalentsV H  — J
f \
Antioxidants 
GSH homeostasis 
Production of reducing equivalents
Fig. 1.7 - The inhibitory effects of Nrf2 activation on the progression of cellular 
injury. Through regulating the expression of genes encoding proteins that serve to 
detoxify reactive chemical species and maintain redox homeostasis, Nrf2 protects 
against the potential deleterious effects of chemically reactive intermediates and reactive 
oxygen species, and thus promotes cell survival. Adapted from Osbum e t al. (2007).
1.7.4.1.1 Insights into Nrf2 function from transgenic knockout mice
Although N rf2  knockout (N rf2"/") animals exhibit no significant developmental 
phenotype (Chan e t a l., 1996), they do develop vacuolar leukoencephalopathy (the 
abnormal development of cavities in the brain and deterioration of the myelin sheaths 
that cover neurons) (Hubbs e t  a l., 2007) and lupus-like autoimmune symptoms, 
including multiorgan inflammation, oxidative lesions, deposition of immunoglobulin 
complexes in blood vessels, and nephritis (Vargas e t  a l., 2006; Yoh e t a l., 2001). Two 
notable characteristics demonstrate the severely compromised defence systems in N rf2  
knockout mice; a) lower basal and/or inducible expression of detoxification/antioxidant 
genes in a variety of tissues, including liver (Chan e t a l., 2000; Chanas e t  a l., 2002; Iida 
e t  a l., 2004; Itoh e t a l., 1997; Kwak e t a l., 2001; Ramos-Gomez e t  a l., 2001), lung (Chan 
e t  a l., 1999; Cho e t a l., 2002; Ishii e t  a l., 2005; Rangasamy e t a l., 2005), gastrointestinal 
tract (Itoh e t a l., 1997; Khor e t a l., 2006; McMahon e t a l., 2001; Ramos-Gomez e t  a l., 
2001), brain (Kraft e t a l., 2006; Lee e t  a l., 2003; Shih e t  a l., 2005), skin (Xu e t  a l., 2006) 
and bladder (Iida e t a l., 2004), and b) enhanced susceptibility to the toxicities associated 
with various xenobiotics and environmental stresses (for a review, see Copple e t  a l.,
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2008). Furthermore, the chemopreventative actions of oltipraz (Iida e t a l., 2004; Ramos- 
Gomez e t  a l., 2003; Ramos-Gomez e t a l., 2001) and sulforaphane (Xu e t a l., 2006) are 
abolished in N r/2 '1' mice. Taken together, these findings demonstrate the importance of 
Nrf2 for cellular defence.
1.7.4.2 Kelch-like ECH-associated Protein 1 (Keapl)
In the absence of cellular stress, Nrf2 is tethered within the cytosol by an inhibitory 
partner, which binds to Nrf2 via the Neh2 domain of the transcription factor (Itoh e t a l., 
1999). Due to similarities with sequence motifs found in the D ro so p h ila  cytoskeleton- 
binding protein Kelch (Xue e t a l., 1993), the repressor of Nrf2 was named Kelch-like 
ECH-associated protein 1 (Keapl). Keapl resides within the cytosol of mammalian 
cells, where it interacts with the actin cytoskeleton (Kang e t a l., 2004) and, in the 
absence of chemical/oxidative stress, associates with Nrf2 (Dhakshinamoorthy e t  a l., 
2001; Itoh e t a l., 1999). Over-expression of Keapl reduces Nrf2-mediated 
transactivation of ARE-regulated genes (Dhakshinamoorthy e t  a l., 2001; Itoh e t a l., 
1999; Wakabayashi e t a l., 2004). Exposure to chemical/oxidative stress enables Nrf2 to 
evade Keapl-mediated repression, accumulate within the nucleus via a NLS located 
within the Nehl domain (Jain e t a l., 2005) and transactivate ARE target genes 
(Dhakshinamoorthy e t  a l., 2001; Itoh e t a l., 1999). A detailed discussion of the 
molecular mechanisms thought to underlie the liberation of Nrf2 from Keapl-mediated 
repression is presented in section 1.7.4.6 . The features of the three major functional 
domains of Keapl are summarised in Figure 1.8 and Table 1.4.
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Figure 1.8 - Keapl functional domains. Schematic overview of the three major 
functional domains in Keapl, drawn to scale, with each domain labelled. BTB, bric-a- 
brac/tram-track/broad complex; IVR, intervening region; DGR, double glycine repeat. 
The line at the top of the panel indicates 50 amino acid sections of the protein. The 
position of each cysteine in the mouse Keapl protein is indicated. See Table 1.4 for 
functional characteristics of each domain.
Domain Location Function(s) and 
Comments
Reference(s)
BTB 67-178 Bric-a-brac/tram- 
track/broad complex 
Heterodimerisation 
Interaction with CUL3
Zipper et al. (2002)
IVR 179-321 Intervening region 
Cysteine-rich (6.3 % of 
amino acids)
DGR 322-608 Double-glycine (kelch) 
repeat
Interaction with Nrf2 
Interaction with actin 
cytoskeleton
Dhakshinamoorthy et al. (2001) 
Itoh et al. (1999)
Kang et al. (2004)
Li et al. (2004)
McMahon et al. (2006)
Tong et al. (2006a)
Table 1.4 - Keapl functional domains.
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1.7.4.2.1 Insights into Keapl function from transgenic knockout mice
Attempts to investigate the role of Keapl in regulating Nrf2-mediated cell defence in 
vivo were initially hindered due to the retarded growth and death of Keapl knockout 
(K ea p l/ ) mice within 2 1  days of birth, due in part to malnutrition resulting from 
hyperkeratotic lesions in the eosophagus and forestomach, which obstruct the upper 
digestive tract (Wakabayashi et al., 2003). Co-knockout of Nrf2 (Keapl','::Nrf2'1') 
rescued this phenotype, indicating that Nrf2 is the central downstream target of Keapl in 
vivo (Wakabayashi et al., 2003). Recently, however, hepatocyte-specific knockout of 
Keapl has been achieved using the Cre-loxP system, which facilitates tissue-specific 
gene knockout (Okawa et al., 2006). Briefly, an Alb-Cre mouse, expressing a Cre 
recombinase transgene under the control of the liver-specific albumin promoter, is 
crossed with a Keapl-loxP mouse, in which exons 4-6 of the Keapl gene are flanked by 
loxP sites. In the double-transgenic Alb-Cre::Keapl-loxP mouse, Cre catalyses 
recombination between target loxP sites, resulting in excision of the flanked segment 
(exons 4-6) within Keapl and thus translation of a truncated form of the protein, lacking 
the double glycine repeat (DGR) domain that interacts with Nrf2 (Nagy, 2000; Okawa et 
al., 2006). Without the growth retardation and malnutrition observed in Keapl'1' 
animals, hepatocyte-specific knockout of Keapl results in an increase in basal 
expression of numerous ARE-driven genes in the liver, including Nqol, Gclc, Gpx and 
carbonyl reductase (Okawa et al., 2006). Moreover, Alb-Cre::Keapl-loxP mice are 
highly resistant to doses of paracetamol that are hepatotoxic and lethal in wild-type mice 
(Okawa et al., 2006). Therefore, Keapl is a major regulator of cell defence, due to its 
repressive influence over Nrf2.
1.7.4.3 The role of ubiquitination in the regulation of Nrf2 activity
Although the physical restriction of Nrf2 is an important aspect of its repression by 
Keapl, this cannot fully account for the relatively short-half life of the transcription 
factor (10-30 minutes) in the absence of cellular stress (Alam et al., 2003; Furukawa et
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a l., 2005; He e t  a l ,  2006; Itoh e t  a l ,  2003; McMahon e t  a l ,  2003; Stewart e t  a l ,  2003; 
Zhang e t a l ,  2003a). Notably, protéasome inhibition causes the stabilisation and nuclear 
accumulation of Nr£2, which in turn leads to an increase in ARE-driven gene 
transactivation (Alam e t a l ,  2003; Chen e t  a l ,  2005a; Furukawa e t  a l ,  2005; Itoh e t  a l ,  
2003; McMahon e t a l ,  2003; Nguyen e t a l ,  2003; Sekhar e t  a l ,  2000; Stewart e t  a l ,  
2003; Usami e t  a l ,  2005; Yamamoto e t a l ,  2007). Furthermore, ubiquitinated Nrf2 has 
been detected under such conditions (Cullinan e t a l ,  2004; Kobayashi e t  a l ,  2004; 
Nguyen e t a l ,  2003; Stewart e t a l ,  2003; Zhang e t a l ,  2003a). This evidence suggests 
that Nrf2 is rapidly degraded by the ubiquitin-proteasome pathway, thus accounting for 
its relatively short half-life and the well-known difficulties associated with its detection 
in unstressed cells/tissues.
Recent evidence has demonstrated that, similar to other BTB family proteins (Pintard e t 
a l ,  2004), Keapl functions as a substrate adaptor for a Cullin-dependent E3 ubiquitin 
ligase complex (Cullinan e t  a l ,  2004; Furukawa e t  a l ,  2005; Kobayashi e t a l ,  2004; 
Zhang e t a l ,  2004). Cullin proteins (in this case CUL3) act as molecular bridges, 
bringing together a substrate adaptor protein and substrate (in this case Keapl and Nrf2, 
respectively) and the ring-box protein ROC1/RBX1, which recruits a ubiquitin-charged 
E2 protein (Pickart, 2001). Immunoprécipitation of Keapl from established cell lines 
reveals association with CUL3 (Cullinan e t  a l ,  2004; Furukawa e t a l ,  2005; Kobayashi 
e t  a l ,  2004; Zhang e t  a l ,  2004; Zhang e t a l ,  2005) and RBX1 (Furukawa et a l ,  2005; 
Zhang e t  a l ,  2004; Zhang e t a l ,  2005), and this association appears to occur via the 
BTB domain of Keapl (Cullinan e t  a l ,  2004; Furukawa e t  a l ,  2005). Inhibition of 
CUL3 function, through expression of a dominant negative CUL3 mutant or targeted 
depletion by RNA interference (RNAi), results in a decrease in Nrf2 turnover, a 
concomitant increase in the basal levels of Nrf2 (Cullinan e t a l ,  2004; Furukawa e t  a l ,  
2005; Zhang e t  a l ,  2004), and induction of an ARE-driven reporter transgene (Cullinan 
e t  a l ,  2004). CUL3 associates with Nrf2, and promotes its ubiquitination (Cullinan e t 
a l ,  2004; Zhang e t  a l., 2004), but only through interaction with Keapl (Cullinan e t  a l ,  
2004). Despite Nrf2 containing 39 lysines, compound mutation of the seven residues 
found within the Neh2 domain effectively abrogates Keapl-directed ubiquitination of
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Nrf2 and increases its steady-state half-life threefold (Zhang et al., 2004). Reversion of 
individual mutant residues back to lysines facilitates Nrf2 ubiquitination (Zhang et al., 
2004), indicating that the targeting of this subset of lysines within the Neh2 domain is 
critical for Keapl-mediated repression ofNrf2.
1.7.4.4 The role of Keapl cysteine residues in the regulation of Nrf2 activity
The human and mouse Keapl proteins contain 27 and 25 cysteines respectively, 
representing 4.3 and 4.0 % of the 624 total amino acids. This compares to the average 
occurrence of cysteine of 2.3 % across all human and mouse proteins (Miseta et al., 
2000). In light of this high cysteine content, and given its inhibitory influence over Nrf2, 
Keapl was suggested as a putative ‘sensor’ for chemical/oxidative stress. Such a view 
was based on the following observations; a) although the array of phase II enzyme- 
inducing molecules is structurally diverse (Table 1.5), almost all are electrophilic 
(Presterà et al., 1993a; Talalay et al., 1988) and share a common capacity for 
modification of sulphydryl groups via alkylation, oxidation or reduction (Dinkova- 
Kostova et al., 2001); b) the potency of benzylidene-alkanone and -cycloalkanone 
Michael acceptors (Dinkova-Kostova et a l, 2001) and heavy metals (Presterà et al., 
1993a) as inducers of phase II enzymes is related to their reactivity towards sulphydryl 
groups; c) the potency of isothiocyanate compounds as inducers of phase II enzymes 
mirrors their non-enzymatic second-order rate constants of conjugation with GSH 
(Presterà et al., 1993a; Zhang, 2001); d) many of the cysteine residues in Keapl have 
low predicted pKa values, and thus high relative reactivities, as they are flanked by one 
or more basic amino acid (arginine, lysine, histidine; Fig. 1.9), which stabilise cysteine 
in the more nucleophilic thiolate form (-S') (Snyder et a l, 1981). Notably, both Cys-273 
and -297 are immediately preceded and followed by basic amino acids, and Cys-151, - 
257, -434 and -613 have two or more basic residues nearby in the primary structure (Fig. 
1.9). Therefore, these residues are anticipated to be highly reactive towards 
electrophiles. This body of evidence implies that Keapl functions as a ‘sensor’ for 
chemical/oxidative stress, and thus governs the adaptive cellular response to such stress.
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Category Example Reference(s)
Alkenes 4-Hydroxynonenal Chen e t al. (2005b) 
Ishii e t al. (2004) 
Zhang e t  al. (2006) 
Zhang e t  al. (2007a)
Arsenicals Arsenite / arsenate
X  ?'
f s —O- o—/|p—O'
O 0
Aono e t  al. (2003) 
Gong e t al. (2002) 
He e t al. (2006)
Pi e t  al. (2003)
Dithiolethiones Oltipraz
0
s
Petzer e t al. (2003) 
Ramos-Gomez e t al. (2001)
Enones Acrolein
„ X ^
Kwak e t  al. (2003) 
Tirumalai e t al. (2002)
Isothiocyanates Sulforaphane
l
H3C^ S^  ^  N=C=S
Fahey e t  al. (2002) 
Jakubikova e t al. (2006) 
Shinkai e t al. (2006) 
Thimmulappa e t al. (2002)
Mercaptans / 
disulphides
Diallyl disulphide Chen e t al. (2004) 
Fisher e t  al. (2007)
Michael acceptors Diethylmaleate
f
^  V X CHi
o
Itoh e ta l .  (1999)
Diphenols / quinones tert-Butylhydroquinone Lee e t  al. (2001b) 
Li e t  al. (2005)
Reactive oxygen / 
nitrogen species
Nitric oxide
: N = 0
Buckley e t al. (2003) 
Dhakshinamoorthy e t  al. (2004) 
Liu e t  al. (2007)
Table 1.6 - Common classes of Nrf2-activating molecules.
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1 MQPEPKLSGA PRSSQFLPLW S§§PEGAGDA VMYASTEg§A EVTPSQDGNR TFSYTLEDHT
61 KQAFGVMNEL RLSQQL|DVT LQVKYEDIPA AQFMAHKWL ASSSPVFKAM FTNGLREQGM
151 171
121 EWSIEGIHP KVMERLIEFA YTASISVGEj |VL§VMNGAV MYQIDSW|a fSDFLVQQLD
226
181 PSNAIGIANF AEQIG|TELH QRAREYIYMH FGEVAKQEEF FNLSBQLAT LISRDDLNV|
241 249 257 273 288 297
241 |esevf§a| i dwv§ye§ pq| rfyvq a l l r a v|(}§altprf lqtqlqPIei lqada§c|dy
319
301 LVQIFQELTL HKPTQAVP^| APKVGRLIYT AGGYFRQSLS YLEAYNPSNG SWLRLADLQV
361 PRSGLAGfW GGLLYAVGGR NNSPDGNTDS SALD|YNPMT NQWSPgASMS VPRNRIGVGV 
434
421 IDGHIYAVGG S|G|l|SSV ERYEPERDEW HLVAPMLTRR IGVGVAVLNR LLYAVGGFDG
513 518
481 tnrlnsae|y ypernewrmi t pmntirsga gv§vl§n|xy a aggydgqdq LNSVERYDVE
541 TETWTFVAPM RHHRSALGIT VHQGKIYVLG GYDGHTFLDS VE§YDPDSDT WSEVTRMTSG 
613
601 RSGVGVAVTM EPC^QIDQQ n|t|
Fig. 1.9 - Mouse Keapl cysteine residues with low predicted pKa values. The full- 
length mouse Keapl protein sequence is shown. Cysteines are highlighted in blue. Basic 
amino acids flanking cysteine residues are highlighted in red. The residue numbers of 
cysteines flanked by basic amino acids are indicated.
1.7.4.4.1 Insights from site-directed mutagenesis studies
The extensive use of site-directed mutagenesis has served to highlight the critical roles 
of certain cysteine residues, particularly Cys-151, -273 and -288, in the function of 
Keapl (Kobayashi et al., 2006; Levonen et al., 2004; Wakabayashi et al., 2004; Zhang 
et al., 2003a). Cys-151, which resides within the BTB domain of Keapl, appears to be 
important for the loss of Nrf2 repression and ubiquitination stimulated by 
chemical/oxidative stress (Zhang et al., 2003a; Zhang et al., 2004). As such, it would 
appear that Cys-151 is not integral to the function of Keapl in the absence of 
chemical/oxidative stress, but is critical to its ability to respond to such conditions. In 
contrast, Cys-273 and -288, both located within the intervening region (IVR) of Keapl,
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are essential for the repressive activity of the protein under basal conditions (Kobayashi 
et a l., 2006; Levonen et a l., 2004; Wakabayashi et a l., 2004; Zhang et a l., 2003a). 
Although mutation of Cys-273 and/or -288 to serine or alanine does not affect the 
association between Keapl and CUL3 (Kobayashi et a l., 2004), it does render Keapl 
unable to direct ubiquitination of Nrf2, inhibit the nuclear accumulation of the 
transcription factor, or repress transactivation of an ARE-driven reporter transgene 
(Kobayashi e t a l., 2006; Levonen e t  a l., 2004; Wakabayashi e t  a l., 2004; Zhang e t  a l., 
2003a). Furthermore, the responsiveness of Nrf2 to known activating molecules is 
diminished or abolished in cells expressing Keapl Cys-273/288 mutants (Levonen e t a l., 
2004; Zhang e t  a l., 2003a). Notably, the mutation of other cysteines within the IVR, N- 
terminal and C-terminal domains has essentially no effect on Keapl function 
(Wakabayashi e t a l., 2004; Zhang e t a l., 2003a). Interestingly, phylogenetic comparison 
of 34 Keapl-like proteins reveals that residues 273 and 288 are cysteines only in the six 
homologues (human, mouse, rat, zebrafish, D ro so p h ila  and mosquito) that are regarded 
as the stress ‘sensing’ sub-family of Keapl-related proteins (Zhang e t  a l., 2003b). 
Therefore, in light of the evidence discussed, the integrities of Cys-151, -273 and -288 
are important for the function of Keapl, and these residues represent plausible targets 
for electrophilic inducers of Nrf2.
1.7.4.4.2 Evidence for the chemical modification of Keapl cysteines
Compelling evidence for the chemical modification of Keapl has been provided through 
the use of biotinylated analogues of Nrf2-activating molecules (Itoh e t a l., 2004; 
Levonen e t  a l., 2004), spectroscopic binding experiments (Dinkova-Kostova e t  a l., 
2002) and mass spectrometry (Dinkova-Kostova e t a l., 2002). Exposure of HepG2 cells 
to the Nrf2-activating NSAID indomethacin alters the thiol oxidation state of 
ectopically-expressed FLAG-tagged Keapl, as demonstrated by a change in isoelectric 
point (pi) of FLAG-Keapl subjected to isoelectric focussing, following reaction with 
iodoacetamide, which introduces a negative charge via alkylation of sulphydryl groups 
(Sekhar e t  a l., 2003). Furthermore, exposure of cells to low micromolar concentrations
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of a biotinylated form of 15-deoxy-Al2,14-prostaglandin J2 (15d-PGJ2), an endogenous 
cyclopentenone molecule with two electrophilic a,P-unsaturated carbonyl moieties, leads 
to the formation of adducts with Keapl and an associated activation of Nrf2 (Itoh et al., 
2004; Levonen et al., 2004).
In the only previous investigation to employ tandem mass spectrometry (MS/MS) as a 
tool to identify the residues in Keapl targeted by a model electrophile, the thiol-reactive 
steroid dexamethasone 21-mesylate (dex-mes) was shown to preferentially modify Cys- 
257, -273, -288 and -297, located within the IVR domain, and the C-terminal Cys-613, 
of recombinant mouse Keapl (Dinkova-Kostova et al., 2002). It is important to note that 
this study used bacterially-expressed, purified Keapl protein in which all cysteines were 
free for adduction, due to prior incubation with the reducing agent dithiothreitol (DTT). 
Hence, this study actually assessed the relative reactivities of Keapl cysteines towards 
different electrophiles, and such in vitro observations cannot be directly extrapolated to a 
cellular context, particularly as it has yet to be demonstrated that, in its native 
environment, all cysteines in Keapl are free sulphydryls. Nevertheless, a Keapl protein 
in which Cys-257, -273, -288 and -297 are mutated to alanine binds dex-mes at 50 % of 
the rate of the wild-type protein in vitro (Wakabayashi et al., 2004). Hence, although the 
current body o f evidence suggests that modification of Keapl cysteines may be an 
important triggering event in the activation of Nrf2, further characterisation of the 
residue selectivities of Nrf2-activating molecules, both in vitro and in a cellular context, 
is required to fully elucidate the role of Keapl cysteine modification in the induction of 
adaptive cell defence.
1.7.4.5 The role of phosphorylation in the regulation of Nrf2 activity
Although the modification of, or at least the potential to modify, cysteine residues 
appears to be a common characteristic amongst Nrf2-activating molecules, the 
stimulation of phosphorylation signalling pathways may also underlie the ability of some 
molecules to induce Nrf2-dependent cell defence. Notably, the phosphatase inhibitor
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okadaic acid, which promotes hyperphosphorylation (Cohen e t  a l ,  1990), stimulates 
Nrf2 accumulation and ARE reporter transgene activation in HepG2 cells (Nguyen e t  
a l ,  2003). Although the majority of studies that have implicated phosphorylation as a 
regulatory influence on Nrf2 function have done so through the use of pharmacological 
inhibitors of specific protein kinases, which attenuate Nrf2 induction by known 
activating molecules, disparate studies have demonstrated direct phosphorylation of 
Nrf2 by protein kinase C (PKC) (Bloom e t a l ,  2003; Huang e t  a l ,  2002; Nguyen e t  a l ,  
2000), extracellular signal-regulated kinase 1 (ERK-1) (Papaiahgari e t a l ,  2006) and 
protein kinase R-like endoplasmic reticulum kinase (PERK) (Cullinan e t  a l ,  2003). In 
addition, several recent reports have described the phosphorylation of Nrf2, at Tyr-568, 
by the tyrosine kinase Fyn, an event that is required for the nuclear export of the 
transcription factor (Jain e t a l ,  2007; Jain e t a l ,  2006; Karman e t a l ,  2006; Salazar e t  
a l ,  2006). Chemical inhibition or RNAi depletion of Fyn, or its upstream regulator 
glycogen synthase kinase 30, appears to attenuate nuclear export of Nrf2 and augment 
ARE-driven gene transactivation (Jain e t  a l ,  2007; Jain e t a l ,  2006; Karman e t  a l ,  
2006; Salazar e t a l ,  2006). Hence, phosphorylation may be an important signalling 
event in both the activation and deactivation of Nrf2, through promotion of both nuclear 
accumulation and export, respectively.
At present, the general importance of phosphorylation in the regulation of Nrf2 activity 
is unclear. For instance, it is not known whether specific inducers stimulate specific 
kinase pathways, perhaps in a cell or species -dependent manner, or whether the 
simultaneous induction of numerous pathways is characteristic of all Nrf2-activating 
molecules. To demonstrate the ambiguity surrounding this issue, Table 1.7 provides a 
summary of protein kinases implicated in ?er/-butylhydroquinone (tBHQ) -induced Nrf2 
activation. In light of these unresolved issues, current consensus regards the 
modification of cysteine residues within Keapl as the most likely trigger for Nrf2- 
dependent cell defence.
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Cell Type Species PKC PI3K p38 ERK Reference
HepG2 Human V Huang e t  al. (2000)
IMR-32 Human V X Lee e t al. (2001a)
Neurons/glia Mouse V Johnson e t  al. (2002)
H4IIE Rat S Kang e t al. (2 0 0 2 )
HepG2 Human X V Nguyen e t  al. (2003)
HepG2 Human V X X X Bloom e t al. (2003)
Neurons/glia Mouse ✓ Kraft e t al. (2004)
Hepatic 
stellate cells Rat
X Reichard e t  al. (2006)
Hepa-lclc7 Mouse s Lee-Hilz e t  al. (2006)
Table 1.7 - Summary of protein kinases implicated in Nrf2 activation by tBHQ.
PKC, protein kinase C; PI3K, phosphatidyl inositol 3-kinase; p38, p38 mitogen- 
activated protein kinase; ERK, extracellular signal-regulated kinase; ■C inhibition affects 
tBHQ-induced activation of the Nrf2-ARE pathway; * inhibition does not affect tBHQ- 
induced activation of the Nrf2-ARE pathway.
1.7.4.6 The ‘hinge and latch’ model of Nrf2 regulation by Keapl
The recently proposed ‘hinge and latch’ mechanism (Tong e t a l ,  2006b) of Nrf2 
regulation advocates the continuous degradation of Nrf2, via its association with Keapl - 
CUL3, under basal conditions. Evidence suggests that Keapl exists as a dimer in 
mammalian cells (McMahon e t a l ,  2006) and binds to Nrf2 in this form (i.e. two 
molecules of Keapl per molecule of Nrf2) (Lo e t a l ,  2006; Tong e t  a l ,  2006a; 
Wakabayashi e t  a l ,  2004; Zipper e t a l ,  2002). Binding via the high-affinity ETGE motif 
(Kobayashi e t a l., 2002), within the Neh2 domain of Nr£2, provides the ‘hinge’ through 
which the transcription factor can move in space relatively freely (McMahon e t  a l ,  
2006). Concomitant binding via the lower affinity DLG motif, also located within the 
Neh2 domain of Nrf2, provides the ‘latch’ that tightly restricts Nrf2 to enable optimal 
positioning of target lysines for conjugation with ubiquitin (McMahon e t a l ,  2006; Tong 
e t a l ,  2006a). In keeping with this, deletion of the ETGE motif attenuates the interaction 
between Nrf2 and Keapl (Furukawa e t a l ,  2005; Kobayashi e t a l ,  2004; Kobayashi e t  
a l ,  2002), resulting in the stabilisation of Nrf2 (Furukawa e t a l ,  2005; Kobayashi e t  a l ,  
2004). In contrast, deletion of the DLG motif, or mutation of residues within, has no
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effect on the association of Nrf2 and Keapl, but renders the latter unable to direct Nrf2 
for degradation (McMahon e t  a l., 2006; McMahon e t a l., 2004), also causing an increase 
in the stability of the transcription factor.
Although chemical inducers are capable of promoting the stabilisation and nuclear 
accumulation of Nrf2, evidence suggests that they do not evoke its complete dissociation 
from, nor impair its ability to associate with, Keapl (Eggler e t  a l., 2005; Kobayashi e t  
a l., 2006; Zhang e t a l., 2003a; Zhang e t a l., 2004). In fact, such Nrf2-activating 
molecules may increase the association of the transcription factor with Keapl (He e t  a l., 
2006; Hong e t  a l., 2005; Kobayashi e t  a l., 2006), most probably due to diminished 
degradation of Keapl-bound Nrf2. Notably, when d e  n ovo  protein synthesis is inhibited 
by cyclohexamide, Nrf2 does not accumulate within the nuclei of cells exposed to 
diethylmaleate (Itoh e t  a l., 2003) or tBHQ (Kobayashi e t a l., 2006). In the ‘hinge and 
latch’ model, the ubiquitination of Nrf2 is attenuated under conditions of 
chemical/oxidative stress (He e t  a l., 2006; Kobayashi e t a l., 2006; Zhang e t a l., 2004), 
and this is thought to be the result of disruption of the Nrf2-Keap 1-CUL3 complex. This 
destabilisation is postulated to occur through loss of DLG motif binding, via a local 
conformational change in the IVR domain provoked by modification of critical 
cysteines, which leads to the improper spatial positioning of target lysines (McMahon e t  
a l., 2006); further evidence for this is required, however. As a result of the 
destabilisation of the Nrf2-Keapl-CUL3 complex, the transcription factor is not directed 
for degradation, but remains associated with Keapl via the ETGE motif. This leads to 
the saturation of Keapl, such that any newly-synthesised Nrf2 can evade Keapl and 
accumulate within the nucleus, leading to the transactivation of ARE target genes (Tong 
e t  a l., 2006b). An overview of the ‘hinge and latch’ model of Nrf2 regulation is 
presented in Figure 1.10. In summary, the antioxidant response pathway, regulated by 
the transcription factor Nrf2, represents a major component of the cellular defensive 
machinery that serves to protect against chemical/oxidative stress.
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B Keapl
Figure 1.10 - Summary of the current ‘hinge and latch’ model of Nrf2 regulation.
(A) In the absence of cellular stress, the Keapl homodimer binds both the ETGE and 
DLG motifs of a single Nrf2 molecule, tightly positioning the transcription factor to 
enable the efficient transfer of ubiquitin, and thus directing Nrf2 for proteasomal 
degradation. (B) Under conditions of chemical/oxidative stress, binding through the low- 
affinity DLG ‘latch’ is perturbed, probably via a conformational change in Keapl 
brought about through modification of one or more cysteine residues, whilst binding 
through the high-affinity ETGE ‘hinge’ is maintained. Although Nrf2 still associates 
with Keapl, the transcription factor is no longer held in the correct position to facilitate 
ubiquitin transfer, and thus Nrf2 is not directed for proteasomal degradation. As a result, 
Keapl becomes saturated by Nrf2, and any newly-synthesised Nrf2 is able to 
accumulate within the nucleus and transactivate cytoprotective genes. Adapted from 
Tong et al. (2006b).
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1.7.5 The coordinated regulation of transcription factor activity
Although the transcription factors highlighted in this section regulate the activity of 
discrete pathways in their own right, there is significant overlap between certain aspects 
of these pathways, particularly the signalling mechanisms that control their activation 
and the target genes that are induced as a result of an increase in transactivation. For 
example, GCL has been reported to be regulated by Nrf2, NF-kB and AP-1 (Lu, 1999). 
As such, the relative actions of several transcription factors may have a significant 
influence on the response, and eventual fate, of a cell following exposure to a given 
stimulus. Intriguingly, a number of transcription factors involved in the adaptive 
response to cellular stress appear to share a common means of control - the targeted 
ubiquitination, and consequent proteasomal degradation, of specific regulatory 
components, which represents a molecular switch that facilitates the rapid 
activation/inactivation of cytoprotective pathways (for a review, see Tong et al., 2006b). 
For example, as discussed in section 1.7.4.3, Nrf2 is directed for proteasomal 
degradation in the absence of cellular stress, via association with its cytosolic repressor, 
Keapl. A similar mechanism inhibits the basal activity of HIF-1; the onset of hypoxia 
inhibits the 0 2 -dependent hydroxylation of HIF-1, perturbing recognition by its specific 
E3 ubiquitin ligase complex, and thus enabling an increase in its cytoprotective activity 
(Kallio et al., 1999). On the other hand, the onset of ubiquitination signals the activation 
of the NF-kB pathway; upon the receipt of appropriate stimuli, NF-kB escapes 
repression following the ubiquitination and destruction of IkB (Hayden et al., 2004). 
Hence, the transcriptional regulation of highly coordinated and, in some instances, 
overlapping signalling pathways endows cells with a multifaceted and inducible defence 
system.
1.8 THESIS AIMS
In light of the critical role played by transcription factors in the defence against toxic 
insult, an understanding of the molecular mechanisms that govern the adaptive response
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to chemical/oxidative stress is vital to gain insights into the signalling events that 
determine the progression, and outcome, of adverse drug reactions such as DILI. The 
Nrf2-ARE pathway represents the major regulator of inducible cell defence, and 
deficiencies in this pathway may have a significant impact on the pathogenesis of DILI. 
As such, this thesis aims to investigate the role o f the Nrf2-ARE pathway in DILI, by 
addressing key questions, namely; a) how important is the Nrf2-ARE pathway in the 
regulation of basal and inducible hepatic cell defence? b) is the Nrf2-ARE pathway 
activated by molecules that are known to cause DILI? c) do Nrf2 activators selectively 
modify cysteines within Keapl? d) does modification of Keapl correlate with the 
activation of Nrf2 in cells? e) is there overlap between the Keapl cysteine residues 
targeted by structurally-distinct Nrf2-activating molecules?
By increasing our appreciation of the role of the Nrf2-ARE pathway in the protection 
against DILI, it may be possible to develop a predictive toxicity screen, based on the 
activation of certain aspects of the pathway, for example, the adduction of Keapl 
cysteines. In addition, the promise of manipulating the Nrf2-ARE pathway as a 
therapeutic strategy for the prevention and/or treatment of certain diseases is highly 
dependent upon advances in our understanding of the biochemistry that underlies this 
versatile cytoprotective system. Overall, therefore, this thesis aims to broaden our 
awareness of the role of the Nrf2-ARE pathway in the protection against DILI.
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CHAPTER 2
Cell defence responses to N-acetyl-/j-benzoquinoneimine 
and structurally distinct electrophiles
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2.1 INTRODUCTION
Mammalian cells can defend themselves against chemical and oxidative stress via the 
inducible expression of detoxification enzymes and antioxidant proteins (Prestera e t a l ,  
1993b). A major regulator of this adaptive response is the transcription factor Nrf2, 
which controls the inducible expression of several cytoprotective genes (for a review, 
see Kensler e t a i ,  2007), through its action on the ARE regulatory motif (Wasserman e t  
a l ,  1997). Under non-stressed conditions, the activity of Nrf2 is repressed by Keapl 
(Itoh e t a l ,  1999), a cysteine-rich protein which acts as a substrate adaptor for CUL3- 
dependent ubiquitination of Nrf2 (Kobayashi e t a l ,  2004), thereby directing the 
transcription factor for proteasomal degradation (McMahon e t  a l ,  2003). Under 
conditions of chemical or oxidative stress, the negative regulation of Nrf2 is disrupted, 
enabling it to accumulate within the nucleus and transactivate target genes (Itoh e t  a l ,
2003) .
Research from this laboratory has previously shown that the Nrf2-ARE pathway is 
activated in mouse liver following administration of hepatotoxic and non-hepatotoxic 
doses of paracetamol, a model metabolism-dependent hepatotoxin (Goldring e t a l ,
2004) . Paracetamol-induced hepatotoxicity, the single biggest cause of acute liver failure 
in both the UK (Davem e t  a l ,  2006) and USA (Larson e t a l ,  2005), is inextricably 
linked to the formation of a chemically reactive metabolite, NAPQI (Fig. 2.1), which 
causes chemical and oxidative stress, and inhibits the function of critical proteins within 
hepatocytes (for a review, see Park e t  a l ,  2005a). Whilst the molecular mechanisms 
underlying the activation of Nrf2 by chemical inducers are yet to be fully defined, it is 
clear that the Nrf2-ARE pathway is responsive to numerous chemicals that are all 
chemically reactive and capable of modifying sulphydryl groups (Dinkova-Kostova e t 
a l ,  2001). Given that NAPQI is known to react with cysteine thiols in v itro  and in v ivo  
(Hoffmann e t a l ,  1985a; Hoffmann e t a l ,  1985b), a plausible hypothesis to explain the 
activation of Nrf2 following paracetamol administration is that chemical modification of 
Keapl cysteines by NAPQI perturbs its ability to repress the transcription factor.
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The aims of the studies presented in this chapter were, firstly, to validate the Hepa-lclc7 
mouse liver cell line as a suitable model system for investigating the molecular 
regulation of the Nrf2-ARE pathway, using an RNAi approach to deplete cellular levels 
of Nrf2 or Keapl, and assess the effect of these changes on cell defence. Following the 
functional validation of Hepa-lclc7, this cell line was used to examine the ability of the 
synthetic metabolite NAPQI to activate Nrf2 and stimulate adaptive cell defence; the 
latter was assessed by measuring levels of Gclc messenger RNA (mRNA) and GSH 
following direct exposure to the electrophile. The chemical, biochemical, and 
toxicological aspects of Nrf2 activation by NAPQI were further explored through the 
use of a panel of structurally distinct electrophiles. Specifically, two cysteine-reactive 
molecules were employed; 2,4-dinitrochlorobenzene (DNCB; Fig. 2.1), an aromatic 
electrophile that reacts with nucleophiles via bimolecular nucleophilic substitution 
(Sn2), leading to displacement of the halogen leaving group (chlorine), and 15-deoxy-A- 
(l2 l4)-prostaglandin J2 (15d-PGJ2; Fig. 2.1), a cyclopentenone that reacts with 
nucleophiles via 1,4 addition. In order to explore the importance of cysteine reactivity 
and GSH depletion in the activation of Nrf2, these cysteine-reactive molecules were 
used in conjunction with trimellitic anhydride (TMA; Fig. 2.1), which acylates the 
amino group of lysine. As TMA lacks the cw-carbon-carbon double bond present in 
some anhydride molecules, the irreversible reaction with a sulphydryl group is not 
possible (de la Escalera et al., 1989). Therefore, TMA is non-reactive towards cysteines 
in proteins and the sulphydryl group of GSH.
Fig. 2.1 - Chemical structures of NAPQI, DNCB, 15d-PGJ2 and TMA.
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2.2 METHODS
2.2.1 Materials and reagents
Nunclon A cell culture flasks, dishes and multi-well plates, and LabTek II chamber 
slides were from Nalge-Nunc International (c/o VWR International, Lutterworth, UK). 
DMEM and trypsin/versene were from Lonza Bioscience (Wokingham, UK). The 
Wilovert D6330 light microscope was from Will-Wetzlar (Wetzlar, Germany). 15d-PGJ2 
was from Alexis Biochemicals (Lausen, Switzerland). The rabbit anti-goat HRP- 
conjugated secondary antibody was from Dako (Ely, UK). The rabbit anti-sheep HRP- 
conjugated secondary antibody was from Calbiochem (Nottingham, UK). Protein assay 
dye reagent, Precision Plus protein Kaleidoscope standards, non-fat dry milk and the 
GS-710 calibrated imaging densitometer were from Bio-Rad (Hemel Hempstead, UK). 
FBS, NuPAGE Novex 4-12 % Bis-Tris gels, NuPAGE LDS sample buffer, sample 
reducing agent and antioxidant, the XCell Surelock mini-cell, the iBlot gel transfer 
device and transfer stacks, Alexa Fluor 594, Hoechst 33258, pCMV-SPORT p- 
galactosidase, Lipofectamine 2000 and RNasezap were from Invitrogen (Paisley, UK). 
TotalLab 100 software was from Nonlinear Dynamics (Newcastle, UK). Vectashield 
was from Vector Laboratories (Peterborough, UK). The SP2 AOBS confocal 
microscope was from Leica Microsystems (Milton Keynes, UK). The pGL3B- 
\0l6/nqo5'-luc reporter plasmids and rabbit anti-mouse Nrf2 primary antibody were 
kindly donated by Prof. John Hayes (Biomedical Research Centre, University of 
Dundee, UK). The sheep anti-Gclc primary antibody was kindly donated by Dr. Leslie 
McLellan (Biomedical Research Centre, University of Dundee, UK). GeneJuice was 
from Novagen (Nottingham, UK). Reporter lysis 5X buffer, the P-galactosidase Enzyme 
Assay System, the Bright-Glo Luciferase Assay System and QuantiLum recombinant 
luciferase were from Promega (Southampton, UK). The Cytotoxicity Detection Kit was 
from Roche Diagnostics (Burgess Hill, UK). The Nrf2, Keapl and control siRNA 
duplexes were from Dharmacon (Lafayette, USA). The DU640 UV spectrophotometer 
was from Beckman Coulter (High Wycombe, UK). The TaqMan Reverse Transcription 
Kit, universal PCR master mix, and gene expression assay probes, MicroAmp optical
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96-well reaction plates, the GeneAmp 9700 PCR system and the ABI PRISM 7000 
sequence detection system were from Applied Biosystems (Warrington, UK). Absolute 
QPCR seals and the adhesive seal applicator were from ABgene (Epsom, UK). The 
FL600 fluorescence microplate reader was from BioTek Instruments (Winooski, USA). 
The MRX microplate reader was from Dynatech Laboratories (Billingshort, UK). The 
goat anti-Keapl primary antibody was from Santa Cruz Biotechnology (Heidelberg, 
Germany). Western Lightening chemiluminescence reagents were from PerkinElmer, 
Beaconsfield, UK. Hyperfilm ECL was from Amersham (Little Chalfont, UK). 
Penicillin-streptomycin solution, Trypan Blue solution, NAPQI, DNCB, TMA, DMSO, 
Hank’s balanced salt solution, BSA, spermidine, spermine, protease inhibitor cocktail, 
MOPS, the rabbit anti-actin primary antibody, the goat-anti rabbit HRP-conjugated 
secondary antibody, the Kodak BioMax MS intensifying screen, Kodak developer and 
fixer solutions, Ponceau S solution, Tween 20, PBS tablets, paraformaldehyde, DTNB, 
GSH, GSH reductase, NADPH, sulphosalicylic acid, chloroform DNase/RNase-free 
water and TRI reagent were from Sigma-Aldrich (Poole, UK). All other reagents were of 
analytical or molecular grade, and were from Sigma-Aldrich.
2.2.2 Cell culture
The mouse hepatoma cell line Hepa-lclc7, which has been employed by others in 
previous studies of the Nrf2-ARE pathway (Jowsey et al., 2003; Me Walter et al., 2004; 
Petzer et al., 2003), was maintained in conventional growth medium (Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 584 mg/L L-glutamine, 10 % 
fetal bovine serum (FBS), 100 U/mL penicillin and 100 pg/mL streptomycin). Cells 
were maintained in a humidified incubator, at 37 °C, in a 5 % carbon dioxide (C 02) 
atmosphere. Cells were grown in 75 cm2 Nunclon A culture flasks and routinely 
passaged every 3-4 days, at around 80 % confluency. Following a single wash with 
unsupplemented DMEM, cells were incubated for 1 min with 5 mL trypsin/versene at 
room temperature. Following the removal of the trypsin/versene, the cells were 
incubated for 5 min at 37 °C, sufficient time to enable the complete detachment o f cells
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from the flask surface. Detached cells were resuspended in 10 mL growth medium and 
passed three times through a 21-gauge needle, using a 10 mL syringe, to break up any 
cell clumps. For continuation, cells were re-seeded at a cells:growth medium ratio of 
1:4.
For the analysis of nuclear Nrf2 content, cells were seeded onto 56.7 cm2 Nunclon A 
culture dishes, at 5 x 106 cells/dish, in a total volume of 10 mL growth medium, and 
allowed to grow for 24 h. To ensure that an accurate number of cells were seeded, cells 
were counted using Trypan Blue solution (0.4 % w/v) and a haemocytometer. Briefly, 
cells were detached from the surface of a culture flask, as described above. A 45 pL 
aliquot of cells was combined with 5 pL Trypan Blue solution. 10 pL of this mixture 
was transferred to the edge of a haemocytometer and allowed to spread evenly across the 
surface by capillary action. Cells were visualised using the 20X objective of a Wilovert 
D6330 light microscope. Viable cells (those that did not take up the Trypan Blue dye) 
within the central 5 x 5  square (equivalent to 0 .1  mm3) were counted and the original 
cell density was calculated as follows:
Number o f  cells counted x 1.1 (to correct fo r  dilution with Trypan Blue solution) = cells
3 3
per 0.1 mm x 10,000 = cells per 1 cm = cells per 1 mL
2.2.3 Treatment of cells with electrophiles
Under sterile conditions, Hepa-lclc7 cells, seeded onto 56.7 cm2 Nunclon A culture 
dishes at 5 x 106 cells/dish the previous day, were washed once with unsupplemented 
DMEM, and then 9.95 mL unsupplemented DMEM was added to each dish. NAPQI, 
DNCB and TMA were dissolved, at 200x the required final concentration, in dimethyl 
sulphoxide (DMSO). As 15d-PGJ2 was supplied pre-dissolved in methyl acetate, the 
solvent was removed by evaporation, under a gentle stream of nitrogen gas, immediately 
prior to each treatment. The solute was then reconstituted in DMSO, at 200x the 
required final concentration. To appropriate dishes of Hepa-lclc7 cells, 50 pL DMSO
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or electrophile were added (i.e. 1:200 dilution). The overall concentration of DMSO in 
the cell culture medium was 0.5 % (volume/volume; v/v). The cells were then returned 
to a humidified incubator (37 °C, 5 % CO2) for the indicated period of time.
2.2.4 Preparation of cytosolic/nuclear fractions
Following treatment, cells were washed once with Hank’s balanced salt solution, 
removed from the surface of the culture dish by scraping and resuspended in 1 mL 
buffer A (lysis; 50 mM NaCl, 10 mM 4-(2-hydroxyethyl)-l-piperazineethanesulfonic 
acid (HEPES), 1 mM ethylenediaminetetraacetic acid (EDTA), 0.5 mM sucrose, 0.5 mM 
spermidine, 0.15 mM spermine, 10 mM P-mercaptoethanol, 0.2 % (v/v) protease 
inhibitor cocktail, 0.2 % (v/v) Triton X-100). Lysates were clarified by centrifugation at 
1150 g, 4 °C, for 5 min, and the supernatant retained as the cytosolic fraction. For the 
extraction of nuclear proteins, the pellet was washed in 0.5 mL buffer B (wash; 25 % 
(v/v) glycerol, 50 mM NaCl, 10 mM HEPES, 1 mM EDTA, 0.5 mM spermidine, 0.15 
mM spermine, 10 mM P-mercaptoethanol, 0.2 % protease inhibitor cocktail) and 
centrifuged at 1150 g, 4 °C, for 5 min. Following removal of the supernatant, the pellet 
was resuspended in 0.1 mL buffer C (extraction; 0.35 M NaCl, 25 % (v/v) glycerol, 10 
mM HEPES, 1 mM EDTA, 0.5 mM spermidine, 0.15 mM spermine, 10 mM P- 
mercaptoethanol, 0.2 % protease inhibitor cocktail) and incubated on ice for 30 min, to 
facilitate the osmotic extraction of nuclear proteins, which were isolated following a 
final centrifugation at 1150 g, 4 °C, for 5 min. All subcellular fractions were stored at - 
80 °C prior to analysis by Western blot.
2.2.5 Determination of protein content
The total protein content of subcellular fractions was determined using Protein Assay 
Dye Reagent, in accordance with the manufacturer’s instructions. Based on the method 
of Bradford (1976), this assay relies on the binding of Coomassie Brilliant Blue G-250
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dye to basic and aromatic amino acids, an event that results in a change in colour of the 
dye (red to blue), and a consequent change in absorbance maximum from 465 to 595 
nm. Hence, the increase in absorbance at 570 nm, measured using a MRX microplate 
reader, is proportional to the amount of bound dye, and thus to the amount of protein 
present. A standard curve, ranging from 0.25-5 pg bovine serum albumin (BSA), was 
used to calculate sample protein content.
2.2.6 Western blot analysis
Nuclear (5 pg) or cytosolic (15 pg) protein fractions were denatured via the addition of 5 
pL loading buffer (70 % (v/v) NuPAGE sample loading buffer, 30 % (v/v) NuPAGE 
reducing agent) and incubated at 80 °C for 5 min. Samples were loaded onto pre-cast 4- 
12 % NuPAGE Novex bis-tris polyacrylamide gels, alongside PrecisionPlus protein 
Kaleidoscope standards. Samples were resolved by electrophoresis in a XCell Surelock 
mini-cell, using a 3-(N-morpholino)propanesulphonic acid (MOPS) running buffer (50 
mM MOPS, 50 mM Tris base, 3.5 mM sodium dodecyl sulphate, 1 mM EDTA, 0.25 % 
(v/v) NuPAGE antioxidant), at 90 V for 10 min, followed by 60 min at 170 V. Separated 
proteins were transferred to nitrocellulose membranes using the iBlot dry blotting 
system, in accordance with the manufacturer’s instructions. To ensure the transfer 
process was successful, membranes were stained for 10 sec with Ponceau S solution. 
Membranes were blocked for 15 min, on an orbital shaker, in tris-buffered saline (TBS; 
0.15 M NaCl, 25 mM Tris base, 3 mM KC1, pH 7.0) containing 0.1 % (v/v) Tween 20 
and 10 % (weight/volume; w/v) non-fat dry milk. Blocked membranes were probed for 1 
h with rabbit anti-mouse Nrf2 (1:5000 in TBS-Tween containing 2 % (w/v) BSA), goat 
anti-Keapl (1:2000 in TBS-Tween containing 2 % (w/v) non-fat dry milk) or sheep anti- 
Gclc (1:5000 in TBS-Tween containing 2 % (w/v) non-fat dry milk) primary antisera. 
Following several washes in TBS-Tween, membranes were probed for 1 h with goat 
anti-rabbit (1:10,000 in TBS-Tween containing 2 % (w/v) BSA), rabbit anti-goat 
(1:3000 in TBS-Tween containing 2 % (w/v) non-fat dry milk) or rabbit anti-sheep 
(1:10,000 in TBS-Tween containing 2 % (w/v) non-fat dry milk) horseradish peroxidase
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(HRP) -conjugated secondary antisera. Immunoblots were visualised with Western 
Lightening chemiluminescence reagents and exposed to Hyperfilm ECL under darkroom 
conditions, using a Kodak BioMax MS intensifying screen. Blots were developed using 
Kodak developer and fixer solutions. In order to ensure equal loading across gels, 
membranes were probed with rabbit anti-P-actin primary (1:5000 in TBS-Tween 
containing 2 % (w/v) BSA) and goat anti-rabbit HRP-conjugated secondary antisera. 
Recombinant mouse Nrf2 or mouse Keapl, or mouse liver lysate (Gclc standard), were 
loaded as standards to confirm antibody specificity. Films were scanned using a GS-710 
calibrated imaging densitometer, immunoreactive band volumes were quantified using 
TotalLab 100 software, in accordance with the manufacturer’s instructions, and 
normalised to P-actin.
2.2,7 Confocal microscopy
Hepa-lclc7 cells were seeded onto Lab-TEK II chamber slides, at 2 x 105 
cells/chamber, 24 h prior to treatment. Treatments were performed essentially as 
described in section 2.2.3. Following treatment, cells were washed via 2 x 3  min 
incubations with 0.5 mL of IX phosphate-buffered saline (PBS; 0.137 M NaCl, 10 mM 
Na2HPC>4, 1.8 mM KH2PO4, 2.7 mM KC1, pH 7.4). The removal of media from the 
chambers was achieved by inverting the slide and gently tapping onto a paper towel, to 
avoid dislodging cells through repeated pipetting. Cells were fixed in 0.5 mL fresh 4 % 
(w/v) paraformaldehyde at 4 °C for 30 min, followed by 4 x 3 min washes with 0.5 mL 
PBS. Fixed cells were permeabilised with 0.3 mL of 0.2 % (v/v) Triton X-100, quenched 
with 0.3 mL of 0.1 M glycine and blocked with 0.3 mL of 10 % (v/v) FBS, for 10 min 
each. Cells were then incubated with 0.2 mL of 2 % (v/v) FBS containing anti-mouse 
Nrf2 antiserum (1:500) at 37 °C for 1 h. Following 3 x 3  min washes with 0.5 mL PBS, 
cells were incubated with 0.2 mL of 2 % (v/v) FBS containing 8 pg/mL Alexa Fluor 
594-conjugated goat anti-rabbit IgG, at 37 °C for 1 h. To prevent bleaching of the 
fluorescent signal, during this and subsequent steps, the chamber slide was wrapped in 
aluminium foil. Cells were washed for 3 x 3 min with 0.5 mL PBS and nuclear DNA
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was counterstained at room temperature, for 10 min, with 0.2 mL PBS containing 2 
pg/mL Hoechst 33258. Cells were washed with 0.5 mL PBS for 3 x 3 min. Chambers 
were carefully detached from slides, using the splitting tool provided by the 
manufacturer, and slides were allowed to dry at room temperature for 5 min. Coverslips 
were mounted using VectaShield hard-set medium, in accordance with the 
manufacturer’s instructions. Slides were wrapped in aluminium foil and stored at 4 °C 
prior to confocal analysis. Immunofluoresence was visualised using a SP2 AOBS 
confocal microscope, with a 63X 1.4 oil objective. A total of five separate fields were 
evaluated for each treatment group (representative fields are presented).
2.2.8 Analysis of mouse N q o l ARE reporter transgene activity
Hepa-lclc7 cells were seeded onto 96-well plates, at 2 x 104 cells/well, 24 h prior to 
transfection. Cells were then transfected for 24 h with 100 ng of either pGL3B- 
\0\6/nqo5'-luc wild-type reporter plasmid or a mutant plasmid containing an entirely 
scrambled ARE sequence, as previously described by Nioi et al. (2005). pGL3B- 
\0\6/nqo5'-luc represents the pGL3 basic luciferase vector into which a 1016 bp 5’- 
upstream region of the mouse Nqol gene has been subcloned, enabling ARE-mediated 
regulation of modified firefly luciferase gene expression. To control for any differences 
in the amount of reporter plasmid DNA transfected between wells, all cells were co­
transfected with 100 ng of pCMV SPORT-p-galactosidase plasmid, in which the E. coli 
P-galactosidase gene is under the control of the upstream cytomegalovirus (CMV) 
promoter. Transfections were performed using GeneJuice reagent, in accordance with 
the manufacturer’s instructions. For treatments, cells were washed once with 
unsupplemented DMEM, and then 199 pL unsupplemented DMEM was added to each 
well. NAPQI was dissolved, at 200x the required final concentration, in dimethyl 
sulphoxide (DMSO) and 1 pL was added to appropriate wells (i.e. 1:200 dilution). The 
overall concentration of DMSO in the cell culture medium was 0.5 % (v/v). The cells 
were then returned to a humidified incubator (37 °C, 5 % CO2) for the indicated period 
of time. Following treatment, the media was removed and cells were lysed in situ with
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0.1 mL of IX Reporter Lysis Buffer. Lysates (20 pL) were transferred to a white 96-well 
plate and 20 pL Bright-Glo Luciferase Assay Reagent was added. 15 pg QuantiLum 
recombinant firefly luciferase was used as a positive control for the assay. Air bubbles 
were removed via brief centrifugation of the plate at 3000 revolutions per minute (rpm). 
Firefly luciferase activity was measured immediately on a FL600 fluorescence 
microplate reader, adapted to measure luminescence. Blank readings were obtained from 
wells containing IX Reporter Lysis Buffer and Bright-Glo Reagent, and subtracted from 
sample readings. The P-Galactosidase Enzyme Assay System was used to measure 0- 
galactosidase activity within the lysates; a separate 20 pL aliquot of each lysate was 
transferred to a clear 96-well plate, combined with 20 pL of 2X Assay Buffer, and 
incubated at 37 °C for 30 min. 1 unit (U) recombinant p-galactosidase was used as a 
positive control for the assay. The reaction was stopped by the addition of 60 pL of 1 M 
sodium carbonate. Air bubbles were removed via brief centrifugation of the plate at 
3000 rpm. P-Galactosidase activity was measured at 405 nm, on a MRX microplate 
reader. Blank readings were obtained from wells containing IX Reporter Lysis Buffer 
and IX Assay Buffer, and subtracted from sample readings. Luciferase activity was 
normalised to P-galactosidase activity for all samples, to control for transfection 
efficiency.
2.2.9 Determination of total glutathione levels
Total GSH content was quantified using the 5,5'-dithiobis(2-nitrobenzoic acid) (DTNB) 
-GSH reductase recycling method, as previously described by Vandeputte et al. (1994), 
whereby:
1) 2GSH + DTNB -*■ GSSG + TNB
2) GSSG + NADPH + PC —> 2GSH + NADP+ (catalysed by GSH reductase)
In this method, GSH is oxidised by DTNB to yield GSSG and the 5-thio-2-nitrobenzoic 
acid (TNB) chromophore, which has an absorbance maximum of 412 nm. Thus, the rate
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of formation of TNB, as followed at 405 nm, is proportional to the sum of GSH and 
GSSG present in each sample. Briefly, cells in 24-well plates (seeded at 2 x 105 
cells/well) were harvested by scraping in 0.125 mL of 10 mM HC1. Appropriate aliquots 
were taken to enable the determination of total protein content, as described in section 
2.2.5. To the remaining samples, sulphosalicylic acid was added to a final concentration 
of 1.3 % (w/v), and protein precipitation was facilitated by incubating on ice for 10 min. 
Protein was pelleted by centrifugation at 18,000 g for 5 min. 20 pL supernatant was 
transferred to a clear 96-well plate, and combined with 20 pL assay buffer (0.143 M 
NaH2P 0 4, 6.3 mM EDTA, pH 7.4) to neutralise pH. Samples were incubated, at room 
temperature, with 0.2 mL assay reagent (1.0 mM DTNB, 0.34 mM NADPH, in 0.143 M 
NaH2P 0 4, 6.3 mM EDTA, pH 7.4) for 5 min. The enzymatic reaction was initiated by 
the addition of 0.35 U GSH reductase and followed kinetically at 405 nm for 5 min on a 
MRX microplate reader. The rate of TNB formation was calculated as the change in 
absorbance min'1. Sample GSH concentrations were calculated via reference to a 
standard curve ranging from 1-50 nmol/mL GSH. The GSH concentration for each 
sample was normalised to total protein content.
2.2.10 Determination of lactate dehydrogenase leakage
Overt cytotoxicity was assessed by measuring the leakage of the cytoplasmic enzyme 
lactate dehydrogenase (LDH) into the cell culture media. LDH reduces NAD+ to NADH 
+ H+, via the oxidation of lactate to pyruvate. The transfer of 2H from NADH + H+ to 
the tétrazolium salt 2-[4-iodophenyl]-3-[4-nitrophenyl]-5-phenyltetrazolium chloride by 
a catalyst (diaphorose) yields a formazan dye with an absorbance maximum of 500 nm:
Lactate
LDH
Pyruvate
NAD+ NADH + H+
Formazan salt
Diapharose
Tétrazolium salt
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Thus, the amount of formazan formed over time is directly proportional to the LDH 
activity in the culture media, and therefore correlates to the degree of cell death. As the 
leakage o f LDH is particularly indicative of the degree of membrane damage, it is 
typically used as a marker o f cellular necrosis.
Hepa-lclc7 cells were seeded onto 96-well plates at 1 x 104 cells/well and treated as 
described in section 2.2.3. Following treatment, the plate was briefly centrifuged at 3000 
rpm to pellet cells, and the cell-free culture media was removed to a new 96-well plate. 
Cells were lysed via the addition of 40 pL DMEM containing 2 % (v/v) Triton X-100, 
followed by centrifugation at 3000 rpm for 5 min. 50 pL cell-free culture media (diluted 
1:4 in DMEM) and cell lysate (diluted 1:20 in DMEM) were separately transferred to 
new 96-well plates. LDH leakage was measured using a Cytotoxicity Detection Kit; 50 
pL assay reagent (1 pL catalyst per 45 pL dye solution) was then added to each well. 
Following incubation in the dark for 30 min, air bubbles were removed via brief 
centrifugation of the plates at 3000 rpm. Formazan salt formation was measured at 490 
nm on a MRX microplate reader. Blank readings were obtained from wells containing 
50 pL DMEM, and subtracted from sample readings. LDH leakage from cells into the 
culture media (extracellular) is expressed as a percentage of total LDH (intracellular plus 
extracellular).
2.2.11 RNA interference
Depletion of Nrf2 or Keapl in Hepa-lclc7 cells was achieved by RNAi, which exploits 
a natural cellular process that facilitates the post-transcriptional silencing of specific 
genes, through the targeted degradation of mRNA (for a review, see Novina et al., 
2004). RNAi is typically triggered when a cell encounters a long double-stranded RNA 
(dsRNA) molecule (Fig. 2.2) (Fire et al., 1998). The dsRNA is cleaved into smaller 
fragments, called short interfering RNAs (siRNA), by the enzyme Dicer (Bernstein et 
al., 2001). siRNA molecules are 21-23 nucleotide strands of dsRNA, with symmetric 3’ 
overhangs of 2-3 nucleotides in length, and 5’-phosphate and 3’-hydroxyl groups
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(Elbashir et al., 2001b). The sense strand of the siRNA is degraded, whilst the antisense 
strand becomes incorporated into an RNA-induced silencing complex (RISC), which 
then targets complementary mRNA sequences for destruction (Fig. 2.2) (Hammond et 
al., 2000). As a result of this mRNA destruction, no protein is translated. Hence, gene 
expression is effectively silenced in a post-transcriptional manner. As such, RNAi has 
proved to be a major advance in the field of biomedical research, and the targeted 
silencing of a large number of genes is now possible through the widespread availability 
of synthetic siRNA molecules (Elbashir et al., 2001a).
U_L l l l l l l l
1
mRNA degradation
Post-transcriptional 
gene silencing
Fig. 2.2 - Overview of RNAi pathway. The endogenous RNAi pathway is typically 
triggered when a cell encounters a long double-stranded RNA (dsRNA) molecule. The 
dsRNA is cleaved into smaller short interfering RNAs (siRNA) by the enzyme Dicer. 
The sense strand of the siRNA is degraded, whilst the antisense strand becomes 
incorporated into an RNA-induced silencing complex (RISC), which then targets 
complementary mRNA sequences for destruction. As a result of this mRNA destruction, 
no protein is translated, and gene expression is effectively silenced in a post- 
transcriptional manner.
Predesigned siRNA duplexes targeted against mouse Nrf2 (si-Nrf2) or Keapl (si- 
Keapl), and a scrambled, non-targeting control siRNA duplex (si-Con), were purchased 
from Dharmacon’s siGENOME library. The siRNA duplex sequences were as follows;
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si-Nrf2 #1 sense 5’-GCA AGA AGC CAG AUA CAA AUU-3’, antisense 5’-P UUU 
GUA UCU GGC UUC UUG CUU-3’; si-Nrf2 #2 sense 5’-AGA CUC AAA UCC CAC 
CUU AUU-3’, antisense 5’-P UAA GGU GGG AUU UGA GUC UUU-3’; si-Keapl #1 
sense 5’-GAA GCA AAU UGA UCA ACA AUU-3\ antisense 5’-P UUG UUG AUC 
AAU UUG CUU CUU-3’; si-Keapl #2 sense 5’-GCU AUG ACC CGG ACA GUG 
AUU-3’, antisense 5’-P UCA CUG UCC GGG UCA UAG CUU-3’, si-Con sense 5’- 
AUG UAU UGG CCU GUA UUA GUU-3’, antisense 5’-P CUA AUA CAG GCC 
AAU ACA UUU-3’. Hepa-lclc7 cells were seeded onto 12-well plates at 2.5 x 105 
cells/well for RNA isolations, or 24-well plates at 1.25 x 105 cells/well for all other 
experiments, and allowed to grow for 6  h. Cells were transfected with 10 nM siRNA for 
48 h, using Lipofectamine 2000, in accordance with the manufacturer’s instructions.
2.2.12 RNA isolation
Total RNA was isolated from Hepa-lclc7 cells using TRI reagent, an acidic solution 
containing guanidinium thiocyanate, sodium acetate, phenol and chloroform, which 
enables centrifugal separation of RNA from DNA and protein {Chomczynski, 1987 
#724}. All surfaces and equipment were rendered RNase-free, by wiping with 
RNasezap, prior to the isolation of RNA. Briefly, cells in 12-well plates were harvested 
in 0.5 mL TRI reagent per well, transferred to RNase-free microcentrifuge tubes and 
incubated at room temperature for 5 min. Working inside a laminar flow cabinet, 0.1 mL 
chloroform was added to all samples, which were then vortexed for 15 sec and incubated 
at room temperature for 2 min. Following centrifugation at 12,000 g, 4 °C, for 15 min, 
the RNA-containing clear aqueous phase was removed to a new RNase-free 
microcentrifuge tube, combined with 0.25 mL isopropyl alcohol, and incubated at room 
temperature for 10 min, to precipitate RNA. Following centrifugation at 12,000 g, 4 °C, 
for 10 min, the RNA pellet was washed in 0.5 mL DNase/RNase-free water containing 
75 % (v/v) ethanol. RNA was pelleted at 12,000 g, 4 °C, for 5 min; the supernatant was 
discarded and the pellet allowed to air-dry, at room temperature, for 10 min. The dried
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RNA pellet was reconstituted in 25 pL DNase/RNase-free water and incubated at 55 °C 
for 2 min. RNA was stored at -80 °C until required.
2.2.13 Determination of RNA quantity and purity
RNA concentration and purity were assessed using a DU640 ultraviolet (UV) 
spectrophotometer. RNA was diluted 1:100 in IX TE buffer (10 mM Tris base, 1 mM 
EDTA, pH 7.5); the latter was used to blank the spectrophotometer. From the average of 
triplicate measurements, and given that an absorbance of 1.0 at 260 nm equates to 40 
pg/mL RNA, the concentration of RNA in each sample was determined as follows:
Absorbance at 260 nm x 100 (to correct fo r  dilution) x  40 = RNA concentration (pg/mL)
The purity of RNA in each sample was determined via reference to the 260:280 nm 
ratio, as protein is detected at 280 nm. RNA samples with a 260:280 nm ratio of below
1.7 were rejected as impure.
2.2.14 cDNA synthesis
RNA was reverse-transcribed to cDNA using the TaqMan Reverse Transcription Kit. 
Reactions (20 pL) contained 2 pg RNA, 0.7X reverse transcription buffer, 3.6 mM 
MgCh, 2.9 mM deoxyribonucleotide triphosphate (dNTP), 1.8 pM random hexamers, 
14.4 U RNase inhibitor and 36.0 U RTase multiscribe. Reverse-transcription was 
performed using the GeneAmp 9700 polymerase chain reaction (PCR) system, with 
reactions held for 10 min at 25 °C, followed by 30 min at 48 °C.
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2.2.15 TaqMan real-time PCR
cDNA (1 pL, approximately 0.1 pg) was combined with 10 pL of 2X TaqMan Universal 
PCR Master Mix, 1 pL of the appropriate Gene Expression Kit, pre-optimised by 
Applied Biosystems for detection of mouse Nrf2 (Mm00477784_ml), Gclc 
(Mm00802655_ml) or the housekeeping gene p2 microglobulin (fhM\ 
Mm00437762_ml), and 8 pL DNase/RNase-free water, in a clear MicroAmp optical 96- 
well reaction plate. Plates were sealed with Absolute QPCR seals, using an adhesive seal 
applicator, and briefly centrifuged at 3000 rpm to remove air bubbles. Gene expression 
was analysed by quantitative real-time PCR on an ABI PRISM 7000 Sequence 
Detection System, in accordance with the manufacturer’s instructions. Levels of Nrf2 
and Gclc gene expression were calculated via reference to standard curves ranging from 
1-300 ng cDNA, and normalised to /?2M
2.2.16 Data analysis
Where appropriate, experiments were performed at least in duplicate, and all 
experiments were replicated on separate occasions. Data are expressed as mean ± 
standard deviation of the mean (SD). One-way analysis of variance (ANOVA), with 
Dunnett’s post-test applied, was used to assess the significance of any differences in the 
data compared to appropriate controls. A two-sided P value of <0.05 was considered to 
be statistically significant.
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2.3 RESULTS
2.3.1 Validation of Hepa-lclc7 as a model for studying the Nrf2-ARE pathway
In order to ascertain that the Hepa-lclc7 cell line was a valid model for studying the 
Nrf2-ARE pathway, the functional operation of this pathway was determined using an 
RNAi approach. siRNA duplexes targeting two distinct regions of the mouse Nr/2 (si- 
Nrf2 #1 and #2) or mouse Keapl (si-Keapl #1 and #2) transcripts were designed. The 
introduction of a siRNA duplex into a cell can cause off-target effects, typically due to 
activation of non-specific innate immune responses, such as the interferon response 
(Bridge et al., 2003; Sledz et al., 2003), or because of inadvertent complementarity to 
non-target mRNA sequences. Aversion of the latter off-target effect is fairly 
straightforward; database search engines, such as BLAST (Basic local alignment search 
tool; http://www.ncbi.nlm.nih.gov/blast/Blast.cgi), can be used to examine all known 
mRNA sequences for complementarity to candidate siRNA target sequences. Such a 
procedure was performed for all of the siRNA duplexes used in this study; no 
complementarity with non-target mRNA sequences was found. Other off-target effects, 
such as activation of the interferon response, are typically observed following the 
introduction of siRNA into cells at relatively high concentrations, particularly > 100 nM 
(Persengiev et al., 2004; Semizarov et al., 2003). Therefore, it is important to optimise 
the amount of siRNA transfected into cells in order to achieve a final concentration that 
enables maximal target gene depletion with minimal off-target effects. To this end, 
preliminary optimisation experiments were performed, using a range of siRNA 
concentrations between 1-100 nM, and it was determined that for each of the siRNA 
duplexes, transfecting Hepa-lclc7 cells for 48 h with 10 nM siRNA provided 
considerable depletion of the respective target gene, without noticeably affecting the 
cellular mRNA level of the housekeeping gene fi2M  (Nrf2 analysis; Fig. 2.3) or the 
protein level of the cytoskeletal protein P-actin (Keapl analysis; data to be presented in 
Mr. Alvin Chia’s thesis). Transfection of Hepa-lclc7 cells with Nrf2 or Keapl siRNA 
did not result in any major changes in cell viability or morphology, as determined by 
visual assessment using a light microscope (data not shown). Using siRNA at
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concentrations below 20-30 nM is generally considered to be unlikely to stimulate non­
specific innate immune responses and/or other off-target effects (Persengiev et al., 2004; 
Semizarov et al., 2003).
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Fig. 2.3 - Preliminary analysis of N rf2  mRNA depletion by RNAi. Hepa-lclc7 cells 
were mock-transfected, or transfected with 1, 10 or 100 nM of one of two Nrf2-targeting 
siRNA duplexes (si-Nrf2 #1 or #2), or a scrambled, non-targeting control siRNA duplex 
(si-Con), for 48 h. Total RNA was isolated, reverse-transcribed to cDNA and Nrf2 gene 
expression was measured by TaqMan real-time PCR. Results are normalised to the 
housekeeping gene p2 microglobulin, and are expressed relative to the mock-transfected 
Nrf2 mRNA level, which was arbitrarily set at 100 %. Bars represent the mean mRNA 
level from duplicate transfections, n=l.
2.3.1.1 RNAi depletion of Nrf2 and Keapl
Due to the difficulties in detecting endogenous Nrf2 protein in the absence of cellular 
stress, RNAi depletion of the transcription factor was confirmed by measuring Nrf2 
mRNA. Transfection of Hepa-lclc7 cells with the siRNA duplexes targeted against the 
Nrf2 transcript resulted in a depletion of the transcription factor mRNA to 23.0 ±3 .0  % 
(si-Nrf2 #1) or 25.4 ± 2.3 % (si-Nrf2 #2) of the mock-transfected control level (Fig. 2.4). 
In contrast, a scrambled, non-targeting control siRNA duplex (si-Con) had no 
discernible effect on Nrf2 mRNA (Fig. 2.4), demonstrating that the observed depletion 
of Nrf2 mRNA was not simply due to activation of the RNAi pathway per se, but due to
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sequence-specific targeting of the Nrf2 transcript. Notably, none of the siRNA duplexes 
significantly affected the mRNA level of the housekeeping gene demonstrating a 
lack of non-target effects.
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Fig. 2.4 - RNAi depletion of N rf2  mRNA. Hepa-lclc7 cells were mock-transfected, or 
transfected with 10 nM of one of two AV/2-targeting siRNA duplexes (si-Nrf2 #1 or #2), 
or a scrambled, non-targeting control siRNA duplex (si-Con), for 48 h. Total RNA was 
isolated, reverse-transcribed to cDNA and Nrf2 gene expression was measured by 
TaqMan real-time PCR. Results are normalised to the housekeeping gene p2 
microglobulin, and are expressed relative to the mock-transfected Nrf2 mRNA level, 
which was arbitrarily set at 100 %. One-way ANOVA, # P  <0.001 versus mock, @ P  
<0.001 versus si-Con. Error bars = standard deviation of mean, n=3.
At the same time that RNAi depletion of Nrf2 was confirmed in Hepa-lclc7 cells, a 
laboratory colleague, Mr. Alvin Chia, successfully optimised the depletion of Keapl 
using targeted siRNA duplexes. At a concentration of 10 nM, both siRNA duplexes 
targeted against the Keapl transcript caused a considerable depletion of the protein to 
below 35 % of the levels in mock-transfected cells (data to be presented in Mr. Alvin 
Chia’s thesis). The specificity of these changes was demonstrated by the fact that si-Con 
had no effect on Keapl protein level, and that neither K eapl-targeting siRNA duplex 
had any discernible effect on levels of P-actin (data to be presented in Mr. Alvin Chia’s 
thesis). Importantly, in light of the fact that Keapl is known to repress the basal activity
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of Nrf2, in part by tethering it within the cytosol, and therefore restricting the access of 
the transcription factor to the nucleus (Dhakshinamoorthy et a i, 2001; Itoh et al., 1999), 
it was shown that RNAi depletion of Keapl resulted in a concomitant increase in the 
nuclear level of Nrf2 protein, compared with the mock-transfected control level (data to 
be presented in Mr. Alvin Chia’s thesis). These results demonstrate that Keapl serves as 
a functional repressor of Nrf2 in Hepa-lclc7 cells.
2.3.1.2 Effect of RNAi depletion of Nrf2 or Keapl on the basal expression of GCLC
In order to confirm that Nrf2 controls the expression of ARE-regulated genes in Hepa- 
lc lc7  cells, the effect of RNAi depletion of the transcription factor, or Keapl, on the 
expression of Gclc, a typical ARE-regulated cytoprotective enzyme (Chan et al., 2000; 
Jeyapaul et al., 2000; Sekhar et al., 2000; Wild et al., 1999), was assessed by Western 
blot. Targeted depletion of Nrf2 decreased the basal protein level of Gclc by 20-30 % 
compared to mock-transfected cells (Fig. 2.5), whereas depletion of Keapl, which 
results in the nuclear accumulation of Nrf2 under resting conditions, increased Gclc 
protein level by 50-60 % (Fig. 2.5). These results demonstrate that Nrf2 regulates the 
expression of an important ARE-containing gene in Hepa-lclc7, and that Keapl 
antagonises this activity, probably through repression of the transcription factor.
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Fig. 2.5 - Effect of RNAi depletion of N rf2  or K ea p l on the basal expression of Gclc.
Hepa-lclc7 cells were mock-transfected, or transfected with 10 nM Nrf2-targeting (si- 
Nrf2 #1 or #2) or Keapl-targeting (si-Keapl #1 or #2) siRNA duplexes, or si-Con, for 
48 h. Cytosolic fractions were prepared and the Gclc protein level was assessed by 
Western blot analysis. Gclc protein bands were quantified by densitometry and 
expressed relative to P-actin, to enable comparison with the mock-transfected Gclc level, 
which was arbitrarily set at 1. Mouse liver lysate was loaded onto the gel as a standard 
(Std). Representative gels from n=3 are presented.
2.3.1.3 Effect of RNAi depletion of N rf2  or K ea p l on the basal level of GSH
Gclc is the rate-limiting enzyme in the GSH synthetic pathway (for a review, see 
Kaplowitz et al., 1985). Therefore, the changes in expression of Gclc observed in 
response to RNAi depletion of Nrf2 or Keapl should result in concomitant changes in 
the level of GSH in Hepa-lclc7 cells. Indeed, Nrf2-targeting siRNA decreased, whereas 
Keapl-targeting siRNA increased, basal levels of GSH (Fig. 2.6), demonstrating that 
Nrf2-mediated induction of a typical ARE-regulated gene results in the upregulation of 
cell defence. In summary, the Nrf2-ARE pathway appears to be functional in Hepa- 
lc lc7  cells. As such, Hepa-lclc7 is a valid model for investigating the molecular 
regulation of the Nrf2-ARE pathway.
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Fig. 2.6 - Effect of RNAi depletion of N rf2  or K ea p l on the basal level of GSH.
Hepa-lclc7 cells were mock-transfected, or transfected with 10 nM Nrf2-targeting (si- 
Nrf2 #1 or #2) or Keapl-targeting (si-Keapl #1 or #2) siRNA duplexes, or si-Con, for 
48 h. Total GSH levels were quantified, using the DTNB-GSH reductase recycling 
method (Vandeputte et al., 1994). The GSH concentration for each sample was 
normalised to total protein content. Results are expressed as the change in GSH relative 
to mock-transfected cells. The GSH content in mock-transfected cells was 35.8 ± 4.5 
nmol/mg. One-way ANOVA, # P  <0.001 versus mock, @ P  <0.001 versus si-Con. Error 
bars = standard deviation of mean, n=3.
2.3.2 Activation of the Nrf2-ARE pathway by NAPQI
Activation of the Nrf2-ARE pathway has previously been observed in mouse liver 
following administration of paracetamol in vivo (Goldring et al., 2004). In order to test 
the hypothesis that paracetamol may activate Nrf2 via the formation of the reactive 
metabolite NAPQI, Hepa-lclc7 cells were directly exposed to NAPQI, and changes in 
the Nrf2-ARE pathway were assessed.
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2.3.2.1 Effect of NAPQI on the subcellular distribution of Nrf2
Following exposure of Hepa-lclc7 cells to NAPQI for 1 h, the subcellular distribution 
of Nrf2 was determined by immunocytochemistry and confocal microscopy. In the 
absence of NAPQI, Nrf2 appeared to be ubiquitously distributed throughout the cells, at 
low levels (Fig. 2.7). In contrast, Nrf2 accumulated within the nuclei of Hepa-lclc7 
cells, as demonstrated by co-localisation with Hoechst 33258 DNA staining, following 
direct exposure to NAPQI (Fig. 2.7).
o
in
2
Q
O
k
Z
Anti-Nrf2 Hoescht Merge
Fig. 2.7 - Effect of NAPQI on the subcellular distribution of Nrf2.
Immunocytochemical analysis of subcellular Nrf2 localisation in Hepa-lclc7 cells 
exposed to 0.5 % DMSO (top panels) or 50 pM NAPQI (bottom panels) for 1 h. Treated 
cells were fixed, permeabilised and incubated with a rabbit anti-mouse Nrf2 antibody, 
followed by Alexa Fluor 594-conjugated goat anti-rabbit IgG (i and iv). Nuclei were 
counterstained with Hoechst 33258 (ii and v). (iii and vi) Merged images of Nrf2 and 
Hoechst signals. Immunofluoresence was visualised by confocal microscopy. 
Representative fields are presented. Scale bar = 25 pm.
73
Chapter 2
2 3 .2 .2  Effect of NAPQI on the activity of an ARE-regulated reporter transgene
In order to confirm that the observed increase in nuclear Nrf2 was functionally relevant, 
the activity of a reporter transgene controlled by the promoter region of the mouse Nqol 
gene, which contains a functional ARE motif, was assessed. Hepa-lclc7 cells were 
transfected for 24 h, exposed to NAPQI for 1 h, the medium was then exchanged for 
NAPQI-free DMEM, and the cells were incubated for a further 15 h. In the absence of 
NAPQI, activity of the wild-type ARE reporter transgene was more than double that of a 
scrambled, mutant ARE construct (Fig. 2.8), indicating the constitutive activity of 
factors that bind to the ARE under resting conditions. Compared with vehicle-treated 
cells, a 42 % increase in ARE-driven reporter transgene activity was observed following 
exposure to NAPQI (Fig. 2.8). However, NAPQI failed to augment the luciferase 
activity of the mutant reporter transgene (Fig, 2.8), indicating that the observed increase 
in luciferase activity was mediated by one or more ARE-binding factors, such as Nrf2.
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Fig. 2.8 - Effect of NAPQI on the activity of an ARE-regulated reporter transgene.
Hepa-lclc7 cells were co-transfected with pCMV SPORT-P-galactosidase and pGL3B- 
I0\6/nqo5,-luc Nqol luciferase reporter plasmid containing a wild-type (WT) or a 
scrambled ARE sequence (Mut), as depicted in the top panel (mutated bases are 
underlined). Following 1 h exposure to 0.5 % DMSO (□) or 50 pM NAPQI (■), and a 
further 15 h incubation in drug-free medium, cells were lysed and luciferase activity was 
determined as described in 2.2.8. Results are normalised to P-galactosidase internal 
control activity and expressed as the change in relative light units compared to WT 
plasmid-transfected, vehicle-treated control cells. One-way ANOVA, *** P  <0.001. 
Error bars = standard deviation of mean, n=3.
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2.3.3 Induction of an adaptive defence response by NAPQI
Activation of Nrf2 and induction of ARE-regulated genes typically enhances cell 
defence. Therefore, the effect of NAPQI on markers of cell defence was assessed in 
Hepa-lclc7 cells.
2.3.3.1 Time-dependent induction of GSH synthesis by NAPQI
Levels of GSH were measured over a period of 24 h, following exposure of Hepa-lclc7 
cells to NAPQI for 1 h. Consistent with its known reactivity with GSH (Albano et al., 
1985; Dahlin et al., 1984; Potter et al., 1986; Rosen et al., 1984), NAPQI stimulated an 
initial depletion of GSH at 1 h, which was then followed by a time-dependent increase in 
GSH, which rose 2.1-fold, compared with the pre-treatment level, at the 24 h timepoint 
(Fig. 2.9). In contrast, vehicle-exposed cells experienced only a slight increase in GSH 
over the same time period (Fig. 2.9). These results indicate that NAPQI provokes an 
adaptive defence response, characterized by the induction of GSH synthesis.
+DMSO/NAPQI
Time (h)
Fig. 2.9 - Induction of GSH synthesis by NAPQI. Hepa-lclc7 cells were exposed to 
0.5 % DMSO (A) or 25 pM NAPQI (•)  for 1 h, followed by a further 23 h incubation in 
drug-free medium. Total GSH was measured at the indicated timepoints. The GSH 
concentration for each sample was normalised to total protein content. Results are 
expressed as the change in GSH relative to 0 h control cells. GSH content in 0 h control 
cells was 37.7 ± 2.5 nmol/mg. One-way ANOVA, *** P  <0.001 versus DMSO. Error 
bars = standard deviation of mean, n=3.
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2.3.3.2 Nrf2- and time-dependent induction of Gclc and GSH by NAPQI
In order to gain a mechanistic insight into the observed induction of GSH by NAPQI 
(Fig. 2.9), particularly in terms of the role of the Nrf2-ARE pathway in this adaptive 
response, Hepa-lclc7 cells transfected with AV/2-targeting siRNA were exposed to 
NAPQI for 1 h, and Gclc mRNA was measured over 8 h, by TaqMan real-time PCR. At 
4 h, in mock-transfected cells, and cells transfected with control siRNA, Gclc mRNA 
increased 2.1-fold, compared with the pre-treatment level (Fig. 2.10). In cells 
transfected with Nrf2-targeting siRNA, basal Gclc mRNA was reduced to around 45 % 
of levels measured in mock-transfected cells (Fig. 2.10). Nrf2-targeting siRNA also 
antagonised the NAPQI-induced increase in Gclc mRNA at 4 h (Fig. 2.10). Furthermore, 
the NAPQI-induced, time-dependent increase in GSH was suppressed by Ar/2-targeting 
siRNA, but not control siRNA (Fig. 2.11). Therefore, the adaptive defence response to 
NAPQI, characterised by a time-dependent elevation of cellular GSH, involves an Nrf2- 
mediated induction of Gclc.
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Fig. 2.10 - Nrf2- and time-dependent induction of Gclc by NAPQI. Hepa-lclc7 cells 
were transfected with 10 nM Ar/2-targeting siRNA (si-Nrf2 #1 or #2) or a scrambled, 
non-targeting control siRNA duplex (si-Con) for 48 h. Cells were exposed to 25 pM 
NAPQI for 1 h, followed by a further 7 h incubation in drug-free medium. At the 
indicated timepoints, total RNA was isolated, reverse-transcribed to cDNA and Gclc 
gene expression was measured by TaqMan real-time PCR. Results are normalised to p2 
microglobulin, and expressed relative to mock-transfected Gclc mRNA level, which was 
arbitrarily set at 100 %. One-way ANOVA, § P <0.001 si-Nrf2 #1 versus mock, ]f P 
<0.001 si-Nrf2 #2 versus mock. Error bars = standard deviation of mean, n=3.
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Fig. 2.11 - Nrf2- and time-dependent induction of GSH by NAPQI. Hepa-lclc7 cells 
were transfected with 10 nM Nrf2-targeting siRNA (si-Nrf2 #1 or #2) or a scrambled, 
non-targeting control siRNA duplex (si-Con) for 48 h. Cells were exposed to 25 pM 
NAPQI for 1 h, followed by a further 7 h incubation in drug-free media. Total GSH was 
measured at the indicated timepoints. The GSH concentration for each sample was 
normalised to total protein content. Results are expressed as the change in GSH relative 
to 0 h mock-transfected cells, which was arbitrarily set at 100 %. The GSH content in 0 
h mock-transfected cells was 51.1 ± 10.0 nmol/mg. One-way ANOVA, § P <0.001 si- 
Nrf2 #1 versus mock, f  P <0.001 si-Nrf2 #2 versus mock. Error bars = standard 
deviation of mean, n=3.
2.3.4 The role of cysteine reactivity in the activation of the Nrf2-ARE pathway by 
NAPQI
In an attempt to understand the chemical and biochemical aspects of the activation of the 
Nrf2-ARE pathway by NAPQI, the dose-dependency of Nrf2 nuclear accumulation was 
measured following exposure of cells to NAPQI, the model cysteine-reactive 
electrophiles DNCB and 15d-PGJ2, and the lysine-reactive molecule TMA. NAPQI (Fig. 
2.12a), DNCB (Fig. 2.12b) and 15d-PGJ2 (Fig. 2.12c) stimulated Nrf2 nuclear 
accumulation in a dose-dependent manner, with maximum increases over vehicle control 
of 4-fold (250 pM NAPQI) and 3-fold (50 pM DNCB, 10 pM 15d-PGJ2). In contrast, 
the lysine-reactive molecule TMA had no effect on nuclear Nrf2 content over the 
concentration range studied (Fig. 2.12d). These results are in agreement with the current
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consensus that cysteine-reactivity is an important property of Nrf2-activating molecules, 
and suggest that modification of cysteine residues within Keapl may be a plausible 
hypothesis to explain the ability of NAPQI to activate the Nrf2-ARE pathway.
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Fig. 2.12 - The role of cysteine reactivity in the activation of the Nrf2-ARE pathway 
by NAPQI and other model electrophiles. Hepa-lclc7 cells were exposed to (A) 
NAPQI, (B) DNCB, (C) 15d-PGJ2 or (D) TMA, at the indicated concentrations, for 1 h. 
Nuclear fractions were prepared and the Nrf2 protein level was assessed by Western blot 
analysis. Nrf2 bands were quantified by densitometry and expressed relative to ß-actin, 
to enable comparison with vehicle-treated control (0 pM) Nrf2 levels, which were 
arbitrarily set at 100 %. Recombinant Nrf2-His, which runs slightly quicker than the 
endogenous protein, was loaded onto the gels as a standard (Std). Non-specific proteins 
that cross-react with the antibody are labeled *. Representative gels from n=3 are 
presented.
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2.3.5 The role of GSH depletion in the activation of the Nrf2-ARE pathway by 
NAPQI
To assess the role of GSH depletion in the activation of Nrf2 by NAPQI and the model 
electrophiles, levels of GSH were measured in Hepa-lclc7 cells following a 1 h 
exposure. NAPQI and DNCB both caused significant, dose-dependent depletion of GSH 
at, or above, 5 pM, whereas TMA had no significant effect on cellular GSH levels (Fig. 
2.13a). Notably, 15d-PGJ2 had no discernible effect on GSH over the same 
concentration range that induced Nrf2 nuclear accumulation (Fig. 2.13b), indicating that 
GSH depletion is not an absolute prerequisite for the activation of Nrf2.
A B
Fig. 2.13 - The role of GSH depletion in the activation of the Nrf2-ARE pathway by 
NAPQI and other model electrophiles. Hepa-lclc7 cells were exposed to (A) NAPQI, 
DNCB or TMA, or (B) 15d-PGJ2, at the indicated concentrations, for 1 h, and total GSH 
levels were quantified. The GSH concentration for each sample was normalised to total 
protein content. Results are expressed as the change in GSH relative to the vehicle- 
treated control (0 pM) GSH level. The GSH content in vehicle-treated control cells was 
35.5 ± 1.5 nmol/mg. One-way ANOVA, *** P  <0.001 versus vehicle-treated control. 
Error bars = standard deviation of mean, n=3.
2.3.6 The role of cytotoxicity in the activation of the Nrf2-ARE pathway by NAPQI
To examine the relationship between Nrf2 activation and cytotoxicity, LDH leakage 
from Hepa-lclc7 cells was measured following exposure to the electrophiles. Notably,
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none of the molecules caused significant cytotoxicity following a 1 h exposure (Fig. 
2.14a-b), at which time point Nrf2 activation was observed at the concentrations studied 
(Fig. 2.12). At 24 h, however, NAPQI, DNCB and 15d-PGJ2 (Fig. 2.14c-d) provoked 
dose-dependent increases in LDH leakage, compared to vehicle control. In contrast, 
TMA had no discernible effect on LDH leakage at 24 h (Fig. 2.14c).
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Fig. 2.14 - The role of cytotoxicity in the activation of the Nrf2-ARE pathway by 
NAPQI and other model electrophiles. Hepa-lclc7 cells were exposed to (A and C) 
NAPQI, DNCB or TMA, or (B and D) 15d-PGJ2, at the indicated concentrations, for 1 h 
(A and B) or 24 h (C and D). Cytotoxicity was assessed by measuring leakage of LDH 
into the culture medium. Extracellular LDH activity is expressed as a percentage of total 
(extracellular plus intracellular) LDH activity. One-way ANOVA, *** P  <0.001 versus 
vehicle-treated control. Error bars = standard deviation of mean, n=3.
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2.4 DISCUSSION
The Nrf2-ARE pathway represents an inducible defence mechanism that protects 
mammalian cells against the deleterious effects of chemical/oxidative stress (for a 
review, see Kensler et al., 2007). Work in this research group has demonstrated that 
administration of paracetamol in vivo stimulates the Nrf2-ARE pathway in mouse liver, 
inducing an adaptive response characterised by the increased expression of 
cytoprotective enzymes (Goldring et a l, 2004). The over-arching hypothesis of the work 
described in this chapter is that the activation of the Nrf2-ARE pathway in mouse liver 
by paracetamol is linked to the formation of the reactive metabolite NAPQI, which has 
the potential to modify cysteine residues within Keapl, the cytosolic repressor of Nrf2. 
The main aim of the studies carried out in this chapter was to ascertain whether NAPQI 
was able to directly activate the Nrf2-ARE pathway in a mouse liver cell line, Hepa- 
lclc7 . The results presented in section 2.3.1 demonstrate that Hepa-lclc7 is a 
functionally valid model for studying the Nrf2-ARE pathway, as has been shown 
previously by others (Jowsey et al., 2003; McWalter et al., 2004; Petzer et al., 2003).
The results presented in section 2.3.2 demonstrate that NAPQI can directly activate the 
Nrf2-ARE pathway in Hepa-lclc7 cells. NAPQI was used as a metabolite per se, to 
eliminate the potentially confounding effects of other paracetamol metabolites on Nrf2 
activation. Due to the practical difficulties associated with measuring levels of unstable 
reactive intermediates, the threshold intracellular concentration of NAPQI that is 
associated with hepatotoxicity following paracetamol overdose is not precisely known. 
However, a reasonable, although somewhat simplistic, estimate can be made on the basis 
that the average liver (1.5 L volume) contains 6  mmol GSH (DeLeve et al., 1991), and 
that paracetamol-induced hepatotoxicity is associated with the depletion of hepatic GSH 
to at least 70 % of basal levels (Mitchell et al., 1973). Assuming the conjugation of GSH 
and NAPQI is stoichiometric, 4.2 mmol NAPQI (70 % of 6  mmol) would be required to 
cause the necessary degree of hepatic GSH depletion (Mitchell et al., 1974; Rumack, 
2002). This translates into a cellular concentration of 2.8 mM NAPQI (4.2 mmol per 1.5 
L). Therefore, the concentrations of NAPQI used in this study (5-250 pM) are within the
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range of concentrations that are estimated to occur in the liver following ingestion of a 
hepatotoxic.dose of paracetamol.
Although there is a general consensus that the direct exposure of cells to NAPQI can 
provide valuable information on the signaling pathways that are involved in the cellular 
response to this reactive intermediate (Albano et al., 1985; Andersson et al., 1990; 
Bender et al., 2004; Dahlin et al., 1984; Harman et al., 1991; Holme et al., 1984; Holme 
et al., 1982a; Holme et al., 1982b; Rundgren et al., 1988), it is important to consider the 
physiological limitations of such an approach. Due to the predominant abundance of 
CYP450 enzymes on the cytoplasmic surface of the smooth endoplasmic reticulum 
(Guengerich, 1990), the majority of reactive intermediates are formed in or around this 
region in vivo. The direct application of NAPQI to cells may, therefore, not accurately 
represent the relative subcellular concentrations of NAPQI formed during the metabolic 
bioactivation of paracetamol in vivo. Indeed, the half-life of NAPQI is estimated to be 
less than 10 sec in the presence of nucleophiles and reductants (Miner et al., 1979). 
Therefore, the direct exposure of cells to NAPQI most likely results in a ‘short, sharp 
hit’, with cell surface proteins bearing the greatest degree of exposure. In contrast, 
hepatocytes exposed to paracetamol generate the reactive metabolite at relatively low 
levels, over a longer period of time. Hence, it is important to consider the physiological 
site of NAPQI generation in any future attempts to dissect the mechanism(s) of Nrf2 
activation by paracetamol in vivo. This issue should be addressed, initially, by 
employing metabolically competent cells that are capable of bioactivating paracetamol 
to NAPQI, and in which the Nrf2-ARE pathway is known to function. This would 
facilitate the direct application of the parent molecule, as opposed to the metabolite, and, 
through the pharmacological inhibition of CYP450 enzyme activity, would better enable 
the process of drug metabolism to be linked to the activation of Nrf2 by paracetamol. 
Interestingly, it has recently been demonstrated that, whilst localising predominantly 
within the perinuclear region of the cytoplasm, Keapl is found to be present in the 
endoplasmic reticulum (Watai et al., 2007). It is possible that such localisation enables 
Keapl to ‘sense’ chemical stress at the initial point of generation.
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Consistent with the observation that activation of Nrf2 by paracetamol induces cell 
defence in mouse liver in vivo (Goldring et al., 2004), stimulation of the Nrf2-ARE 
pathway by NAPQI in Hepa-lclc7 cells was associated with an adaptive defence 
response, characterised by the time-dependent induction of GSH synthesis. Such a 
response would augment the redox buffer within cells, and should enable the enhanced 
bioinactivation of NAPQI, therefore protecting cells against the toxic insult associated 
with this reactive intermediate. The adaptive response was shown to be mediated via an 
Nrf2-dependent induction of Gclc, the ARE-regulated rate-limiting enzyme in the 
synthesis of GSH (Wild et al., 1999). The Nrf2-mediated adaptive response to NAPQI 
may serve as a critical determinant of the threshold for paracetamol toxicity, as separate 
studies have demonstrated that Nrf2~'~ mice are more vulnerable to paracetamol-induced 
liver injury (Chan et al., 2001; Enomoto et al., 2001), whereas hepatocyte-specific 
knockout of the murine Keapl gene, which enhances Nrf2-dependent cell defence, 
confers protection against paracetamol hepatotoxicity (Okawa et al., 2006). Therefore, it 
would be informative in future experiments to examine the effects of RNAi depletion of 
Nrf2 ox Keapl on the cytotoxic effects of NAPQI towards Hepa-lclc7 cells.
The currently favoured model of Nrf2 regulation suggests that the transcription factor 
only accumulates within the nucleus in response to cellular stress (Dhakshinamoorthy et 
al., 2001; Itoh et al., 1999), since it is targeted for proteasomal degradation, via Keapl- 
directed ubiquitination, under resting conditions (Kobayashi et al., 2004; McMahon et 
al., 2003; Nguyen et al., 2003; Stewart et al., 2003; Zhang et al., 2003a). Therefore, 
Nrf2 has primarily been regarded as a key regulator of inducible cell defence. However, 
the results presented in section 2 .3.2 . 2  demonstrate the constitutive activity of factors, 
probably including Nrf2, that bind to the ARE in the absence of cellular stress, as 
indicated by the differences in basal activity of the Nqol reporter transgenes containing 
wild-type and mutated AREs. Furthermore, this study has demonstrated a decrease in the 
basal expression of Gclc, and levels of GSH, following RNAi depletion of Nrf2. These 
findings are consistent with those of recent studies that have employed RNAi to 
demonstrate the importance of Nrf2 as a regulator of mammalian cell defence (Cao et 
al., 2005; Chen et al., 2005b; Dhakshinamoorthy et al., 2004; Gong et al., 2006b; So et
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al., 2006; Warabi et al., 2007; Zhang et al., 2006b). A number of independent studies 
have also demonstrated the decreased basal expression of various ARE-regulated genes 
in mice lacking Nrf2 (Chan et al., 2000; Lee et al., 2003; McMahon et al., 2001 ; Ramos- 
Gomez et al., 2001). It therefore appears that the activity of Nrf2 extends beyond that of 
mediating the adaptive response to cellular stress, by regulating the basal transcription of 
certain defence genes. As such, in addition to directing the response to cellular stress, 
Nrf2 may define the initial threshold for toxicity, by controlling, at least in part, the 
constitutive tier of cell defence. However, the current model of Nrf2 regulation does not 
fully address this latter point. It is possible that the expression of Nrf2 relative to Keapl 
is tightly balanced, such that, in the absence of cellular stress, a small pool of Nrf2 is 
able to evade repression by Keapl, facilitating the basal transactivation of ARE- 
regulated genes. Thus, it is particularly interesting that putative ARE motifs have 
recently been identified in the promoter region of the mouse Keapl gene (Lee et al., 
2007). It is possible, therefore, that the expression of Keapl is, at least partly, regulated 
by Nrf2 itself. Alternatively, background levels of oxidative stress, such as that caused 
by the generation of ROS as byproducts of mitochondrial aerobic respiration, may 
provide low-level stimulation of the Nrf2 pathway. In any case, this ambiguity in the 
current model of Nrf2 regulation has yet to be fully resolved.
Whilst the molecular mechanisms underlying the activation of Nrf2 by chemical 
inducers are yet to be fully defined, it is clear that the Nrf2-ARE pathway is responsive 
to a range of structurally diverse chemicals that are all electrophilic (Presterà et al., 
1993a; Talalay et al., 1988) and capable of modifying sulphydryl groups (Dinkova- 
Kostova et al., 2001). It has been postulated that the modification of critical cysteine 
residues within Keapl represents a molecular ‘sensing’ mechanism that provides the 
trigger for activation of the Nrf2-dependent defence response (Dinkova-Kostova et al., 
2001). Nrf2-activating molecules can be broadly grouped into the following classes: 
alkenes, arsenicals, dithiolethiones, enones, isothiocyanates, mercaptans and disulphides, 
Michael acceptors, and diphenols and quinones. Given that NAPQI is a quinoneimine, 
which is known to react with cysteine thiols via 1,4-addition in vitro and in vivo 
(Hoffmann et al., 1985a; Hoffmann et al., 1985b; Streeter et al., 1984), it is plausible
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that NAPQI activates the Nrf2-ARE pathway through the modification of cysteine 
residues within Keapl, and this may form the molecular basis for the activation of the 
Nrf2-ARE pathway in mouse liver by paracetamol (Goldring et al., 2004).
In order to test the role of cysteine reactivity in the activation of the Nrf2-ARE pathway 
by NAPQI, the responsiveness of Nrf2 to a panel of structurally distinct molecules, with 
different electrophilic chemistries, was assessed. Amongst the cysteine-reactive 
molecules employed, DNCB is a known Nrf2-dependent inducer of HO-1 in mouse 
primary macrophages (Ishii et al., 2000), and 15d-PGJ2 has been shown to activate Nrf2 
in a number of cell types (Chen et al., 2006; Hosoya et al., 2005; Itoh et al., 2004; Yu et 
al., 2006). It can be seen in section 2.3.4 that the cysteine reactive molecules NAPQI, 
DNCB and 15d-PGJ2 stimulated the nuclear accumulation of Nrf2 in a concentration- 
dependent manner, whereas the lysine-reactive hard electrophile TMA did not. DNCB, 
along with many other skin sensitizers, has recently been verified as a potent inducer of 
ARE-driven gene expression (Natsch et al., 2007). The authors of this recent study 
hypothesised that the activation of Nrf2-dependent cell defence by some skin sensitizers 
may account for the lack of sensitivity observed in the majority of the population. As 
such, the idiosyncrasy associated with some sensitizations, and indeed other adverse 
drug reactions, may be partly determined by deficiencies in the Nrf2-ARE pathway. 
Therefore, it will be important to determine whether there is variability in the Nrf2-ARE 
pathway within the general population that may alter the inter-individual threshold for, 
and susceptibility to, drug-induced toxicity. The study by Natsch et al. (2007) also 
demonstrated that, similar to TMA, the lysine-reactive molecule phtalic anhydride is 
unable to activate the Nrf2-ARE pathway. Although TMA is incapable of reacting 
irreversibly with sulphydryl groups (de la Escalera et al., 1989), related structures are 
capable of forming labile adducts with cysteine (Ahlfors et al., 2005; Brinegar et al., 
1981; Palacian et al., 1990). Therefore, it would be interesting to measure the response 
o f the Nrf2-ARE pathway to TMA under conditions which may favour the modification 
o f cysteine sulphydryls, for example following the depletion of cellular GSH. Indeed, 
molecules which can be classified as hard electrophiles have been shown to activate the 
Nrf2-ARE pathway, albeit by a redox-sensitive mechanism (Wang et a l, 2006c). Taken
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together, these data support the notion that cysteine reactivity is an important chemical 
property of Nrf2-activating molecules, and indirectly support the hypothesis that the 
modification of cysteines within Keapl may underlie the ability of NAPQI to activate 
the Nrf2-ARE pathway.
Through the use of several experimental approaches, the direct chemical modification of 
cysteine residues within Keapl has gained support as a triggering mechanism for the 
activation of Nrf2 (Dinkova-Kostova et al., 2002; Itoh et al., 2004; Levonen et al., 2004; 
Sekhar et al., 2003). However, the common thiol reactivity of Nrf2-activating molecules 
also raises the possibility that the depletion of GSH, through conjugation at its 
nucleophilic sulphydryl group, may represent an indirect means of stimulating the 
transcription factor. Indeed, it is possible that, via the generation of an oxidising 
environment, the depletion of GSH may cause changes in the redox state of certain 
cysteines within Keapl, thus triggering Nrf2 activation. However, although it cannot be 
discounted that an alteration of the redox balance may contribute to the activation of 
Nrf2 by NAPQI and DNCB, the fact that 15d-PGJ2 was able to induce the nuclear 
accumulation of the transcription factor without significantly affecting GSH levels 
indicates that depletion of GSH is not an absolute prerequisite for the stimulation of 
Nrf2.
Notably, components of the ubiquitin-proteasome pathway, which has a major role in 
regulating the basal activity of Nrf2 (Kobayashi et al., 2004; McMahon et al., 2003; 
Nguyen et al., 2003; Stewart et al., 2003; Zhang et al., 2003a), are redox sensitive 
(Jahngen-Hodge et al., 1997), and the function of this important cellular pathway is 
known to be inhibited by thiol-reactive molecules (Obin et al., 1998), including 15d- 
PGJ2 (Ishii et al., 2005a; Mullally et al., 2001; Shibata et al., 2003). Cyclopentenone 
prostaglandins have also been shown to disrupt the actin cytoskeleton (Gayarre et al., 
2006), to which Keapl is anchored (Kang et al., 2004). Therefore, the ability of 15d- 
PGJ2 to activate Nrf2 may be independent of the direct antagonism of Keapl through 
chemical modification of critical cysteines. Further work is required to examine this 
hypothesis. Taken together, these results imply that biochemical mechanisms other than
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the depletion of GSH, such as the modification of cysteine residues within Keapl, may 
have an important role in the activation of Nrf2 by certain molecules. Given that the 
mutual activation of multiple signaling pathways, in a chemical-specific manner, may 
contribute to the activation of the Nrf2-ARE pathway, further work, employing a broad 
panel of chemical inducers with well-characterised effects on cell signaling pathways, is 
required to fully elucidate the nature of the biochemical mechanisms that regulate Nrf2 
activity.
Concentrations of NAPQI, DNCB and 15d-PGJ2 that were not cytotoxic over lh, but 
induced significant leakage of LDH over 24 h, stimulated the nuclear accumulation of 
Nr£2. These results, in keeping with our previous observation that Nrf2 is activated in 
murine liver by paracetamol at non-hepatotoxic, as well as hepatotoxic, doses (Goldring 
et al., 2004), suggest that the Nrf2-ARE pathway is able to ‘sense’ and respond to 
chemical stress before the onset of overt cytotoxicity. However, it should also be noted 
that concentrations of NAPQI that caused almost complete cytotoxicity after 24 h 
incubations did so in spite of activating the Nrf2-ARE pathway. Therefore, it is clear 
that induction of Nrf2-dependent cell defence does not guarantee survival following 
exposure to cytotoxic chemicals. What is, perhaps, more important is the balance 
between the extent of the cytotoxic insult and the activation of Nrf2, and other 
cytoprotective signaling pathways. At lower levels of exposure, deleterious cytotoxic 
effects may be surmountable by the induction of cytoprotective systems. As the level of 
exposure increases, however, defensive barriers may simply be overwhelmed by the 
increasing scale of cellular stress. In keeping with this concept, the dose threshold of 
paracetamol required to induce hepatotoxicity is markedly reduced in Nrf2-null mice 
(Chan et al., 2001; Enomoto et al., 2001) and increased in hepatocyte-specific Keapl 
knockout animals (Okawa et al., 2006). Thus, cytoprotective signaling pathways may 
enable cells, and indeed whole organisms, to withstand low-level exposure to toxic 
environments, but cannot provide complete protection against cytotoxic insults.
In summary, the results presented in this chapter demonstrate that NAPQI, the reactive 
metabolite of paracetamol, can directly activate the Nrf2-ARE pathway in a mouse liver
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cell line, inducing an adaptive defence response characterised by the Nrf2-dependent 
induction of Gclc and GSH. Through the use of a panel of structurally distinct 
electrophiles, the activation of Nrf2 has been shown to be associated with the cysteine 
reactivity of a molecule, but not to be entirely dependent on the depletion of GSH. 
Therefore, it is possible that NAPQI activates the Nrf2-ARE pathway via the 
modification of cysteine residues within Keapl, and the subsequent chapters o f this 
thesis are aimed towards investigating this potential signaling mechanism.
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CHAPTER 3
Development of a cell-free in vitro system for investigating the 
chemical modification of Keapl by Nrf2-activating electrophiles
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3.1 INTRODUCTION
The results presented in chapter 2, and the work of others (Dinkova-Kostova et a l, 
2001; Prestera et al., 1993a; Talalay et a l, 1988; Zhang, 2001), have demonstrated that 
cysteine reactivity is an important chemical property of Nrf2-activating molecules. 
Given that Keapl is the major regulator of Nrf2 activity (Itoh et a l, 1999), and that 
Keapl is a highly cysteine-rich protein, it has been proposed that the modification of one 
or more cysteine residues within Keapl may evoke a conformational change in the 
protein, rendering it unable to efficiently repress Nrf2, and thus providing a trigger for 
activation of the transcription factor (Dinkova-Kostova et a l, 2002).
Site-directed mutagenesis has been employed to demonstrate the importance of certain 
cysteine residues, particularly Cys-151, -273 and -288, in the function of Keapl 
(Kobayashi et a l, 2006; Levonen et a l, 2004; Wakabayashi et a l, 2004; Zhang et a l, 
2003a). In addition, recent work has provided compelling evidence for the chemical 
modification of Keapl, through the use of biotinylated analogues of Nrf2-activating 
molecules (Itoh et a l,  2004; Levonen et a l, 2004), spectroscopic binding experiments 
(Dinkova-Kostova et a l, 2002) and mass spectrometry (Dinkova-Kostova et a l, 2002). 
Although it appears that other triggers for Nrf2 activation may exist, including direct 
phosphorylation of the transcription factor (Cullinan et a l,  2003; Huang et a l, 2002; 
Nguyen et a l, 2000), there is a far more substantial weight of evidence indicating that 
certain cysteines within Keapl may be the targets of electrophiles, and that modification 
of Keapl may underlie the ability of these molecules to induce Nrf2-dependent cell 
defence. The studies presented in this and subsequent chapters aim to explore the role of 
Keapl modification in the regulation of Nrf2 activity.
The results presented in chapter 2 demonstrate that NAPQI, the electrophilic metabolite 
of paracetamol, directly activates the Nrf2-ARE pathway in a mouse liver cell line. 
Given that NAPQI is known to react with cysteine thiols in vitro and in vivo (Hoffmann 
et a l, 1985a; Hoffmann et al., 1985b), a plausible hypothesis to explain the activation of 
the Nrf2-ARE pathway by paracetamol in vivo (Goldring et a l, 2004), and by NAPQI in
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established cells, is that chemical modification of Keapl by NAPQI perturbs its ability 
to repress the transcription factor. In order to explore this hypothesis, a cell-free in vitro 
test system has been developed, based on the expression and purification of recombinant 
polyhistidine-tagged mouse Keapl protein, and its use in combination with mass 
spectrometry to enable the examination of Keapl modification by NAPQI and other 
Nrf2-activating electrophiles. The work presented within this chapter describes the 
development and validation of this in vitro test system.
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3.2 METHODS
3.2.1 Materials and reagents
The mouse Keapl I.M.A.G.E. cDNA clone was from Geneservice (Cambridge, UK). 
PCR and sequencing primers were custom-synthesised by Sigma-Genosys (Haverhill, 
UK). Expand High Fidelity PCR System and the 100 bp DNA ladder were from Roche 
Diagnostics (Burgess Hill, UK). pET-21a(+) was from Novagen (Nottingham, UK). AseI 
was from New England Biolabs (Hitchin, UK). BL21 (DE3) competent E. coli, SOC 
media, UltraPure agarose and the SilverXpress silver staining kit were from Invitrogen 
(Paisley, UK). XL 10-Gold ultracompetent E. coli were from Stratagene (Amsterdam, 
Netherlands). Isopropyl-ß-D-thiogalactopyranoside and sequencing-grade modified 
trypsin were from Promega (Southampton, UK). The BCA Protein Assay Kit was from 
Pierce (Cramlington, UK). The Soniprep 150 ultrasonic disintegrator was from MSE 
(London, UK). aCHCA matrix was from Laserbio Labs (Valbonne, France). The 
GeneAmp 9700 PCR system, MALDI target plate, Voyager-DE PRO MALDI-TOF 
Biospectrometry Workstation, API QSTAR Pulsar i MS/MS spectrometer, and Analyst 
QS and ProteinPilot software packages were from Applied Biosystems (Warrington, 
UK). DTT was from USB Corporation (Cleveland, USA). Perfectprep gel cleanup kit 
was from Eppendorf (Cambridge, UK). ChromasPro software was from Technelysium 
(Tewantin, Australia). The integrated LCPackings System and C l8 PepMap column 
were from Dionex (Camberley, UK). PicoTip emitters were from New Objective 
(Woburn, USA). Power Broth was from Athena Enzyme Systems (Baltimore, USA). 
Sex pheromone inhibitor peptide iPDl was from Bachem (St Helens, UK). GenElute 
plasmid mini-prep kit, ethidium bromide, BglII, Hindlll, Ndel, Sacl, Xbal, Xhol, the 
QuickLink DNA ligation kit, LB agar tablets, LB broth powder, ampicillin, imidazole, 
HIS-Select nickel-charged agarose beads, sepharose 6 B beads, Iodoacetamide, N- 
ethylmaleimide, ProteoMass MALDI-MS standards (angiotensin II, ACTH fragment 18- 
39, oxidised insulin chain B), caesium iodide and the monoclonal anti-polyhistidine 
HRP-conjugated antibody were from Sigma-Aldrich (Poole, UK). All other reagents 
were o f analytical or molecular grade, and were from Sigma-Aldrich.
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3.2.2 Preparation of mouse K ea p l coding sequence DNA template
An I.M.A.G.E. cDNA clone (# 6404252) for mouse Keapl was supplied streaked onto 
an agar slope; a small amount of this agar was used to inoculate 2 mL LB broth 
containing 50 pg/mL ampicillin, which was incubated overnight at 37 °C, 250 rpm. The 
clone vector was purified using a GenElute plasmid mini-prep kit, in accordance with 
the manufacturer’s instructions.
3.2.3 Polymerase chain reaction
The purified vector, containing the mouse Keapl cDNA clone, was used as a template 
for hot-start PCR amplification of the mouse Keapl coding sequence. A forward primer 
(5 ’ -TCGATTAATAGCATGCAGCCCGAACCCAA-3 ’) was designed to introduce an 
AseI restriction site, flanked on either side by three bases, at the start of the Keapl 
coding sequence. A reverse primer (5’-CGACTCGAGCTCGCAGGTACAGTTT 
TGTT-3’) was designed to omit the stop codon (TGA) and to introduce a Xhol 
restriction site flanked on either side by three bases, at the end of the Keapl coding 
sequence. Hot-start PCR (see Table 3.1) was performed using the Expand High Fidelity 
PCR System. Reactions (50 pL) contained 1 pL purified vector, IX Expand buffer, 2.5 
mM MgCh, 0.2 mM dNTP mix and 0.2 nM forward and reverse primer. Reactions were 
heated to 80 °C in a GeneAmp 9700 PCR system and held at this temperature to allow 
the addition of 2.6 U Expand enzyme mix.
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Step Cycles Denaturing Annealing Elongation
# 1 1 2 min at 95 °C — —
# 2 2 5 sec at 95 °C 30 sec at 6 8  °C 1.5 min at 72 °C
#3 2 5 sec at 95 °C 30 sec at 6 6  °C 1.5 min at 72 °C
#4 2 5 sec at 95 °C 30 sec at 64 °C 1.5 min at 72 °C
#5 2 5 sec at 95 °C 30 sec at 62 °C 1.5 min at 72 °C
# 6 2 5 sec at 95 °C 30 sec at 60 °C 1.5 min at 72 °C
#7 2 5 sec at 95 °C 30 sec at 58 °C 1.5 min at 72 °C
# 8 2 5 sec at 95 °C 30 sec at 56 °C 1.5 min at 72 °C
#9 2 5 sec at 95 °C 30 sec at 54 °C 1.5 min at 72 °C
# 1 0 2 5 sec at 95 °C 30 sec at 52 °C 1.5 min at 72 °C
# 1 1 24 5 sec at 95 °C 30 sec at 50 °C 1.5 min at 72 °C
Table 3.1 - Steps and cycles for hot-start PCR amplification of mouse K ea p l coding 
sequence.
3.2.4 Sub-cloning of K ea p l into pET-21a(+)
The pET-21a(+) vector was opened by restriction digest with Ndel and Xhol for 2 h at 
37 °C. The digestion reaction (20 pL) contained 5 pL pET-21a(+), 10 U Ndel, 10 U 
Xhol and IX buffer SH. The mouse Keapl PCR product from 3.2.3 was digested with 
AseI and Xhol for 2 h at 37 °C. The digestion reaction (20 pL) contained 5 pL PCR 
product, 10 U Ase I, 10 U Xhol, and IX buffer 3. As Ndel and Ase I yield compatible ends 
following restriction digest, it was possible to ligate 4.s-eI/A7?oI-digested Keapl into 
Afafel/ATzoI-digested pET-21a(+). An Ase I restriction site, and not a Ndel restriction site, 
was introduced at the start of the Keapl coding sequence as the Ndel restriction site 
contains an ATG initiation codon, which would have resulted in premature translation of 
the construct. The pET-2 la(+) and Keapl restriction products, alongside a 100 base pair 
(bp) DNA ladder, were resolved by electrophoresis on a 1 % agarose gel supplemented 
with 0.5 pg/mL ethidium bromide. The agarose gel was made by dissolving 0.5 g 
UltraPure agarose in 50 mL TBE buffer (89 mM Tris-base, 89 mM boric acid, 2 mM 
EDTA, pH 8.3) and heating the solution to boiling point. Ethidium bromide was added, 
and the solution was poured into a casting tray and allowed to set at room temperature. 
The resolved DNA fragments were purified using a Perfectprep gel cleanup kit, in
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accordance with the manufacturer’s instructions. The gel-purified restriction products 
were ligated using a QuickLink DNA ligation kit, in accordance with the manufacturer’s 
instructions. XL 10-Gold ultracompetent E. coli were immediately transformed with the 
ligated construct (0.6 pL per 30 pL bacteria), via a 30 sec heat-shock at 42 °C, and 
incubated in 0.25 mL nutrient-rich SOC media for 1 h, at 37 °C, 250 rpm. The bacteria 
were streaked onto a sterile LB-agar plate, made with LB-agar tablets, containing 50 
pg/mL ampicillin, and incubated at 37 °C overnight. Antibiotic-resistant colonies were 
picked from the plate and used to inoculate 2 mL LB broth containing 50 pg/mL 
ampicillin; these cultures were incubated for 24 h at 37 °C, 250 rpm. The construct was 
purified by mini-prep. Diagnostic restriction digests were performed with BgEl (5 pL 
PCR product, 10 U Bglll, IX buffer SM, 37 °C, 1 h), HindlWXhol (5 pL PCR product, 
10 U Hindlll, 10 U Xho\, IX buffer SB, 37 °C, 1 h) and Xbal/Sacl (5 pL PCR product, 
10 U Xbal, 10 U SacI, IX buffer SA, 37 °C, 1 h). BL21 (DE3) competent E. coli were 
transformed with pET-21a(+)/Keapl, via a 30 sec heat-shock at 42 °C, and incubated in 
0.25 mL SOC media for 1 h, at 37 °C, 250 rpm. The bacteria were streaked onto a sterile 
LB-agar plate, containing 50 pg/mL ampicillin, and incubated at 37 °C overnight. 
Antibiotic-resistant colonies were picked from the plate and used to inoculate 2 mL LB 
broth containing 50 pg/mL ampicillin; these cultures were incubated for 24 h at 37 °C, 
250 rpm. The construct was purified by mini-prep, and diagnostic restriction digests 
were performed to confirm successful transformation with pET-21a(+)/Keapl, as 
described above. Glycerol stocks of a pET-21a(+)/Keapl-transformed BL21 (DE3) 
colony were made by supplementing a mid-log phase culture with 15 % (v/v) glycerol; 
these stocks were stored at -80 °C until required.
3.2.5 DNA two-strand sequencing
BL21 (DE3), transformed with pET-21a(+)/Keapl, and primers (at 3.2 pM) were sent to 
Geneservice for two-strand sequencing of pET-21a(+)/Keapl. Sequencing primers were 
custom-synthesised by Sigma-Genosys, in accordance with the requirements of 
Geneservice; external forward 5’-TAATACGACTCACTATAGGG-3’, internal forward
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5’-CCACCCTAAGGTCATGGAAA-3’, external reverse 5’-GCTAGTTATTGCTCAG 
CGG-3’, internal reverse 5’-GCTAGTTATTGCTCAGCGG-3\ Sequencing results were 
analysed using ChromasPro software.
3.2.6 Expression and purification of Keapl-His
LB broth (0.125 L), supplemented with 50 pg/mL ampicillin, was inoculated with 3 mL 
pET-2 la(+)/Keapl-transformed BL21 (DE3) glycerol stock and incubated at 37 °C, 250 
rpm, overnight. The culture was then diluted to 1.2 L in LB broth containing 50 pg/mL 
ampicillin, and incubated at 37 °C, 250 rpm, for 30 min. At this point, the optical density 
at 600 nm (OD60onm) was measured using a spectrophotometer, to ensure that the culture 
was at early-log phase of growth (OD6oonm of approximately 0.4). Keapl-His protein 
expression was induced over 4 h, at 37 °C, 250 rpm, with 1 mM isopropyl-p-D- 
thiogalactopyranoside (IPTG). Following induction, bacteria were pelleted at 5000 g, for 
5 min, and washed in 50 mL refolding buffer (0.5 M NaCl, 50 mM Tris base, 20 mM 
imidazole, pH 8.0). The washed pellet was resuspended in 50 mL ice-cold isolation 
buffer (2 M urea, 0.5 M NaCl, 50 mM Tris base, 2 % (v/v) Triton X-100, pH 8.0), 
divided into two equal aliquots in 50 mL tubes and disrupted in an ultrasonic 
disintegrator (10 sec, followed by 10 sec recovery, x 4 repeats). Disrupted bacteria were 
pelleted at 10,000 g for 5 min, resuspended in 30 mL binding buffer ( 6  M guanidine 
HC1, 0.5 M NaCl, 50 mM Tris base, 20 mM imidazole, 1 mM P-mercaptoethanol, pH 
8.0) and shaken vigorously at 4 °C for 30 min. After making 1.5 mL aliquots o f this 
solution, cell debris was pelleted at 18,000 g for 1 0  min; the supernatants were pooled 
and incubated with 0.6 mL (dry volume) HIS-Select nickel (Ni2+) -charged agarose, or 
Sepharose 6 B, beads at 4 °C for 30 min. Beads were pelleted by making 1.5 mL aliquots 
of the binding solution and centrifuging at 5000 g for 1 min. Beads were washed once 
with 1 mL binding buffer, three times with 1 mL wash buffer ( 6  M urea, 0.5 M NaCl, 50 
mM Tris base, 20 mM imidazole, 1 mM P-mercaptoethanol, pH 8.0) and three times 
with 1 mL refolding buffer. Beads were finally resuspended in an equal volume of ice- 
cold phosphate buffer (13.08 mM KH2PO4, 67.27 mM Na2HP0 4, pH 7.4).
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3.2.7 Western blot analysis
Keapl-His expression and purification were determined by Western blot analysis, 
essentially as described in section 2.2.6. To assess Ni2+ purification of Keapl-His, 
proteins were eluted from agarose beads by resuspending in an equal volume of 
NuPAGE loading buffer. The slurry was heated at 80 °C for 5 min, the beads were 
pelleted by centrifugation at 5000 g for 5 min, and the supernatant loaded onto a pre-cast 
4-12 % NuPAGE Novex bis-tris polyacrylamide gel. The anti-polyhistidine HRP- 
conjugated antibody was used at 1:10,000 in TBS-Tween containing 2 % (w/v) BSA.
3.2.8 Silver stain analysis
Keapl-His expression and purification were determined using a SilverXpress silver 
staining kit, in accordance with the manufacturer’s instructions. Gels were scanned using 
a GS-710 calibrated imaging densitometer.
3.2.9 Determination of on-bead Keapl-His content
The on-bead content of Keapl-His was assessed with a bicinchoninic acid (BCA) 
Protein Assay Kit, with a slight modification of the method of Stich (1990). The BCA 
assay is based on the reduction of Cu2+ to Cu4 by protein in an alkaline environment (the 
biuret reaction). Each Cu+ formed reacts with two molecules of BCA to form a purple 
chromophore that has an absorbance maximum at 562 nm (Smith et al., 1985). For the 
determination of protein immobilised on agarose beads, the BCA assay is preferred to a 
standard Bradford protein assay because the blue chromophore that forms when 
Coomassie Brilliant Blue G-250 reacts with immobilised protein remains associated 
with the agarose beads, which settle at the bottom of the plate/tube. Thus, constant 
stirring of the sample is required to enable spectrophotometric determination of protein 
content. The purple chromophore formed via the reaction of BCA with immobilised
98
Chapter 3
protein is water-soluble, and thus does not remain associated with the agarose beads, 
enabling spectrophotometric determination of protein content without the need for 
constant stirring of the sample. Keapl-His -coupled Ni2+-charged agarose beads (50 pL 
dry volume) were washed three times with 0.2 mL distilled H20  (dH20). A standard 
curve ranging from 0.01-1 mg/mL BSA was prepared in separate tubes (50 pL each). 
Beads and standards were combined with 1 mL BCA assay reagent (0.98 mL reagent A, 
20 pL reagent B) and incubated in a 37 °C water bath for 30 min. All tubes were 
vortexed every 10 min during this incubation period. Following the 30 min incubation, 
tubes were stored on ice to avoid further colour development. The beads were pelleted 
by centrifugation at 5000 g for 1 min. 0.2 mL supernatant, or standards, were transferred 
to a clear 96-well plate and the absorbance at 570 nm was read on a MRX microplate 
reader. A blank reading (dH20  and BCA reagent) was subtracted from all sample and 
standard readings. A bead blank reading (uncoupled Ni2+-charged agarose beads and 
BCA reagent) was subtracted from the sample reading. For the calculation of molar 
ratios, the concentration of Keapl-His (pg/pL) was converted to molarity using the 
following equation:
Protein concentration (pg/pL) x [1/protein molecular weight (pg)] = concentration (pM)
3.2.10 Determination of Keapl-His cysteine redox states
To determine whether Keapl-His cysteines were in sulphydryl or disulphide states, a 
differential chemical capping approach was developed. To cap free sulphydryls, Keapl- 
His -coupled Ni2+-charged agarose beads (50 pL dry volume) were resuspended in 0.13 
mL phosphate buffer and 20 pL of 0.55 M iodoacetamide, and incubated on a 
mechanical roller at 4 °C for 30 min. The beads were washed three times in 0.5 mL 
phosphate buffer to remove residual iodoacetamide. To reduce disulphides, the beads 
were resuspended in 0.148 mL phosphate buffer and 2 pL of 0.1 M DTT, and incubated 
on a mechanical roller at 4 °C for 30 min. The beads were washed three times in 0.5 mL 
phosphate buffer to remove residual DTT. In order to cap the sulphydryls formed from
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the reduction of disulphides, the beads were resuspended in 0.13 mL phosphate buffer 
and 20 pL of 0.2 M N-ethylmaleimide (NEM), and incubated on a mechanical roller at 4 
°C for 30 min. The beads were washed three times in 0.5 mL phosphate buffer to 
remove residual NEM. Prior to digestion with trypsin, the beads were washed once with 
0.5 mL of 25 mM ammonium bicarbonate, and then resuspended in 25 pL of 25 mM 
ammonium bicarbonate. A 400 pg/mL stock solution of sequencing-grade modified 
trypsin was diluted 1:10, in 25 mM ammonium bicarbonate, and 6  pL (240 ng) was 
added to the bead slurry. Tryptic digestion was allowed to proceed overnight at 37 °C.
3.2.11 MALDI-TOF mass spectrometry
Following overnight tryptic digestion, peptide mixtures (0.5 pL) were combined with an 
equal volume of a-cyano-4-hydroxy-cinnamic acid (aCHCA) matrix (10 mg/mL 
aCHCA in 50 % (v/v) acetonitrile (ACN), 0.1 % (v/v) trifluoroacetic acid (TFA)) and 
spotted onto a matrix-assisted laser desorption ionization mass spectrometry (MALDI- 
MS) target plate alongside ProteoMass MALDI-MS standards (angiotensin II, 
adrenocorticotropic hormone fragment 18-39, oxidised insulin chain B, 0.5 pmol each), 
using the dried-droplet method. Peptide mass fingerprints were obtained on a Voyager 
DE Pro MALDI time-of-flight (TOF) Biospectrometry Workstation, in linear positive 
ion mode, and used in a MASCOT protein database search 
(http://www.matrixscience.com) to enable identification of proteins present within the 
sample.
3.2.12 LC-ESI-MS/MS mass spectrometry
Samples were delivered into an API QSTAR Pulsar i system by automated in-line 
reversed phase liquid chromatography (LC), using an integrated LCPackings System 
(Famos autosampler, Ultimate LC pump, Switchos microcolumn switching module) and 
75 pm x 15 cm C l8 PepMap column, via a nano-electrospray source head and 10 pm
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inner diameter PicoTip emitter. A gradient of 5-48 % (v/v) ACN, 0.05 % (v/v) TFA over 
60 min, followed by 10 min at 99 % (v/v) ACN, 0.05 % (v/v) TFA and 15 min at 5 % 
(v/v) ACN, 0.05 % (v/v) TFA, was applied to the column at a flow rate of 0.35 pL/min. 
Across a mass range of 300-2000 atomic mass units (amu), MS and MS/MS spectra 
were acquired automatically in positive ion mode using information-dependent 
acquisition powered by Analyst QS software. Above a threshold of 5 counts per sec, the 
three most intense ions in each MS spectrum were subjected to MS/MS analysis for 1.5 
sec, and subsequently excluded from further analysis for 40 seconds. The instrument 
was routinely calibrated with 0.3 nmol caesium iodide (M+H+ = 132.9) and 30 pmol sex 
pheromone inhibitor peptide iPDl (M+H+ = 829.5) in 50 % (v/v) methanol, 1 % (v/v) 
formic acid. Amino acid modifications were detected with ProteinPilot software v2.0 
using the Paragon™ algorithm (Shilov et al., 2007) and the most recent version of the 
SwissProt database. Carboxyamidomethyl (+57.0 amu) or NEM (+125.0 amu) were 
selected as variable modifications. All adducts were confirmed by visual inspection of 
the MS/MS spectra.
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3.3 RESULTS
3.3.1 PCR amplification of mouse K ea p l coding sequence
The mouse Keapl coding sequence (1875 bp) was amplified by PCR. Primers were 
designed to enable amplification of the coding sequence without the TGA stop codon, to 
facilitate the translation of a polyhistidine-tagged Keapl protein. The primers also 
permitted the introduction of an additional 12  bp at the 5’ and 3’ ends of the coding 
sequence. These inserts, containing Asel (5’) and Xhol (3’) restriction digest sites (Fig. 
3.1), were introduced to enable the ligation of the Keapl coding sequence into the Ndel 
and Xhol restriction sites of pET-21a(+). An Asel restriction site, and not an Ndel site, 
was introduced into the Keapl coding sequence because the latter site contains an ATG 
initiation codon, which would have resulted in the premature translation of the construct.
Asel
tcgattaatagc
agctaattatcg
5• 2' Xhol
gagctcgagtcg 
ctcgagctcagcMouse Keapl CDS
Fig. 3.1 - Schematic diagram showing insertion of A se l and X h o l restriction digest 
sites at the 5’ and 3’ ends, respectively, of the mouse K ea p l coding sequence (CDS).
The restriction sites are shown in bold.
3.3.2 Ligation of mouse K ea p l coding sequence into pET-21a(+)
The tagged Keapl PCR product was digested with Asel and Xhol, whilst pET-2 la(+) 
(Fig. 3.2) was digested with Ndel and Xhol', both restriction fragments were resolved by 
electrophoresis (Fig. 3.3). As digestion with Asel and Ndel yields compatible ends, the 
v4seI/A7zoI-digested Keapl fragment was ligated into MM/ATzoI-digested pET-2la(+). 
XL10-Gold ultracompetent E. coli were transformed with the ligated construct. 
Successful transformation was confirmed by diagnostic restriction digests of construct 
DNA purified from selected bacterial colonies (Fig. 3.4). Specifically, fragments of the
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expected size(s) were visualised following digestion with Bglll (cuts at -106 and 1694 of 
K eapl; 1800 bp fragment), Xhal and Sad  (Xbal cuts at -40, S a d  cuts at 923; 963 bp 
fragment), and Hindlll and Xhol {HindiII cuts at 16, Xho\ cuts at 1879; 1863 fragment). 
These diagnostic restriction digests demonstrate that the Keapl coding sequence ligated 
into pET-21a(+) successfully, and in the correct orientation. In order to confirm that the 
PCR amplification process had not introduced mutations into the Keapl coding 
sequence, the pET-21a(+)/Keapl construct was verified by two-strand sequencing. This 
process confirmed that no non-synonymous mutations, i.e. those that result in the 
translation of a different amino acid, were present in pET-21a(+)/Keapl. An example 
electropherogram, depicting the Xhol restriction site, polyhistidine tag and TGA stop 
codon of pET-21a(+)/Keapl, is presented in Fig. 3.5.
Fig. 3.2 - pET-21a(+) vector map. The tagged Keapl coding sequence was ligated into 
the Ndel and Xhol restriction sites of pET-21a(+). Image taken from Novagen on-line 
catalogue (http://www.merckbiosciences.co.uk/docs/NDIS/TB036-000.pdf).
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Fig. 3.3 - Restriction digested mouse Keapl coding sequence and pET-2 la(+). The
tagged mouse Keapl coding sequence was digested with AseJ and Xhol. pET-21a(+) was 
digested with Ndel and Xhol. Both restriction fragments, alongside a 100 bp DNA 
ladder, were resolved by electrophoresis on a 1 % (w/v) agarose gel, containing 0.5 
pg/mL ethidium bromide. DNA fragments were visualised under UV illumination.
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Fig. 3.4 - Diagnostic restriction digests of pET-2la(+)/Keapl from putative 
transformed XLIO-Gold E. coli. pET-2 la(+)/Keapl was purified from selected 
bacterial colonies by mini-prep. The construct was digested with BglII (cuts at -106 and 
1694 of Keapl ; 1800 bp fragment), Xhal and S a d  (Xbal cuts at -40, S a d  cuts at 923; 
963 bp fragment), and Hindiil and Xhol (Hindlll cuts at 16, Xhol cuts at 1879; 1863 
fragment). The restriction fragments, the undigested construct, and a 100 bp DNA ladder 
were resolved by electrophoresis on a 1 % (w/v) agarose gel, containing 0.5 pg/mL 
ethidium bromide. DNA fragments were visualised under UV illumination.
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Xhoi
restriction
site
C T C C A
Stop
6xHis tag codon
Fig. 3.5 - Sequencing electropherogram of pET-21a(+)/Keapl. pET-2la(+)/Keapl 
was sequenced by Geneservice; the construct was amplified by PCR in the presence of 
the terminator nucleotides dideoxy -adenine (■), -thymine (■), -guanine (■) and - 
cytosine (■). The amplification products were resolved by electrophoresis, visualised 
under UV illumination, and recorded automatically. The region of electropherogram 
shown depicts the Xhol restriction site, polyhistidine (6 xHis) tag and TGA stop codon of 
pET-2 la(+)/Keapl.
3.3.3 Expression and purification of Keapl-His
BL21 (DE3) competent E. coli were transformed with the verified pET-2 la(+)/Keapl 
construct, and Keapl-His expression was induced via supplementation of the culture 
with IPTG. As an analogue of lactose, IPTG displaces the repressor from the lac 
operator o f the BL21 (DE3) T7 polymerase gene (Dubendorff et al., 1991; Studier el al., 
1986), allowing T7 polymerase to drive transcription of the gene of interest via the T7 
promoter (Dubendorff et al., 1991; Studier et al., 1986). The inducible expression of 
Keapl-His was confirmed by Western blot analysis (Fig. 3.6). It was noted that the anti- 
Keapl antibody consistently detected two protein bands of slightly different molecular 
weights (Fig. 3.6). As the exact nature of the two bands was not investigated during this 
work, the cause of this phenomenon is not clear. A large proportion of the recombinant
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Keapl-His protein was insoluble following sonication of the bacterial pellet in IX PBS 
(Fig. 3.6), and was thus unsuitable for purification of Keapl-His using Ni2+-charged 
agarose beads, which could not have been separated from the insoluble pellet by 
centrifugation. Therefore, Keapl-His was purified under denaturing conditions, in order 
to enable maximal recovery of the recombinant protein in a soluble form. Denaturing 
purification of Keapl-His from the crude bacterial lysate was confirmed by silver stain, 
which showed a high degree of purity in the recovered fraction (Fig. 3.7). Western blot 
analysis also showed a high recovery of a polyhistidine-tagged protein that ran at the 
size anticipated for Keapl-His (70.8 kiloDalton; kDa) (Fig. 3.7).
Fig. 3.6 - Inducible expression of Keapl-His in BL21 (DE3) E. coli. BL21 (DE3) 
transformed with pET-21a(+)/Keapl were cultured in LB broth and, at an ODeoonm of 
0.4, were not induced, or induced with 1 mM IPTG, for 4 h at 37 °C, 250 rpm. The 
bacterial pellets were resuspended in IX PBS and disrupted by sonication. The soluble 
lysates and insoluble pellets were resolved by denaturing electrophoresis and Keapl 
expression was assessed by Western blot analysis.
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Fig. 3.7 - Denaturing purification of Keapl-His. Keapl-His expression was induced 
or not by the supplementation of a BL21 (DE3) culture with 1 mM IPTG. Following 
incubation for 4 h at 37 °C, 250 rpm, the bacterial pellets were lysed under denaturing 
conditions, and the soluble lysates were incubated for 30 min, at 4 °C, with HIS-Select 
Ni2+-charged agarose, or Sepharose 6 B, beads. The crude bacterial lysates and the 
proteins eluted from the respective beads were resolved by denaturing electrophoresis. 
Keapl-His expression and purification was confirmed by silver stain and Western blot 
analysis; the latter was performed separately with anti-Keapl and anti-polyhistidine 
antisera.
MALDI-TOF MS analysis revealed that the polyhistidine-tagged protein recovered from 
pET-2la(+)/Keapl -transformed BL21, using Ni2+-charged agarose beads, was Keapl- 
His (Fig. 3.8). The peptide mass fingerprint obtained from this analysis was used in a 
MASCOT protein database search, which identified mouse Keapl as the major 
constituent of the tryptic digest (Fig. 3.9). The amino acid coverage for mouse Keapl, 
from the MALDI-TOF MS analysis, was 82 %, and included Cys-151, -273 and -288,
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which have been shown to be critical for the function of Keapl (Kobayashi et al., 2006; 
Levonen et al., 2004; Wakabayashi et al., 2004; Zhang et al., 2003a). Of the 25 
cysteines in Keapl-His, only Cys-622 and -624 were not routinely covered during MS 
analysis, as they were not released from the Ni2+-charged agarose beads by tryptic 
digestion, due to their proximity to the polyhistidine tag of Keapl-His. Compound 
mutation o f the three cysteines (Cys-613, -622, -624) located within the C-terminal 
domain o f Keapl has no effect on the repressive activity of Keapl towards Nrf2 
(Wakabayashi et al., 2004), implying that Cys-622 and -624 are not essential for Keapl 
function.
Fig. 3.8 - MALDI-TOF mass spectrum of the tryptic digest of protein(s) purified by 
N r  affinity, under denaturing conditions, from pET-2la(+)/Keapl -transformed 
BL21 (DE3). Keapl-His expression was induced via the supplementation of a BL21 
(DE3) culture with 1 mM IPTG. Following incubation for 4 h at 37 °C, 250 rpm, the 
bacterial pellets were lysed under denaturing conditions and the soluble lysates were 
incubated for 30 min, at 4 °C, with HIS-Select Ni2+-charged agarose beads. Bead-bound 
protein(s) were reduced with 1 mM DTT, alkylated with 55 mM iodoacetamide, and 
digested overnight with 240 ng trypsin. The resulting peptide mixture was visualised on 
a Voyager DE Pro MALDI-TOF Biospectrometry Workstation, in linear positive ion 
mode.
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Accession Mass Score Description
1. a1 133416964 69508 319 Kelch-like ECH-associated protein 1 [Mus musculus]
2. gi 137359786 71015 309 mKIAA0132 protein [Mus musculus]
3. gi 174207025 69492 301 unnamed protein product [Mus musculus]
4. gi 126337871 69478 298 unnamed protein product [Mus musculus]
5. gi 174219578 69482 274 unnamed protein product [Mus musculus]
Match to: gi|33416964 Kelch-like ECH-associated protein 1 [Mus musculus]
Sequence Coverage: 82%
1 MQPEPKLSGA PRSSQFLPLW SKCPEGAGDA VMYASTECKA EVTPSQDGNR
51 TFSYTLEDHT KQAFGVMNEL RLSQQLCDVT LQVKYEDIPA AQFMAHKWL
101 ASSSPVFKAM FTNGLREQGM EWSIEGIHP KVMERLIEFA YTASISVGEK
151 CVLHVMNGAV MYQIDSWRA CSDFLVQQLD PSNAIGIANF AEQIGCTELH
201 QRAREYIYMH FGEVAKQEEF FNLSHCQLAT LISRDDLNVR CESEVFHACI
251 DWVKYDCPQR RFYVQALLRA VRCHALTPRF LQTQLQKCEI LQADARCKDY
301 LVQIFQELTL HKPTQAVPCR APKVGRLIYT AGGYFRQSLS YLEAYNPSNG
351 SWLRLADLQV PRSGLAGCW GGLLYAVGGR NNSPDGNTDS SALDCYNPMT
401 NQWSPCASMS VPRNRIGVGV IDGHIYAVGG SHGCIHHSSV ERYEPERDEW
451 HLVAPMLTRR IGVGVAVLNR LLYAVGGFDG TNRLNSAECY YPERNEWRMI
501 TPMNTIRSGA GVCVLHNCIY AAGGYDGQDQ LNSVERYDVE TETWTFVAPM
551 RHHRSALGIT VHQGKIYVLG GYDGHTFLDS VECYDPDSDT WSEVTRMTSG
601 RSGVGVAVTM EPCRKQIDQQ NCTC
Fig. 3.9 - MASCOT protein database search result for peptide mass fingerprint 
obtained from the MALDI-TOF MS analysis of protein(s) purified by Ni2+ affinity, 
under denaturing conditions, from pET-2 la(+)/Keapl -transformed BL21 (DE3).
The peptide mass fingerprint shown in Fig. 3.8 was used in a MASCOT protein database 
search (http://www.matrixscience.com), which identified mouse Keapl as the major 
constituent protein in the tryptic digest. The five proteins identified with the highest 
degree of confidence are shown (all are variant database entries for mouse Keapl). The 
amino acid sequence coverage for mouse Keapl was 82 %. The specific amino acids 
covered by the MALDI-TOF MS analysis are underlined and in bold.
3.3.4 Determination of Keapl-His cysteine redox states
Although the denaturing purification process contained a refolding step, in which all 
denaturing and reducing agents were removed from the protein(s), it was not possible to 
determine if this step facilitated the reliable and correct folding of Keapl-His, partly 
because there is, at present, no point of reference for the whole protein, in that crystal 
structures have only been resolved for the DGR and C-terminal domains of mouse 
Keapl (Padmanabhan et al., 2005). Therefore, because the main application of the 
purified Keapl-His was to be in the analysis of Keapl cysteine modification by Nrf2- 
activating molecules, the consistency of cysteine redox states in Keapl-His across
109
Chapter 3
separate purifications was assessed using a differential chemical capping approach (Fig. 
3.10). One of two procedures was followed: 1) Keapl-His was alkylated, or reduced and 
then alkylated; any cysteines that were alkylated without reduction were likely to be in a 
sulphydryl state, whilst those that were alkylated only following reduction were likely to 
be in a disulphide state, and 2) Keapl-His was exposed to iodoacetamide, then reduced 
with DTT, and exposed to NEM; any cysteines that were alkylated by iodoacetamide 
were likely to be in a sulphydryl state, whilst those that were only alkylated by N- 
ethylmaleimide were likely to be in a disulphide state. This approach, coupled with 
liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI- 
MS/MS), enabled the redox states of the cysteines in mouse Keapl-His to be 
determined, by detecting mass shifts (+57.0 amu for iodoacetamide, +125.0 amu for 
NEM) on each cysteine residue.
SH~{ Keapl )— SH
s —s
CAM -s— ( Keapl ]~s~
I I
CAM
S — S
CAM - S — Keapl
T T ~
SH SH
— S -C A M
CAM - S — Keapl
i  r
— S -C A M
N E M -S  S -N E M
+ lodoacetamide
Capping of free -SH (+57.0 amu)
+ DTT
Reduction of S-S to free -SH
+ N-ethylmaleimide
Capping of former S-S (+125.0 amu)
Fig. 3.10 - Differential chemical capping approach for determining the redox states 
of Keapl-His cysteines. Purified Keapl-His was alkylated with iodoacetamide, reduced 
with DTT and alkylated with N-ethylmaleimide. Cysteines in a -SH state were identified 
by an increase in mass of +57.0 amu (carboxamidomethylation; CAM) prior to 
reduction. Cysteines in a S-S state were identified by a lack of carboxamidomethylation 
prior to reduction and an increase in mass of +125.0 amu (N-ethylmaleimide; NEM) 
only following reduction.
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Across three separate purifications, performed on individual bacterial pellets on the 
same day, inconsistencies in the redox states of Keapl-His cysteines were detected 
(Table 3.1). For example, certain residues were found to be in a sulphydryl state in one 
purification and a disulphide state in another. Some cysteine residues were also found to 
be in both sulphydryl and disulphide states within the same purification. Similar 
inconsistencies were also found across purifications performed on separate days (Table 
3.1). These results indicate that the denaturing and refolding process employed to purify 
Keapl-His could not ensure a consistent redox state for Keapl-His cysteine residues, 
within or across purifications. Therefore, it would not be possible to assume that Keapl- 
His purified on separate occasions was structurally identical. Similarly, it was clearly not 
going to be possible to use the method described here to study the modification of Keapl 
cysteines by Nrf2-activating molecules without first rendering all of the cysteines free 
for adduction (i.e. in a sulphydryl state). It was considered that such an approach would 
not render subsequent studies of Keapl cysteine modification invalid, for the following 
reasons: 1) the native redox states of cysteines other than those residing within the DGR 
domain of human Keapl (Li et al., 2004b) have yet to be elucidated, and so it may 
transpire that many or all of the cysteines in Keapl are naturally in a sulphydryl state, 
and, more importantly, 2) ensuring that all Keapl cysteines were in a sulphydryl state 
would render all of them free for modification, thus enabling the examination of the 
relative reactivities of Keapl cysteines towards chemically distinct Nrf2-activating 
molecules. In summary, then, these data describe the generation of recombinant mouse 
Keapl-His and validation of its use as an in vitro model for studying the modification of 
Keapl cysteines by Nrf2-activating molecules, using LC-ESI-MS/MS.
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3.3.5 Expression and purification of soluble Keapl-His under non-denaturing 
conditions
In the latter stages of this PhD, and with the technical assistance of Mr. Peter Metcalfe, 
the successful expression and purification of a soluble form of Keapl-His was achieved 
using non-denaturing conditions. LB broth was substituted with Power Broth, a nutrient- 
rich, proprietary formulation (Athena Enzyme Systems). pET-21a(+)/Keapl 
-transformed BL21 (DE3) were grown in Power Broth and, at an OD6oonm of 0.4, were 
induced overnight at 20 °C, 250 rpm, via supplementation with 1 mM IPTG. The next 
morning, the pH of the culture was adjusted to 7.5 with 1 M Tris base, the bacteria were 
then pelleted and resuspended in binding buffer (0.5 M NaCl, 20 mM Na2HPC>4, 20 mM 
imidazole, pH 7.4). The bacteria were disrupted by sonication (six bursts of 10 sec, 
interspersed with 10 sec recoveries) and clarified by centrifugation. Polyhistidine-tagged 
proteins were then purified from the soluble fraction using a HisTrap HP affinity column 
(Amersham, Little Chalfont, UK), in accordance with the manufacturer’s instructions. 
Affinity-purified proteins were eluted from the column in elution buffer (0.5 M 
imidazole, 0.5 M NaCl, 20 mM Na2HPC>4, pH 7.4), resolved by denaturing 
electrophoresis, and visualised by staining with Coomassie Brilliant Blue G-250. An 
abundant protein, at the anticipated size of Keapl-His (70.8 kDa) was detected in the 
lysate from induced, but not uninduced, pET-21a(+)/Keapl -transformed BL21 (DE3) 
(Fig. 3.11). The successful purification of Keapl-His was confirmed by MALDI-TOF 
MS analysis of the trypsin-digested proteins eluted from the affinity column (Fig. 3.12). 
The peptide mass fingerprint obtained from this analysis was used in a MASCOT 
protein database search, which identified mouse Keapl as the major constituent of the 
tryptic digest (Fig. 3.13). The amino acid coverage for mouse Keapl, from the MALDI- 
TOF MS analysis, was 45 %. The amino acid coverage from LC-ESI-MS/MS analysis, 
which affords greater resolution due to the chromatographic separation of peptides, was 
85 %. Since this method was developed in the latter stages of the project, there was 
insufficient time to use the protein in further studies into the modification of Keapl 
cysteines by Nrf2-activating molecules.
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‘Power Broth’ -  IPTG ‘Power Broth’ + IPTG
Fig. 3.11 - Coomassie Brilliant Blue stain of proteins eluted from a HisTrap HP 
affinity column, following non-denaturing expression of Keapl-His. Keapl-His 
expression was not induced or induced via the supplementation of a BL21 (DE3) Power 
Broth culture with 1 mM IPTG. Following overnight incubation at 20 °C, 250 rpm, the 
bacterial pellets were lysed under non-denaturing conditions and the soluble lysates were 
passed through a HisTrap HP affinity column. Proteins eluted from the column were 
resolved, alongside the flow-through fraction and protein molecular weight markers, by 
denaturing electrophoresis on a bis-tris polyacrylamide gel, which was subsequently 
stained with Coomassie Brilliant Blue G-250.
114
Chapter 3
Fig. 3.12 - MALDI-TOF mass spectrum of the tryptic digest of protein(s) purified 
by Ni2+ affinity, under non-denaturing conditions, from pET-2la(+)/Keapl - 
transformed BL21 (DE3). Keapl-His expression was induced via the supplementation 
of a BL21 (DE3) Power Broth culture with 1 mM IPTG. Following overnight incubation 
at 20 °C, 250 rpm, the bacterial pellets were lysed under non-denaturing conditions and 
the soluble lysates were passed through a HisTrap HP affinity column. Affinity purified 
protein(s) were reduced with 1 mM DTT, alkylated with 55 mM iodoacetamide, and 
digested overnight with 240 ng trypsin. The resulting peptide mixture was visualised on 
a Voyager DE Pro MALDI-TOF Biospectrometry Workstation, in linear positive ion 
mode.
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Accession Mass Score Description
1. gi| 7710044 69508 161 kelch-like ECH-associated protein 1 [Mus musculus]
2. gi| 74181739 69492 161 unnamed protein product [Mus musculus]
3. gi| 26337871 69478 161 unnamed protein product [Mus musculus]
4. gi| 37359786 71015 159 mKIAA0132 protein [Mus tuscuius]
5. gi 174212473 69482 143 unnamed protein product [Mus musculus]
Match to: gi|7710044 kelch-like ECH-associated protein 1 [Mus musculus]
Sequence Coverage: 45%
1 MQPEPKLSGA PRSSQFLPLW SKCPEGAGDA VMYASTECKA EVTPSQDGNR 
51 TFSYTLEDHT KQAFGVMNEL RLSQQLCDVT LQVKYEDIPA AQFMAHKWL 
101 ASSSPVFKAM FTNGLREQGM EWSIEGIHP KVMERLIEFA YTASISVGEK 
151 CVLHVMNGAV MYQIDSWRA CSDFLVQQLD PSNAIGIANF AEQIGCTELH 
201 QRAREYIYMH FGEVAKQEEF FNLSHCQLAT LISRDDLNVR CESEVFHACI 
251 DWVKYDCPQR RFYVQALLRA VRCHALTPRF LQTQLQKCEI LQADARCKDY 
301 LVQIFQELTL HKPTQAVPCR APKVGRLIYT AGGYFRQSLS YLEAYNPSNG 
351 SWLRLADLQV PRSGLAGCW GGLLYAVGGR NNSPDGNTDS SALDCYNPMT 
401 NQWSPCASMS VPRNRIGVGV IDGHIYAVGG SHGCIHHSSV ERYEPERDEW 
451 HLVAPMLTRR IGVGVAVLNR LLYAVGGFDG TNRLNSAECY YPERNEWRMI 
501 TPMNTIRSGA GVCVLHNCIY AAGGYDGQDQ LNSVERYDVE TETWTFVAPM 
551 RHHRSALGIT VHQGKIYVLG GYDGHTFLDS VECYDPDSDT WSEVTRMTSG 
601 RSGVGVAVTM EPCRKQIDQQ NCTC
Fig. 3.13 - MASCOT protein database search result for peptide mass fingerprint 
obtained from the MALDI-TOF MS analysis of protein(s) purified by Ni2+ affinity, 
under non-denaturing conditions, from pET-2la(+)/Keapl -transformed BL21 
(DE3). The peptide mass fingerprint shown in Fig. 3.12 was used in a MASCOT protein 
database search (http://www.matrixscience.com), which identified mouse Keapl as the 
major constituent protein in the tryptic digest. The five proteins identified with the 
highest degree of confidence are shown (all are variant database entries for mouse 
Keapl). The amino acid sequence coverage for mouse Keapl was 45 %. The specific 
amino acids covered by the MALDI-TOF MS analysis are underlined and in bold.
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3.4 DISCUSSION
The Nrf2-ARE pathway represents an inducible defence mechanism that affords 
protection to mammalian cells against chemical/oxidative stress (for a review, see 
Kensler et al., 2007). The work presented in this chapter describes the development of a 
cell-free in vitro test system, based on the use of recombinant mouse Keapl protein in 
combination with mass spectrometry, that provides an experimental basis to test the 
hypothesis that NAPQI activates the Nrf2-ARE pathway via the direct chemical 
modification of cysteine residues within Keapl, the cytosolic repressor of Nrf2. This 
system may also provide insights into the molecular mechanism that triggers Nrf2 
activation in mouse liver following administration of paracetamol in vivo (Goldring et 
a l, 2004).
Recombinant DNA technology (Cohen et al., 1973) has contributed greatly to the field 
of biomedicine. The ability to express recombinant proteins has enabled, for example, 
the large-scale and reliable production of human insulin for the treatment of diabetes 
(Crea et al., 1978; Goeddel et al., 1979). The use of recombinant protein technology and 
mass spectrometry has proved to be a fruitful combination for the detection and 
characterisation of post-translational modifications, and is now commonplace within the 
field of biomedical research (see the reviews by Liebler (2002) and Mann et al. (2003) 
for further details). Many groups have used these principles to investigate, for example, 
the oxidation state of the active site cysteine in human protein tyrosine phosphatase IB 
(DeGnore et al., 1998), the inhibition of NF-kB -DNA binding via covalent modification 
of Cys-62 within the p50 subunit by the anti-inflammatory molecules 15d-PGJ2 
(Cemuda-Morollon et al., 2001), andrographolide (Xia et al., 2004) and kamebakaurin 
(Lee et al., 2002), and the modification of apolipoprotein B-100, the major protein 
constituent of low density lipoprotein, by the lipid peroxidation product 4-hydroxy-2- 
nonenal (Bolgar et al., 1996). These and many other investigations have demonstrated 
that the use of mass spectrometry coupled with recombinant protein technology is a 
feasible and accurate means of characterising post-translational modifications at the 
amino acid level. Increasingly, with the improvement of pre-analytical separation
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techniques and the continual evolution and increased sensitivity of mass spectrometers, 
the principles of these in vitro studies are being exploited to enable the characterisation 
o f protein post-translational modifications in cells and in vivo, from samples that are 
inherently much more complex in nature (Ji et al., 2007; Koen et al., 2006; Lemercier et 
al., 2004; Meier et al., 2007; Meier et al., 2005; Shin et al., 2007)..
The use of recombinant proteins has many advantages for the detection of chemical 
modification(s) by mass spectrometry. For instance, the purification and enrichment of a 
protein dramatically reduces the complexity of the sample to be analysed. Such a 
strategy may eliminate the confounding effects of other proteins on the reaction being 
studied. Furthermore, given that only a small fraction of the total protein may be 
modified, protein enrichment effectively increases the sensitivity of the mass 
spectrometer for the detection of modifications. In addition, the prior characterisation of 
residue-specific modifications in vitro, using recombinant proteins, may better inform in 
vivo analyses, by identifying diagnostic data patterns that help the investigator to detect 
specific changes within a complex heterogeneous sample. However, there are also 
limitations to the use of recombinant proteins as biological models. For example, a given 
protein may not fold into its native form when expressed in bacteria. Such misfolding 
can particularly affect proteins which in the native state bear disulphide bonds, the 
formation of which is inhibited in the reducing environment of the E. coli cytoplasm 
(Singh et a l, 2005). It is also important to consider that modifications observed in vitro, 
from the reaction between a chemical and purified recombinant protein, may not 
necessarily occur within a much more complex cellular milieu. Therefore, one should be 
cautious when attempting to extrapolate data obtained from in vitro analyses to a 
cellular, or even whole organism, context.
Recombinant proteins are routinely expressed with conjoined affinity tags, which can be 
defined as amino acid sequences with a high affinity for a specific biological or 
chemical ligand (Amau et a l, 2006). The incorporation of such tags enables the 
purification and enrichment of the protein of interest from the heterogeneous mixture of 
proteins present within the host expression system, such as E. coli. Polyhistidine tags,
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which comprise a short peptide containing (normally six) consecutive histidine residues, 
are amongst the most widely-used affinity tags for recombinant protein purification. The 
principle of immobilised metal-affinity chromatography (Porath et al., 1975), i.e. the 
strong interaction between a transition metal (Ni2+, Co2+, Cu2+, Zn2+) and the side chain 
o f histidine, is central to the use of polyhistidine tags in the process of protein 
purification. Importantly in this case, the binding specificity of this reaction is robust 
under both native and denaturing conditions (Porath, 1992). Competition for transition 
metal binding with imidazole, which contains the same ring structure as the side chain of 
histidine, enables the elution of affinity-purified proteins (Hochuli, 1990). Many other 
affinity tags have been developed, including short peptides such as FLAG 
(‘DYKDDDDK’) and c-Myc (‘EQKLISEEDL’), which enable purification via affinity 
towards an immobilised antibody, and much longer sequences that have a natural 
affinity for a biological molecule, such as streptavidin-binding protein (binds to 
immobilised streptavidin) and GST (binds to immobilised GSH) (Terpe, 2003). 
However, immobilised antibodies are generally expensive, and the incorporation of a 
large peptide or protein, in the case of GST, may have significant effects on the structure 
and/or function of the recombinant protein itself. In this regard, and given its wide­
spread application in the purification of recombinant proteins, the polyhistidine tag was 
chosen as the fusion partner for recombinant Keapl in this study.
E. coli is one of the most commonly-used systems for the expression of recombinant 
proteins, due in part to its rapid growth and well-characterised genetics (Baneyx, 1999). 
However, the use of E. coli for the production of recombinant protein is by no means a 
flawless process; one o f the most frequent problems encountered, particularly with 
expression vectors that contain a strong promoter, is the tendency of highly-expressed 
proteins to misfold and form insoluble aggregates, known as inclusion bodies (Hartley et 
al., 1988; Kane et al., 1991). From the results presented in section 3.3.3, it appears that 
initial attempts at expressing Keapl-His were hindered by aggregation, with a large 
proportion of the protein being insoluble following disruption of the bacteria. 
Importantly, proteins aggregated within inclusion bodies tend to lack biological activity 
(Rudolph et al., 1996). Fortunately, however, methods for the recovery of recombinant
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protein from inclusion bodies have been developed, and have classically involved the 
use of concentrated chemical dénaturants, particularly urea and guanidine hydrochloride, 
which are classified as chaotropes in light of their ability to disrupt non-covalent 
molecular structures (Rudolph et a l, 1996). Reducing agents, such as DTT and 0- 
mercaptoethanol, may also be used to counteract aggregation caused by the misforming 
of disulphide bonds (Rudolph et a l, 1996). To facilitate the refolding of solubilised 
proteins, dénaturants and reductants are gradually removed via dilution or dialysis 
(Rudolph et a l, 1996).
Dénaturants and reductants have been used in this study to enable the enhanced recovery 
o f insoluble recombinant Keapl-His. In this case, it is not possible to fully determine 
whether the recombinant Keapl protein expressed here and in other work (Dinkova- 
Kostova et a l, 2002) is correctly folded, because there is currently no point of reference, 
given that a crystal structure has been resolved only for the DGR and C-terminal 
domains of the mouse protein (Padmanabhan et a l, 2005). Until the complete crystal 
structure of Keapl is determined, the most suitable method for determining the fidelity 
o f the folding of recombinant Keapl may be to ensure that the protein is able to 
associate with its known interaction partners, namely Nrf2, actin, CUL3 and RBX1 
(Cullinan et a l, 2004; Dhakshinamoorthy et a l, 2001; Furukawa et a l, 2005; Itoh et a l, 
1999; Kang et a l, 2004; Kobayashi et a l, 2004; Zhang et a l, 2004; Zhang et a l, 2005). 
However, given that the redox states of the 25 cysteines in mouse Keapl-His were not 
consistent within or across purifications in section 3.3.4, it was decided that all cysteines 
would be rendered free for adduction via exposure to the reducing agent DTT. 
Therefore, studies of Keapl-His modification by Nrf2-activating molecules in chapter 4 
will examine the relative reactivities of Keapl cysteines towards different electrophiles, 
to explore the possibility that certain residues are preferentially reactive towards all Nrf2 
inducers. In light of this, the precise folding state of Keapl-His following dénaturation 
and renaturation was not deemed to be critical, given that all disulphide bonds were 
subsequently reduced, inhibiting tertiary structure formation. However, in order to 
examine the consequence(s) of cysteine modification on the structure of Keapl, 
correctly-folded soluble protein would need to be readily available. To this end, and
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towards the latter stages of this PhD, a method for the enhanced recovery of soluble 
Keapl-His was developed. Although not used for experimental purposes in this thesis, 
the ability to isolate recombinant Keapl in a soluble form may facilitate circular 
dicroism and/or nuclear magnetic resonance-based structural studies to test the 
hypothesis that modification of one or more cysteines within Keapl causes a 
conformational change in the protein. Indeed, this has been postulated as a critical 
molecular event that leads to the disruption of Nrf2 repression by Keapl, causing the 
induction of adaptive cell defence processes (for a review, see Tong et a l, 2006b). 
Experiments that test this hypothesis will enhance our understanding of the likely 
importance of Keapl cysteine modification in the activation ofNrf2.
In relation to this thesis, the most pertinent example of the use of mass spectrometry to 
characterise the modification of a recombinant protein is the study by Talalay and 
colleagues, who reported the residue-selective adduction of mouse Keapl by the thiol- 
reactive electrophile dex-mes (Dinkova-Kostova et a l, 2002). Although not 
representative of the physiological conditions within a cell, the procedures employed in 
this paper enabled the identification of five cysteines, from a total of 25 in the mouse 
protein, that were preferentially reactive towards dex-mes in vitro at a molar ratio of 
33:1 dex-mes:Keapl (Dinkova-Kostova et a l, 2002). Specifically, these residues were 
Cys-257, -273, -288, -297 and -613 (Dinkova-Kostova et a l, 2002). Indeed, it has 
recently been demonstrated that a Keapl protein in which Cys-257, -273, -288 and -297 
are mutated to alanine binds dex-mes at half the rate of the wild-type protein 
(Wakabayashi et a l, 2004). Other investigations have utilised site-directed mutagenesis 
to demonstrate that the integrities of Cys-273 and -288 in particular are critical for the 
function of Keapl (Kobayashi et a l, 2006; Levonen et a l, 2004; Wakabayashi et a l, 
2004; Zhang et al., 2003). Therefore, it would appear there is value in determining the 
relative reactivities of Keapl cysteine residues towards Nrf2-activating molecules using 
in vitro systems similar to those described by Dinkova-Kostova et a l  (2002) and in this 
chapter.
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In summary, this chapter describes the development and validation of a cell-free in vitro 
test system for exploring the modification of cysteine residues within Keapl by Nrf2- 
activating electrophiles. This system will be employed in chapter 4 to examine the role 
of Keapl modification in the activation of Nrf2 by NAPQI, DNCB and 15d-PGJ2.
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CHAPTER 4
Chemical modification of Keapl in vitro by 
N-acetyl-p-benzoquinoneimine and other Nrf2-activating electrophiles
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The activity of the transcription factor Nrf2 is primarily regulated through its interaction 
with the cysteine-rich protein Keapl (Itoh et a l, 1999). It has been postulated that the 
modification of one or more cysteine residues within Keapl may evoke a 
conformational change in the protein, rendering it unable to efficiently repress Nr£2, and 
thus providing a trigger for activation of the transcription factor (Dinkova-Kostova et 
a l, 2002). To date, compelling evidence for the chemical modification of Keapl has 
been provided through the use of biotinylated analogues of Nrf2-activating molecules 
(Itoh et a l, 2004; Levonen et a l, 2004), spectroscopic binding experiments (Dinkova- 
Kostova et a l, 2002) and mass spectrometry (Dinkova-Kostova et a l, 2002).
In the only investigation to date to employ mass spectrometry as an analytical tool to 
examine the modification of Keapl cysteines, the thiol-reactive steroid dex-mes was 
shown to preferentially modify Cys-257, -273, -288 and -297, located within the IVR 
domain, and the C-terminal Cys-613, of recombinant mouse Keapl (Dinkova-Kostova et 
a l, 2002). Cys-273, -288, -297 and -613 are amongst the many cysteines (see Fig. 1.9) 
in the mouse Keapl protein that have low predicted pKa values, and thus high relative 
reactivities, as they are flanked by at least one basic amino acid (Snyder et a l, 1981). 
Cys-273, -297 and -613 are immediately flanked by two basic residues, and are thus 
anticipated to be particularly reactive toward electrophiles. Therefore, further work is 
required to identify the target residues within Keapl of other Nrf2-activating molecules, 
in order to determine whether a defined cysteine, or subset of cysteines, represents a 
common target for all such molecules.
Insights into the role of specific cysteine residues in the function of Keapl, particularly 
Cys-151, -273 and -288, have mainly come from studies employing site-directed 
mutagenesis (Kobayashi et a l, 2006; Levonen et a l, 2004; Wakabayashi et a l, 2004; 
Zhang et a l, 2003). Cys-151, which resides within the BTB domain of Keapl, does not 
appear to be integral to Keapl function in the absence of chemical/oxidative stress, but 
is critical to its ability to respond to such conditions (Zhang et a l, 2003; Zhang et a l,
4.1 INTRODUCTION
125
Chapter 4
2004). In contrast, Cys-273 and -288, both located within the IVR domain of Keapl, are 
essential for the repressive activity of Keapl under basal conditions (Kobayashi et al., 
2006; Levonen et al., 2004; Wakabayashi et al., 2004; Zhang et al., 2003). Mutation of 
Cys-273 and/or -288 to serine or alanine renders Keapl unable to direct ubiquitination of 
Nr£2, inhibit its nuclear accumulation or repress transactivation of an ARE reporter 
transgene (Kobayashi et al., 2006; Levonen et al., 2004; Wakabayashi et al., 2004; 
Zhang et al., 2003). Furthermore, the responsiveness of Nrf2 to known inducers is 
diminished or abolished by the expression of Keapl Cys-273/288 mutants (Levonen et 
al., 2004; Zhang et al., 2003). Notably, the mutation of other cysteines within the IVR, 
N-terminal and C-terminal domains has essentially no effect on Keapl function 
(Wakabayashi et al., 2004; Zhang et al., 2003). Hence, the structural integrities of Cys- 
151, -273 and -288 are paramount for the function of Keapl. As for Cys-273 and -288, 
Cys-151 is flanked by basic amino acids (see Fig. 1.9), and is thus anticipated to be 
highly reactive towards electrophiles (Snyder et al., 1981). Therefore, in light of the 
evidence discussed, these residues are plausible targets for electrophilic inducers of 
Nrf2.
The work presented in chapter 3 has described the development of a cell-free in vitro 
system for examining the modification of Keapl by Nrf2-activating electrophiles, using 
tandem mass spectrometry to facilitate the identification of specific target residues. 
Through the use of a panel of structurally distinct molecules (NAPQI, DNCB and 15d- 
PGJ2) that were shown to activate Nrf2 in chapter 2, the initial aim of the work presented 
in this chapter is to use this in vitro system to determine the capacity of these molecules 
to modify cysteine residues within Keapl. Furthermore, this study aims to map the 
Keapl adduct patterns associated with different Nrf2-activating electrophiles, to test the 
hypothesis that all such molecules selectively modify one or more cysteines amongst the 
subset of Cys-151, -273 and -288, and that this underlies the ability of these molecules to 
activate Nrf2-dependent cell defence.
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4.2.1 Materials and reagents
Recombinant human His-GSTPl-1 was kindly donated by Samantha Dowdall (School 
of Biomedical Sciences, University of Liverpool, UK). DNFB was from Sigma-Aldrich 
(Poole, UK). All other reagents were of analytical or molecular grade, and were from 
Sigma-Aldrich.
4.2 METHODS
4.2.2 Expression and purification of Keapl-His
Expression and purification of Keapl-His was as described in section 3.2.6.
4.2.3 Determination of on-bead Keapl-His content
Determination of on-bead Keapl-His content was as described in section 3.2.9,
4.2.4 Incubation of Keapl-His with electrophiles
To render all cysteines free for modification, Keapl-His -coupled Ni2+-charged agarose 
beads (50 pL dry volume; -350 pmol) were resuspended in 0.148 mL phosphate buffer 
and 2 pL of 0.1 M DTT, and then incubated on a mechanical roller at 4 °C for 15 min. 
The beads were washed three times in 0.5 mL phosphate buffer to remove residual DTT. 
The beads were resuspended in 0.149 mL phosphate buffer, and 1 pL of 200X NAPQI, 
DNCB, 2,4-dinitrofluorobenzene (DNFB), 15d-PGJ2 or TMA, dissolved in DMSO, was 
added to give the required molar ratio of Keapl : electrophile. Following incubation on a 
mechanical roller for 1 h at 4 °C, the beads were washed three times in 0.5 mL 
phosphate buffer to remove residual electrophile. To cap unmodified cysteines, the
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beads were resuspended in 0.13 mL phosphate buffer and 20 pL of 0.55 M 
iodoacetamide, and incubated on a mechanical roller at 4 °C for 15 min. The beads were 
washed three times in 0.5 mL phosphate buffer to remove residual iodoacetamide. 
Tryptic digestion was performed as described in section 3.2.10.
4.2.5 LC-ESI-MS/MS mass spectrometry
Samples were analysed essentially as described in section 3.2.12. Amino acid 
modifications were detected with ProteinPilot software v2.0, using the Paragon™ 
algorithm (Shilov et a l, 2007) and the most recent version of the SwissProt database. 
Paracetamol (+149.1 amu), dinitrophenyl (DNP; +166.0 amu), 15d-PGJ2 (+316.2 amu), 
TMA (+192.0 amu) or carboxyamidomethyl (+57.0 amu) were selected as variable 
modifications. All adducts were confirmed by visual inspection of the MS/MS spectra.
4.2.6 Generation of peptide modification maps
Keapl peptide modification maps were generated using a software package available at 
http://www.liv.ac.uk/pfg/localtools.html, described previously by Beynon (2005).
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4.3.1 Modification of Keapl-His by Nrf2-activating electrophiles in vitro
In order to ascertain the relative reactivities of the 25 cysteines within mouse Keapl 
towards a panel of Nrf2-activating electrophiles, a dose-ranging study of the selectivity 
of Keapl modifications was conducted in vitro, using LC-ESI-MS/MS. In reporting 
Keapl adducts, the frequency of adducts detected from a total of three independent 
experiments has been used as an indicator of the relative reactivities of individual 
cysteine residues towards the panel of electrophiles. Keapl protein sequence coverage 
from MS/MS spectra averaged 89 % across 12 individual experiments. All cysteines 
were consistently detected, with the exception of Cys-622 and -624, which were not 
released from the Ni2+-charged agarose beads by tryptic digestion, due to their proximity 
to the polyhistidine tag of Keapl-His. Compound mutation of the three cysteines (Cys- 
613, -622, -624) located within the C-terminal domain of Keapl has no effect on the 
repressive activity of Keapl towards Nrf2 (Wakabayashi et al., 2004), implying that 
Cys-622 and -624 are not essential for Keapl function.
4.3 RESULTS
4.3.2 Modification of Keapl-His by NAPQI in vitro
Following incubation of Keapl-His with NAPQI for 1 h, no cysteine adducts were 
detected at a molar ratio of 0.01:1 NAPQTKeapl. At a molar ratio of 0.1:1 
NAPQI:Keapl, there was evidence for the modification of cysteine residues by NAPQI, 
albeit in one of three experiments. In this case, the identification of modified residues 
was based solely on the mass-to-charge ratio (m/z) and retention time of the modified 
peptide, as MS/MS spectra were not generated due to the relative low abundance o f the 
modified peptide ions. Therefore, it was not possible to unequivocally identify the 
modified residues by manually sequencing the corresponding MS/MS spectrum. In light 
of this fact, the cysteine residues that were judged to be the most readily modified by 
NAPQI in vitro were those that were detected following incubation of Keapl with
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NAPQI at a molar ratio of 1:1 NAPQI:Keapl, namely Cys-77, -226, -257, -273, -288, - 
434, -489, -583 and -613 (Table 4.1 and Fig. 4.1). Through inspection of the 
corresponding MS/MS spectra, each of these residues were found to be modified at this 
molar ratio in at least two of three independent experiments. Cys-151, the integrity of 
which has recently been shown to be critical for the ability of Keapl to respond to 
chemical/oxidative stress (Zhang et a l, 2003; Zhang et a l, 2004), was modified by 
NAPQI only at a molar ratio of 5:1 and above. Of the 23 Keapl cysteines that were 
routinely detected by LC-ESI-MS/MS, only eight residues were not modified by NAPQI 
at the highest molar ratio of 10:1, namely Cys-241, -249, -297, -319, -395, -406, -513 
and -518.
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Molar Ratio NAPQI:Keapl
Keapl Domain Cysteine # 0 0.1:1 1:1 5:1 10:1
N-terminal 23 1/3 2/3
N-terminal 38 1/3 2/3
BTB 77 1/3 3/3 3/3 3/3
BTB 151 2/3 2/3
BTB 171 1/3
IVR 196 1/3
IVR 226 3/3 3/3 3/3
IVR 241
IVR 249
IVR 257 2/3 3/3 3/3
IVR 273 1/3 2/3 3/3 3/3
IVR 288 1/3 3/3 3/3 3/3
IVR 297
IVR 319 1/3
DGR 368 1/3 2/3
DGR 395
DGR 406
DGR 434 2/3 2/3 3/3
DGR 489 1/3 3/3 3/3 3/3
DGR 513 1/3
DGR 518 1/3
DGR 583 1/3 3/3 3/3 3/3
C-terminal 613 3/3 3/3 3/3
C-terminal 622 nd nd nd nd nd
C-terminal 624 nd nd nd nd nd
Table 4.1 - Keapl-His cysteines modified by NAPQI in vitro. Ni2+ agarose bead- 
purified mouse Keapl-His (-350 pmol) was reduced on-bead with 1 mM DTT for 15 
min and incubated with NAPQI at the indicated molar ratios for 1 h. Free sulphydryls 
were capped with 55 mM iodoacetamide for 15 min. Keapl-His was digested overnight 
at 37 °C with 240 ng trypsin and the resulting tryptic peptides were analysed for adducts 
of interest by LC-ESI-MS/MS. The frequency of adduct detection, from a total of three 
experiments, is shown. Blank cells indicate that no NAPQI adducts were detected. nd\ 
Cys-622 and -624 were not routinely detected as NAPQI-modified or 
carboxyamidomethylated peptides.
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| +TOF Product (1015.4):
I a=3.57087223371498670e-004, t0*3.98646415190924020e+001
Max. 18.0 counts
CPEGAGD A VM Y ASTECK
) =
[M+2H]2+ = 1015.4 
[M] = (1015.4 X 2 ) - 2 = 2028.8 
Unmodified peptide = 1730.7 
A = +298.1 (2 x APAP)
100 200 300 400 500
Fig. 4.1 - MS/MS spectrum indicating modification of Keapl-His (A) Cys-23/38 and 
(B) Cys-77 by NAPQI in vitro, y- and b-ions are labelled where present. * denotes ions 
for which a mass shift o f +149.1 amu indicates modification by NAPQI. Immonium ions 
are labelled with the one-letter code for their corresponding amino acid.
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Fig. 4.1 - MS/MS spectrum indicating modification of Keapl-His (C) Cys-151 and 
(D) Cys-171/196 by NAPQI in vitro, y- and b-ions are labelled where present. * 
denotes ions for which a mass shift of +149.1 amu indicates modification by NAPQI. 
Immonium ions are labelled with the one-letter code for their corresponding amino acid.
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Fig. 4.1 - MS/MS spectrum indicating modification of Keapl-His (E) Cys-226 and 
(F) Cys-257 by NAPQI in vitro, y- and b-ions are labelled where present. * denotes 
ions for which a mass shift of + 149.1 amu indicates modification by NAPQI. Immonium 
ions are labelled with the one-letter code for their corresponding amino acid.
134
Chapter 4
I +TOF Product (5B4.3): Max. 42.0 count*a= a  57085551386018430e-004, t0=3.98944492153568720e+001
Fig. 4.1 - MS/MS spectrum indicating modification of Keapl-His (G) Cys-273 and 
(H) Cys-288 by NAPQI in vitro, y- and b-ions are labelled where present. * denotes 
ions for which a mass shift of + 149.1 amu indicates modification by NAPQI. Immonium 
ions are labelled with the one-letter code for their corresponding amino acid.
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I a= 3.57088730897253560e-004, t0=3.97840698198015160e+001 
2D.0] C * 510*5
iq n I/L
Max. 20.0 counts
SG L A G C W G G LLY A V G G R
|M+2H]2+ = 899.5 
[M] = (899.5 x 2) - 2 = 1797.0 
Unmodified peptide = 1647.9 
A = +149.1 (APAP)
100 200
Fig. 4.1 - MS/MS spectrum indicating modification of Keapl-His (I) Cys-319 and 
(J) Cys-368 by NAPQI in vitro, y- and b-ions are labelled where present. * denotes ions 
for which a mass shift o f +149.1 amu indicates modification by NAPQI. Immonium ions 
are labelled with the one-letter code for their corresponding amino acid.
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Fig. 4.1 - MS/MS spectrum indicating modification of Keapl-His (K) Cys-434 and 
(L) Cys-489 by NAPQI in vitro, y- and b-ions are labelled where present. * denotes 
ions for which a mass shift of + 149.1 amu indicates modification by NAPQI. Immonium 
ions are labelled with the one-letter code for their corresponding amino acid.
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I a=3.57088730897253560e-004, »=3.97840698198015160e+001
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Fig. 4.1 - MS/MS spectrum indicating modification of Keapl-His (M) Cys-513/518 
and (N) Cys-583 by NAPQI in vitro, y- and b-ions are labelled where present. * 
denotes ions for which a mass shift of +149.1 amu indicates modification by NAPQI. 
Immonium ions are labelled with the one-letter code for their corresponding amino acid.
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F ig . 4 .1  -  M S /M S  sp e c tr u m  in d ica tin g  m o d if ica t io n  o f  K e a p l-H is  (O ) C y s-6 1 3  by  
N A P Q I in vitro, y- and b-ions are labelled where present. * denotes ions for which a 
mass shift o f +149.1 amu indicates modification by NAPQI. Immonium ions are labelled 
with the one-letter code for their corresponding amino acid.
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4 .3 .3  M o d ific a tio n  o f  K e a p l-H is  b y  D N C B  in vitro
Following incubation of Keapl-His with DNCB for 1 h, as for NAPQI, no cysteine 
adducts were detected at a molar ratio of 0.01:1 DNCB:Keapl. Although there was 
evidence, based on the sequencing of MS/MS spectra, for the modification of Cys-77, - 
226, -489 and -613 at a molar ratio of 1:1 DNCB:Keapl, this was limited to one of three 
experiments (Table 4.2 and Fig. 4.2). For this reason, the residues judged to be most 
readily modified by DNCB were those for which adduction was observed in at least two 
o f three independent experiments at a molar ratio of 5:1, namely Cys-77, -226, -257, - 
489, -583 and -613. DNCB did not modify any of Cys-151, -273 and -288, residues 
which have previously been suggested as plausible targets of Nrf2-activating molecules 
(Dinkova-Kostova et a l, 2002; Kobayashi et al., 2006; Levonen et al., 2004; 
Wakabayashi et al., 2004; Zhang et al., 2003; Zhang et al., 2004), implying that these 
cysteine residues are not particularly reactive with DNCB under the experimental 
conditions employed. In order to confirm that DNCB did not form adducts with Cys- 
151, -273 and/or -288 in vitro, the molar ratio was raised to 50:1 DNCB:Keapl; even at 
this ratio, no ions corresponding to the modified forms of these peptides were detected. 
In order to ascertain that Cys-151, -273 and -288 were available for adduction in the 
presence of DNCB, Keapl was co-incubated simultaneously with NAPQI and DNCB; 
all three cysteines were modified by NAPQI, but not by DNCB (data not shown). 
Furthermore, Keapl was incubated with DNFB, which also stimulates Nrf2 nuclear 
accumulation in Hepa-lclc7 cells (Fig. 4.3). DNFB is more reactive than DNCB, as 
fluorine is a better leaving group than chlorine, thus enhancing bimolecular nucleophilic 
substitution. Nevertheless, modification of Cys-151, -273 or -288 by DNFB was not 
detected; indeed, the pattern of cysteine modifications observed matched that of DNCB, 
with modification of Cys-171, -196 and -434 also detected (Fig. 4.4). Consistent with its 
known chemical reactivity (Park et a l, 1987), DNFB formed adducts with tyrosine and 
lysine residues in Keapl at the highest molar ratio of 50:1 (Fig. 4.4). In summary, 
DNCB does selectively modify cysteines within Keapl in vitro, but at different residues 
to NAPQI.
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M o la r  R a tio  D N C B :K e a p l
K e a p l  D o m a in C y ste in e  # 0 0 .1 :1 1:1 5:1 10:1 50:1
N-terminal 23
N-terminal 38
BTB 77 1/3 3/3 3/3 3/3
BTB 151
BTB 171
IVR 196
IVR 226 1/3 1/3 3/3 3/3 3/3
IVR 241
IVR 249
IVR 257 3/3 3/3 3/3
IVR 273
IVR 288
IVR 297
IVR 319
DGR 368 1/3 2/3 2/3
DGR 395
DGR 406
DGR 434
DGR 489 1/3 3/3 3/3 3/3
DGR 513 1/3
DGR 518 1/3
DGR 583 2/3 1/3 1/3
C-terminal 613 1/3 1/3 3/3 3/3 3/3
C-terminal 622 nd nd nd nd nd nd
C-terminal 624 nd nd nd nd nd nd
T a b le  4 .2  -  K e a p l-H is  cy ste in es  m o d ified  b y  D N C B  in vitro. Ni2+ agarose bead- 
purified mouse Keapl-His (-350 pmol) was reduced on-bead with 1 mM DTT for 15 
min and incubated with DNCB at the indicated molar ratios for 1 h. Free sulphydryls 
were capped with 55 mM iodoacetamide for 15 min. Keapl-His was digested overnight 
at 37 °C with 240 ng trypsin and the resulting tryptic peptides were analysed for adducts 
o f interest by LC-ESI-MS/MS. The frequency of adduct detection, from a total of three 
experiments, is shown. Blank cells indicate that no DNCB adducts were detected. nd\ 
Cys-622 and -624 were not routinely detected as DNCB-modified or 
carboxyamidomethylated peptides.
141
C hapter 4
+TOF Product (768.0):
a= 3.57121248857625760e-004, »=4.02995256485810390e+001
Max. 65.0 counts
B
F ig . 4 .2  - M S /M S  sp ec tru m  in d ica tin g  m o d if ica t io n  o f  K e a p l-H is  (A ) C y s-7 7  an d  
(B ) C y s-2 2 6  b y  D N C B  in vitro, y- and b-ions are labelled where present. * denotes ions 
for which a mass shift of + 166.0 amu indicates modification by DNCB. Immonium ions 
are labelled with the one-letter code for their corresponding amino acid.
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I +TOF Product (908.0):
I a=3.57098018353016940e-004, t0=3.95409315568977040e+001
D
SG LA G C W G G LLY A V G G R
|M+2H]2+ = 908.0 
[M] = (908.0 x 2)-2 = 1814.0 
Unmodified peptide = 1647.9 
A = +166.1 (DNP)
F ig . 4 .2  - M S /M S  sp e c tr u m  in d ic a tin g  m o d ifica tio n  o f  K e a p l-H is  (C ) C y s-2 5 7  a n d  
(D ) C y s-3 6 8  b y  D N C B  in vitro, y- and b-ions are labelled where present. * denotes ions 
for which a mass shift o f +166.0 amu indicates modification by DNCB. Immonium ions 
are labelled with the one-letter code for their corresponding amino acid.
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F ig . 4 .2  -  M S /M S  sp ec tru m  in d ic a tin g  m o d if ica t io n  o f  K e a p l-H is  (E ) C y s-4 8 9  an d  
(F ) C y s-5 1 5 /5 1 8  b y  D N C B  in vitro, y- and b-ions are labelled where present. * denotes 
ions for which a mass shift of + 166.0 amu indicates modification by DNCB. Immonium 
ions are labelled with the one-letter code for their corresponding amino acid.
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I +TOF Product (1235.9): Max. 155.0 countsa= a 57101248899757810e-004, t0 -3 .93395167134622170e+001
F ig . 4 .2  - M S /M S  sp e c tr u m  in d ica tin g  m o d ifica tio n  o f  K e a p l-H is  (G ) C y s-5 8 3  and  
(H ) C y s-6 1 3  b y  D N C B  in vitro, y - and b-ions are labelled where present. * denotes ions 
for which a mass shift o f +166.0 amu indicates modification by DNCB. Immonium ions 
are labelled with the one-letter code for their corresponding amino acid.
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DNFB: -  + Std. 
Nrf2 ►
Actin ►
2 500% 
c
O 400%
(/)
>, 300% 
§  200%
|  100%
1  0%
DC -DNFB +DNFB
F ig . 4 .3  -  A c tiv a tio n  o f  N rf2  b y  D N F B . Hepa-lclc7 cells were exposed to vehicle (0 .5  
% DMSO) or DNFB (1 0 0  pM) for 1 h. Nuclear fractions were prepared and the Nrf2 
protein level was assessed by Western blot analysis. Nrf2 bands were quantified by 
densitometry and expressed relative to p-actin, to enable comparison with vehicle- 
treated control Nrf2 level, which was arbitrarily set at 100 %. Recombinant Nrf2-His 
was loaded onto the gels as a standard (Std). Non-specific proteins that cross-react with 
the antibody are labeled *.
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F 3.57101248899757810e-004,10=3.93395167134622170e+001 
370.2189
ACSDFLVQQLDPSNAIGIANFAEQIGCTELHQR
Max. 7.0 counts
A
n o2
|M+3H]j+ = 1307.7 
[M] = (1307.7 x 3) - 3 = 3920.1 
Unmodified peptide = 3587.7 
A = +332.4 (2 x DNP)
900 950 1000 1050 1100 1150 1200 1250 1300
F ig . 4 .4  -  M S /M S  sp e c tr u m  in d ic a tin g  m o d ifica tio n  o f  K e a p l-H is  (A ) C y s-1 7 1 /1 9 6  
a n d  (B ) C y s-4 3 4  b y  D N F B  in vitro, y- and b-ions are labelled where present. * denotes 
ions for which a mass shift o f +166.0 amu indicates modification by DNFB. Immonium 
ions are labelled with the one-letter code for their corresponding amino acid.
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Fig. 4.4 - MS/MS spectrum indicating modification of Keapl-His (C) Tyr-85 and 
(D) Tyr-206 by DNFB in vitro, y- and b-ions are labelled where present. * denotes ions 
for which a mass shift o f +166.0 amu indicates modification by DNFB. Immonium ions 
are labelled with the one-letter code for their corresponding amino acid.
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»= 3.57101248899757810e-004, ©=3.93395167134622170e+001 
403.2528
Max. 18.0 counts
YDVETETW TFVAPM R
[M+2H)2+= 1006.0 
(M] = (1006.0 x 2) - 2 = 2010.0 
Unmodified peptide = 1843.9 
A = +166.1 (DNP)
Fig. 4.4 - MS/MS spectrum indicating modification of Keapl-His (E) Tyr-537 and 
(F) Lys-131 by DNFB in vitro, y- and b-ions are labelled where present. * denotes ions 
for which a mass shift o f +166.0 amu indicates modification by DNFB. Immonium ions 
are labelled with the one-letter code for their corresponding amino acid.
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Fig. 4.4 - MS/MS spectrum indicating modification of Keapl-His (G) Lys-565 by 
DNFB in vitro, y- and b-ions are labelled where present. * denotes ions for which a 
mass shift o f +166.0 amu indicates modification by DNFB. Immonium ions are labelled 
with the one-letter code for their corresponding amino acid.
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Following incubation of Keapl-His with 15d-PGJ2 for 1 h, as for NAPQI and DNCB, no 
cysteine adducts were detected at a molar ratio of 0.01:1 15d-PGJ2:Keapl. However, in 
contrast to NAPQI and DNCB, cysteine adducts were not detected at molar ratios of 
0.1:1 or 1:1 15d-PGJ2:Keapl (Table 4.3 and Fig. 4.5). Indeed, detection of 15d-PGJ2- 
cysteine adducts was limited to low intensity ions, at relatively high molar ratios, in one 
of three experiments. The adducts detected were Cys-226, -368, -513/518 and -613. 
There was no evidence for the modification of Cys-151, -273 and/or -288 by 15d-PGJ2, 
even following incubation of Keapl with a 100-fold molar excess of the cyclopentenone.
In order to confirm that the conditions used for the detection of 15d-PGJ2-cysteine 
adducts were robust, the cyclopentenone was incubated with a reference protein with 
which our research group has extensive experience as a model for chemical modification 
experiments (Jenkins et a l, 2008), namely human GSTP1-1. At an equimolar ratio and 
greater, 15d-PGJ2 reproducibly modified the reactive Cys-47 of GSTP1-1, as did NAPQI 
and DNCB (see Appendix). For some Keapl and GSTP1-1 peptides modified by 15d- 
PGJ2, although it was clear that the parent ions had undergone an increase in mass 
consistent with adduction by 15d-PGJ2 (+316.2 amu), it was not possible to identify 
modified y- and/or b-ions. However, it was noticeable from visual inspection of the 
MS/MS spectra that the peptide fragmentation process had resulted in the dissociation of 
15d-PGJ2 from the cysteine residue; therefore the singly-charged prostaglandin molecule 
(317.2 amu) was detectable. This characteristic ion was not present when Keapl or 
GSTP1-1 was incubated with iodoacetamide alone. Therefore, it appears that cysteines 
within Keapl react weakly with the Nrf2-activating cyclopentenone 15d-PGJ2 in vitro, 
although the lability of the adduct formed between 15d-PGJ2 and cysteine residues in 
Keapl may hinder the detection of modifications under the experimental conditions 
employed here.
4.3.4 Modification of Keapl-His by 15d-PGJ2 in vitro
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Molar Ratio 15d-PGJ2:Keapl
Keapl Domain Cysteine # 0 5:1 10:1 50:1 100:1
N-terminal 23
N-terminal 38
BTB 77
BTB 151
BTB 171
IVR 196
IVR 226 1/3 1/3 1/3 1/3
IVR 241
IVR 249
IVR 257
IVR 273
IVR 288
IVR 297
IVR 319
DGR 368 1/3 1/3 1/3
DGR 395
DGR 406
DGR 434
DGR 489
DGR 513
1/3* 1/3 1/3 1/3
DGR 518
DGR 583
C-terminal 613 1/3 1/3 1/3 1/3
C-terminal 622 nd nd nd nd nd
C-terminal 624 nd nd nd nd nd
Table 4.3 - Keapl-His cysteines modified by 15d-PGJ2 in vitro. Ni2+ agarose bead- 
purified mouse Keapl-His (-350 pmol) was reduced on-bead with 1 mM DTT for 15 
min and incubated with 15d-PGJ2 at the indicated molar ratios for 1 h. Free sulphydryls 
were capped with 55 mM iodoacetamide for 15 min. Keapl-His was digested overnight 
at 37 °C with 240 ng trypsin and the resulting tryptic peptides were analysed for adducts 
of interest by LC-ESI-MS/MS. The frequency of adduct detection, from a total of three 
experiments, is shown. Blank cells indicate that no 15d-PGJ2 adducts were detected. No 
15d-PGJ2-cysteine adducts were detected at molar ratios of 0.01:1, 0.1:1 or 1:1. nd; Cys- 
622 and -624 were not routinely detected as 15d-PGJ2 -modified or 
carboxyamidomethylated peptides. *A mass shift equivalent to the addition of one 
molecule of 15d-PGJ2 was detected on this peptide. Due to the lack of sufficient b-ions, 
however, it was not possible to determine which of the two cysteines, Cys-513 or Cys- 
518, was adducted.
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Fig. 4.5 - MS/MS spectrum indicating modification of Keapl-His (A) Cys-226 and 
(B) Cys-368 by 15d-PGJ2 in vitro, y- and b-ions are labelled where present. * denotes 
ions for which a mass shift of +316.2 amu indicates modification by 15d-PGJ2. 
Immonium ions are labelled with the one-letter code for their corresponding amino acid. 
It was not determined via which of the two electrophilic «,/i-unsaturated carbonyl 
moieties (labelled #) adduction occurred.
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♦TOF Product (1105.3):
' 3  57101997726526510e-004.10=3 93048760968413260e+001 
136.0927^175.1211
s g a g v c v l h n & y a a g g y d g q d q l n s v e r  
#
Max. 8.0 counts
c
COOH
Fig. 4.5 - MS/MS spectrum indicating modification of Keapl-His (C) Cys-513/518 
and (D) Cys-613 by 15d-PGJ2 in vitro, y- and b-ions are labelled where present. * 
denotes ions for which a mass shift of +316.2 amu indicates modification by 15d-PGJ2. 
Immonium ions are labelled with the one-letter code for their corresponding amino acid. 
It was not determined via which of the two electrophilic a,/?-unsaturated carbonyl 
moieties (labelled #) adduction occurred. C) A mass shift equivalent to the addition of 
one molecule of 15d-PGJ2 was detected on this peptide. Due to the lack of sufficient b- 
ions, however, it was not possible to determine which of the two cysteines, Cys-513 or 
Cys-518, was adducted.
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Given that TMA does not activate Nrf2, and is a hard electrophile capable of reacting 
with the amine group of lysine, but relatively incapable of modifying cysteines, it was 
anticipated that TMA would not form adducts with cysteine residues within Keapl in 
vitro. Indeed, no cysteine adducts were detected following incubation of Keapl-His with 
TMA, to a molar ratio of 50:1, although adduction of Lys-108 was identified (Fig. 4.6).
4.3.5 Modification of Keapl-His by TMA in vitro
Fig. 4.6 - MS/MS spectrum indicating modification of Keapl-His Lys-108 by TMA
in vitro, y- and b-ions are labelled where present. * denotes ions for which a mass shift 
of +192.0 amu indicates modification by TMA. Immonium ions are labelled with the 
one-letter code for their corresponding amino acid.
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The only cysteines that were not found to be modified by NAPQI, DNCB and/or 15d- 
PGJ2 in this study were Cys-241, -249, -297, -395 and -406. As evidence that these 
cysteines were available for modification and detectable by LC-ESI-MS/MS analysis, 
MS/MS spectra for peptides containing Cys-241/249, -297 and -395/406 are presented 
as iodoacetamide adducts in Fig. 4.7.
4.3.6 Summary of Keapl-His modifications
Fig. 4.7 - MS/MS spectrum indicating modification of Keapl-His (A) Cys-241/249 
and by iodoacetamide in vitro, y- and b-ions are labelled where present. * denotes ions 
for which a mass shift of +57.1 amu indicates modification by iodoacetamide. 
Immonium ions are labelled with the one-letter code for their corresponding amino acid.
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Fig. 4.7 - MS/MS spectrum indicating modification of Keapl-His (B) Cys-297/319 
and (C) Cys-395/406 by iodoacetamide in vitro, y- and b-ions are labelled where 
present. * denotes ions for which a mass shift of +57.1 amu indicates modification by 
iodoacetamide. Immonium ions are labelled with the one-letter code for their 
corresponding amino acid.
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In summary, the results presented in this chapter demonstrate different patterns of Keapl 
cysteine modification induced by a panel of chemically distinct, Nrf2-activating 
electrophiles (Fig. 4.8); the only residues commonly targeted by NAPQI, DNCB and 
15d-PGJ2 in vitro, at relatively high molar ratios, were Cys-226, -368 and -613.
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■  DNCB 
□I5d-PG J2
C171/196 C257 C273 C288 C513/518 C613
\ /
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Fig. 4.8 - Summary of in vitro Keapl-His cysteine adduct patterns for NAPQI, 
DNCB and 15d-PGJ2. Modification maps for cysteine-containing Keapl-His peptides 
were generated using a software package described previously by Beynon (2005). The 
horizontal lines represent the full-length Keapl protein (amino acids 1-624), the vertical 
lines represent the boundaries between sequential tryptic peptides. Filled boxes represent 
cysteine-containing peptides found to be modified by NAPQI (■), DNCB (■) or 15d- 
PGJ2 (□), at the indicated molar ratios. Multi-shaded boxes represent cysteines modified 
by more than one of the three molecules. The specific cysteines modified are noted at 
the top of the figure. Experiments involving a molar ratio of 50:1 were performed with 
DNCB and 15d-PGJ2, but not NAPQI. Experiments involving a molar ratio of 100:1 
were performed with 15d-PGJ2 only.
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4.4 DISCUSSION
The Nrf2-ARE pathway serves to protect mammalian cells against chemical/oxidative 
stress, via the inducible expression of cytoprotective enzymes and proteins (for a review, 
see Kensler et a l, 2007). It has been proposed that chemical inducers activate the Nr£2- 
ARE pathway through the direct modification of critical cysteine residues within Keapl, 
the cytosolic repressor of Nrf2 (Dinkova-Kostova et a l, 2002). The aim of the work 
presented in this chapter was two-fold, a) to explore the hypothesis that NAPQI activates 
the Nrf2-ARE pathway through the selective modification of cysteine residues within 
Keapl, and b) to test, using a panel of structurally-distinct electrophiles, the hypothesis 
that all Nrf2-activating molecules selectively modify one or more Keapl cysteines 
amongst the subset of Cys-151, -273 and -288. In order to test these hypotheses, 
recombinant mouse Keapl-His (expression and purification described in chapter 3) was 
exposed to NAPQI, DNCB, 15d-PGJ2 and TMA in vitro, and cysteine adducts were 
mapped by MS/MS. Importantly, during the course of this work, a number of 
independent studies have employed a similar methodology to provide compelling 
evidence for the chemical modification of Keapl in vitro by DNCB (Liu et a l, 2005) 
and the Nrf2-activating molecules menadione (Liu et a l, 2005), biotinylated 
iodoacetamide (BIA) (Eggler et a l, 2005; Hong et a l, 2005b), sulforaphane (Hong et 
a l, 2005a), xanthohumol (Dietz et a l, 2005; Luo et a l, 2007), isoliquiritigenin and 10- 
shogaol (Luo et a l, 2007). The results of the work presented in this chapter will be 
discussed in light of these recent investigations.
This study has demonstrated direct chemical modification of Keapl by NAPQI, and 
thereby provides the first evidence for the modification of Keap 1 by the metabolite of a 
widely-used therapeutic drug. At an equimolar ratio of NAPQLKeapl, 10 cysteine 
residues were found to be modified, including Cys-257, -273, -288 and -613, i.e. four of 
the five cysteines in mouse Keapl originally identified as the most reactive towards dex- 
mes in vitro (Dinkova-Kostova et a l, 2002). Indeed, Cys-273 and -288 were amongst 
five residues found to be the most readily modified by NAPQI at the lowest molar ratio 
o f 0.1:1. Additionally, NAPQI modified the BTB domain residue Cys-151, which has
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also been proposed as a target for activators of Nrf2, based on evidence from site- 
directed mutagenesis experiments (Zhang et a l, 2003). Therefore, these findings support 
the concept that Cys-151, -273 and -288 of Keapl may be preferential targets of Nrf2- 
activating molecules, and indirectly support the hypothesis that NAPQI activates the 
Nrf2-ARE pathway through direct modification of Keapl. O f course, it is necessary to 
be cautious when attempting to extrapolate data obtained from such in vitro analyses to a 
cellular context. Therefore, a cell-based method is required to further explore, under 
more biologically-relevant conditions, the association between modification of Keapl 
and activation of Nrf2 by NAPQI.
In an attempt to provide a biochemical rationale for the ability of NAPQI and other 
electrophiles to activate Nrf2-dependent cell defence, the residue-selectivity of Keapl 
modification by structurally-distinct Nrf2-activating molecules (DNCB and 15d-PGJ2) 
has also been determined. Notably, MALDI-TOF MS has recently been used to show 
that DNCB forms adducts with human Keapl, following incubation of the protein with a 
20-fold molar excess of DNCB for 2 h (Liu et al., 2005). Although the authors of this 
study did not explicitly identify the cysteine residues that were modified by DNCB, they 
did note the appearance of new peptide ion signals that correspond to DNCB-modified 
cysteine-containing peptides (Liu et a l, 2005). By comparing the masses of these signals 
to a theoretical tryptic digest of human Keapl, it can be determined that the specific 
residues modified by DNCB in the study of Liu et al. (2005) were Cys-226, -257, -319, - 
489 and -613. With the exception of Cys-319, all of these residues were found to be 
modified in mouse Keapl by DNCB in section 4.3.3 of this thesis, indicating a degree of 
agreement between these independent investigations.
In contrast to NAPQI, it was not possible to detect modification by DNCB of Cys-151, - 
273 or -288, contradicting the notion that these residues are preferentially reactive 
towards all Nrf2-activating molecules. However, DNCB did preferentially modify the 
IVR residue Cys-257 and the C-terminal domain residue Cys-613, two of the five 
cysteines found to be the most reactive towards dex-mes in vitro (Dinkova-Kostova et 
al., 2002), suggesting that modification of reactive Keapl cysteines in general, and not
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of specific residues per se, may be critical for the activation of Nrf2-dependent cell 
defence.
Recently, biotin-tagged analogues of 15d-PGJ2 have been employed to demonstrate 
binding of the cyclopentenone to Keapl in cells (Hosoya et al., 2005; Itoh et al., 2004; 
Levonen et al., 2004). Although such an approach cannot identify specific residues that 
are targeted by 15d-PGJ2, compound mutation of seven cysteines within the IVR domain 
of Keapl abolishes this adduct formation (Hosoya et al., 2005), indicating that one or 
more cysteines within this region are targeted by 15d-PGJ2 in cells. The present study, in 
providing the first mass spectrometry-based evidence for the modification of specific 
Keapl cysteines by 15d-PGJ2 in vitro, has demonstrated adduction of one of these IVR 
residues, Cys-226, in addition to Cys-368, -513/518 and -613. Again, it was not possible 
to detect modification of Cys-151, -273 or -288 by 15d-PGJ2, confirming that, at least in 
vitro, these residues are not preferential targets for all Nrf2-activating molecules.
Notably, the molar amounts of 15d-PGJ2 required to detect Keapl cysteine adducts were 
relatively high, when compared to NAPQI and DNCB. Furthermore, evidence for 
modification of Keapl cysteines by 15d-PGJ2 was apparent in only one of three 
experiments. This may be due to the lability of the adducts formed between 15d-PGJ2 
and sulphydryl moieties, which may be susceptible to decomposition during sample 
preparation or in the course of the MS/MS fragmentation process. Hence, there may be 
value in optimising workup and/or analysis procedures in order to preserve 15d-PGJ2- 
cysteine adducts, in a similar manner to that reported by Hong et al. (2005a) in their 
recent study of Keapl modification by sulforaphane, which also forms relatively labile 
adducts with cysteine. Alternatively, it is possible that, in activating Nrf2, the initial 
point of interaction of 15d-PGJ2 may be with upstream signalling molecules other than 
Keapl. Indeed, evidence exists for an inhibitory effect of 15d-PGJ2 on the ubiquitin- 
proteasome pathway (Mullally et al., 2001; Shibata et al., 2003), which has a major role 
in regulating the basal activity of Nrf2 (Kobayashi et al., 2004; McMahon et al., 2003; 
Nguyen et al., 2003; Stewart et al., 2003; Zhang et al., 2003). Therefore, the ability of 
15d-PGJ2 to activate Nrf2 may be at least partially independent of direct modification of
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Keapl. 15d-PGJ2 has been shown previously to adduct and inhibit the activity of other 
important cellular proteins including the transcription factors NF-kB (Cemuda-Morollon 
et al., 2001) and AP-1 (Perez-Sala et al., 2003), and the GSH-conjugating enzyme 
GSTP1-1 (Sanchez-Gomez et al., 2007); the latter was used in this study as a model 
cysteine-containing protein to confirm that the method used for detecting 15d-PGJ2- 
cysteine adducts was robust. In summary, this work demonstrates that 15d-PGJ2 
selectively modifies Keapl cysteines in vitro, albeit relatively weakly compared to 
NAPQI and DNCB. It is, therefore, imperative that further work is undertaken to 
ascertain the importance of Keapl modification in the activation of Nrf2 by 15d-PGJ2 in 
a cellular context.
In contrast to NAPQI, DNCB and 15d-PGJ2, and in keeping with its known chemical 
reactivity, it was not possible to detect modification of Keapl cysteines by the lysine- 
reactive molecule TMA, which does not activate Nrf2 in Hepa-lclc7 cells. Taken 
together, therefore, the findings of this study indicate that reactivity towards cysteine is 
an important chemical property shared by Nrf2-activating molecules. However, through 
mapping Keapl cysteine modifications by three chemically-distinct electrophiles using 
the same test system, it has been demonstrated that the pattern of adducts associated with 
different Nrf2-activators may vary, at least in vitro, a conclusion that can also be drawn 
from the recent mass spectrometry-based investigations of Keap 1 modification by thiol- 
reactive, Nrf2-activating electrophiles (Table 4.4) (Dinkova-Kostova et al., 2002; Eggler 
et al., 2005; Hong et al., 2005a; Hong et al., 2005b; Luo et al., 2007). Indeed, the only 
residues commonly modified by NAPQI, DNCB and 15d-PGJ2 in this study, at 
relatively high molar ratios, were Cys-226, -368 and -613. Given that Cys-226 and -613 
are flanked by at least one basic amino acid, which should lower their pKa values and 
increase their relative reactivities towards electrophiles (Snyder et al., 1981), it is 
perhaps not surprising that these residues are targeted by all three molecules. Although 
there are no reports at present whereby mutagenesis of these residues alone has been 
used to assess their relative importance for Keapl function, Cys-226 has recently been 
shown to be preferentially modified in vitro by the Nrf2-activating molecules 
sulforaphane (Hong et al., 2005a) and isoliquiritigenin (Luo et al., 2007), but not by dex
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M o u se  K e a p l H u m a n  K e a p l
D o m a in C y s # D ex-m es N A P Q I D N C B 1 5 d -P G J2 B lA a B IA b SU L X A N IS O S H O
N T 13 np np np np
N T 14 np np np np
N T 23
N T 38
B TB 77
B TB 151 n d
B TB 171
IV R 196
IV R 226
IV R 241
IV R 249
IV R 257
IV R 273
IV R 288
IV R 297
IV R 319
D G R 368
D G R 395 n d
D G R 406 n d
D G R 434
D G R 489
D G R 513
D G R 518
D G R 583 n d
C T 613
C T 622 n d n d n d
C T 624 n d n d n d
T a b le  4 .4 . S u m m a ry  o f  K e a p l  cy ste in e  r e sid u es  m o d ified  in vitro b y  N r f2 -a c tiv a tin g  
m o le c u le s , as d e ter m in ed  in  ch a p ter  4  o f  th is  th esis  a n d  b y  in d e p e n d e n t re sea rch  
g ro u p s . Shaded cells represent cysteine residues modified at lowest molar ratio of 
electrophile:Keapl at which there was reliable evidence for modification. Dex-mes, 
dexamethasone 21-mesylate (Dinkova-Kostova et al., 2002); NAPQI, DNCB, 15d-PGJ2 
(chapter 4 of this thesis); BIA, biotinylated iodoacetamide a(Eggler et al., 2005) b(Hong 
et al., 2005b); SUL, sulforaphane (Hong et al., 2005a); XAN, xanthohumol (Luo et al., 
2007); ISO, isoliquiritigenin (Luo et al., 2007); SHO, 10-shogaol (Luo et al., 2007). np, 
residues are not cysteines in the mouse protein, nd, peptide not detected during analysis. 
NT, N-terminal; CT, C-terminal.
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-mes (Dinkova-Kostova et al., 2002), xanthohumol and 10-shogaol (Luo et al., 2007). 
Also, there are conflicting reports regarding the modification of Cys-226 by BIA (Eggler 
et al., 2005; Hong et al., 2005b). The CT domain, containing Cys-613, is apparently 
essential for Keapl-mediated repression of Nrf2 activity (Kang et al., 2004), and Cys- 
613 has been shown to be particularly reactive towards dex-mes (Dinkova-Kostova et 
al., 2002) and xanthohumol (Luo et al., 2007), but not towards IAB (Eggler et al., 2005; 
Hong et al., 2005b), sulforaphane (Hong et al., 2005a), 10-shogaol and isoliquiritigenin 
(Luo et al., 2007). Notably, there are no basic residues flanking Cys-368 in the mouse 
Keapl protein. Hence, it is less likely that Cys-368 is stabilised in the thiolate form (-S') 
(Snyder et al., 1981), and this residue should not be highly reactive towards 
electrophiles. It is therefore surprising that Cys-368 is modified by NAPQI, DNCB and 
15d-PGJ2. Cys-368 has also been shown to be a preferential target of sulforaphane 
(Hong et al., 2005a) and 10-shogaol (Luo et al., 2007), but not of dex-mes (Dinkova- 
Kostova et al., 2002), IAB (Eggler et al., 2005; Hong et al., 2005b), xanthohumol and 
isoliquiritigenin (Luo et al., 2007). Therefore, the potential roles of Keapl Cys-226, - 
368 and -613 in the regulation of Nrf2 function merit further investigation, but, at least 
in vitro, these residues are not selective targets of all Nrf2-activating molecules.
It was noted that, of the three Nrf2-activating molecules tested in this study, only 
NAPQI modified the apparently critical subset of Cys-151, -273 and -288. This suggests 
that, at least within the test system employed, these residues do not react preferentially 
with all Nrf2-activating molecules. In keeping with this, Cys-151 has been shown to be 
preferentially modified in vitro by xanthohumol, isoliquiritigenin and 10-shogaol (Luo et 
al., 2007), but not by dex-mes (Dinkova-Kostova et al., 2002) and sulforaphane (Hong 
et al., 2005a). There is also controversy regarding the preferential reactivity of Cys-151 
towards BIA (Eggler et al., 2005; Hong et al., 2005b), although this has recently been 
attributed to the different procedures used by the two groups for purifying recombinant 
Keapl (Eggler et al., 2007). Cys-273 of Keapl is preferentially adducted in vitro by dex- 
mes (Dinkova-Kostova et al., 2002), but not by sulforaphane (Hong et al., 2005a), BIA 
(Eggler et al., 2005; Hong et al., 2005b), xanthohumol, isoliquiritigenin and 10-shogaol 
(Luo et al., 2007). This is somewhat surprising, given that Cys-273 is flanked on either
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side by basic amino acids, and thus has a low predicted pKa value, and high relative 
reactivity towards electrophiles (Snyder et al., 1981). Cys-288 has recently been shown 
to be selectively targeted in vitro by dex-mes (Dinkova-Kostova et al., 2002) and BIA 
(Eggler et al., 2005; Hong et al., 2005b), but not by sulforaphane (Hong et al., 2005a), 
xanthohumol, isoliquiritigenin and 10-shogaol (Luo et al., 2007). Therefore, at least in 
terms of primary structure, the apparently critical subset of Cys-151, -273 and -288 of 
Keapl are capable of reacting preferentially with some, but not all, Nrf2-activating 
molecules (Table 4.4). Further investigations are required to elucidate the importance of 
direct modification of these residues in the activation of Nrf2.
From the recent mass spectrometry-based investigations of Keapl modification by Nrf2- 
activating electrophiles, is it evident that no single cysteine appears to react 
preferentially with all of the molecules tested, at least in vitro (Table 4.4) (Dinkova- 
Kostova et al., 2002; Eggler et al., 2005; Hong et al., 2005a; Hong et al., 2005b; Luo et 
al., 2007). The different adduct patterns observed between molecules in these studies 
may be a function of the inherent reactivity of a given electrophile toward a specific 
cysteine residue, or may simply reflect slight differences in experimental approaches, or 
both. Of course, it is plausible that modification of any single residue may in itself be 
sufficient to trigger the activation of Nr£2. Indeed, such a non-specific triggering 
mechanism may underlie the chemical versatility of the Nrf2-ARE pathway, in terms of 
its capacity to ‘sense’ and respond to a variety of structurally-distinct molecules. More 
specifically, it is possible that the modification of a single cysteine residue/group of 
residues within a critical domain of Keapl provides the molecular trigger for Nrf2 
activation. Indeed, it is clear that each of the Nrf2-activating molecules tested to date 
preferentially modify one or more cysteine residues within the IVR domain of Keapl in 
vitro (Table 4.4). In keeping with this, it is notable that l-biotinamido-4-(4’- 
[maleimidoethyl-cyclohexane]carboxamido)-butane, which does not activate the Nr£2- 
ARE pathway, modifies human Keapl in vitro, but at cysteine residues outside of the 
IVR domain (Hong et al., 2005b). Taken together, these findings imply that a number of 
alternative target sets are present amongst the reactive cysteines of Keapl, but 
particularly within the IVR domain of the protein (Table 4.4). Further investigations,
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particularly within a cellular context, are therefore required to elucidate the importance 
of modification within the IVR domain in the activation of Nrf2.
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CHAPTER 5
Development of a cell-based method for investigating the chemical 
modification of Keapl and concomitant activation of Nrf2 by electrophiles
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5.1 INTRODUCTION
It has been postulated that the modification of one or more cysteine residues within 
Keapl, the major regulator of Nrf2 activity (Itoh et al., 1999), may provide a 
biochemical trigger for activation of the transcription factor (Dinkova-Kostova et al., 
2002). Through the use of a cell-free in vitro system, the data presented in chapter 4 
demonstrate residue-selective modification of Keapl by structurally distinct Nrf2- 
activating electrophiles. However, these results, and the work of others (Dinkova- 
Kostova et al., 2002; Eggler et al., 2005; Hong et al., 2005a; Hong et al., 2005b; Luo et 
al., 2007), indicate that no single cysteine appears to react preferentially with all of the 
molecules tested, at least in vitro, perhaps implying that a single common target residue 
does not exist for all Nrf2-activating molecules. The different Keapl adduct patterns 
observed between molecules in the highlighted studies may represent the biochemical 
versatility of the Nrf2-ARE pathway, in terms of its ability to ‘sense’ and respond to a 
variety of structurally distinct molecules. However, these differences may also be the 
result of the in vitro methodologies employed.
It is important to consider that, although bacterially-expressed recombinant proteins are 
useful tools for assessing the relative reactivities of cysteine residues towards a given 
molecule in vitro, there are inherent limitations in the capacity of these systems to 
identify the likely targets of a molecule within cells. For instance, such systems may not 
fully represent the accessibility of specific cysteines for modification in cells, where 
protein folding, post-translational modification(s) and the interaction with Nrf2, CUL3 
and/or other partners may mask certain residues in Keapl. Furthermore, in determining 
the relative reactivities of Keapl cysteines towards Nrf2-activating molecules, the work 
reported in chapter 4 and in other recent mass spectrometry-based investigations 
(Dinkova-Kostova et al., 2002; Eggler et al., 2005; Hong et al., 2005a; Hong et al., 
2005b; Luo et al., 2007) have employed bacterially-expressed, purified Keapl proteins 
in which all cysteines are free for adduction, due to prior incubation with reducing 
agents such as DTT or tris(carboxyethyl)phosphine. However, the physiological 
relevance of such a method cannot be determined, at least at present, as the native redox
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states of the numerous cysteines in Keapl have yet to be determined, with the exception 
of the eight residues located within the DGR domain of the human protein (Li et a l, 
2004). In light of this gap in our current knowledge, and in addition to the limitations of 
in vitro systems, it is particularly difficult to infer that selective modifications of Keapl 
observed in vitro also occur in vivo. Hence, there are several key milestones that need to 
be achieved to facilitate a better understanding of the contribution of Keapl 
modification to the activation of the Nrf2-ARE pathway; a) the determination of the 
redox states of all of the cysteine residues in the native Keapl protein, b) the 
comprehensive analysis of residue-selective Keapl modification by Nrf2-activating 
molecules within a cellular and, where bioanalytical techniques permit, in vivo context, 
and c) detailed examination of the effect of cysteine modification on the 
structure/folding of Keapl and its interaction with Nrf2. Such studies should greatly 
enhance our appreciation of the molecular switch that triggers Nrf2-dependent cell 
defence in response to chemical/oxidative stress.
In considering the evidence for modification of Keapl in cells, a review of the published 
literature to date reveals two major issues, a) only two (biotinylated) Nrf2-activating 
molecules have been shown to modify Keapl within a cellular context (Hong et a l, 
2005b; Hosoya et a l, 2005; Itoh et a l, 2004; Levonen et a l, 2004), and b) only one of 
these studies used mass spectrometry to unequivocally identify the target residues within 
Keapl that were modified, in this case, by BIA (Hong et a l, 2005b). Therefore, there is 
a clear need to further determine the role that Keapl modification plays in the activation 
o f Nrf2 in cells, and to identify the target residues that are modified by Nrf2-activating 
molecules. In keeping with this, the initial aim of the work presented in this chapter was 
to develop a cell-based method to enable the characterisation, by MS/MS, of Keapl 
modification within a more biologically-relevant cellular setting, in order to test the 
hypothesis that modification of Keapl is associated with activation ofNrf2 in cells. Two 
approaches were taken; immunoprécipitation of endogenous Keapl, and ectopic 
expression of an epitope-tagged Keapl protein followed by affinity purification. The 
latter model system was used to map the Keapl adduct patterns associated with Nrf2-
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activating molecules, in order to test the hypothesis that a common cysteine, or subset of 
cysteines, is modified by all such molecules within a cellular context.
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5.2 METHODS
5.2.1 Materials and reagents
HotStarTaq DNA polymerase and the QIAfilter Plasmid Midi Kit were from Qiagen 
(Crawley, UK). Eco47lll and Taq DNA polymerase were from Promega (Southampton, 
UK). EcoRl and Ava\ were from Roche Diagnostics (Burgess Hill, UK). pcDNA3.1/V5- 
His-TOPO was from Invitrogen (Paisley, UK). Pme I was from New England Biolabs 
(Hitchin, UK). The sonicating water bath was from Decon (Hove, UK). The monoclonal 
mouse anti-Keapl primary antibody was from R&D Systems (Abingdon, UK). The 
mouse monoclonal anti-human Nrf2 antibody was kindly donated by Dr. Paul Hayter 
(Pfizer Ltd, Sandwich, UK). The Concentrator 5301 was from Eppendorf (Cambridge, 
UK). RIPA buffer, NP-40, protein-G agarose beads, BamHl, EcoRV, Sac I, anti-V5 
agarose beads, Brilliant Blue G colloidal concentrate, the rabbit anti-DNP primary 
antibody and the rabbit anti-mouse HRP-conjugated secondary antibody were from 
Sigma-Aldrich (Poole, UK). All other reagents were of analytical or molecular grade, 
and were from Sigma-Aldrich.
5.2.2 Immunoprécipitation of endogenous Keapl
Eight folly-confluent 75 cm2 flasks of Hepa-lclc7 cells were harvested by 
trypsinisation, as described in section 2.2.2. Following resuspension in growth media, 
cells were pelleted by centrifugation at 1000 g for 5 min, and the supernatant was 
discarded. The pellet was washed in 5 mL IX PBS, divided into two equal aliquots, and 
centrifuged at 1000 g for 5 min. For denaturing immunoprécipitation, following the 
method of Tansey (2007a), one of the pellets was resuspended in 0.2 mL TSD buffer (50 
mM Tris-Cl (Sigma-Aldrich), 1 % (v/v) SDS, 5 mM DTT, 0.2 % (v/v) protease inhibitor 
cocktail), heated at 80 °C for 10 min and clarified by centrifugation at 1000 g for 5 min. 
For non-denaturing immunoprécipitation, following the method of Tansey (2007b), the 
other pellet was resuspended in 0.2 mL radioimmunoprécipitation assay (RIPA) buffer
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(0.15 M NaCl, 1 % (v/v) NP-40, 0.5 % (v/v) sodium deoxycholate, 0.1 % (v/v) SDS, 25 
mM Tris-Cl, 0.2 % (v/v) protease inhibitor cocktail) and centrifuged at 1000g for 5 min. 
The protein content o f clarified lysates was determined as described in section 2.2.5. The 
lysates were split into four aliquots of 1 mg total protein. Each aliquot was diluted to 0.5 
mL with TON buffer (50 mM Tris-Cl, 0.25 M NaCl, 5 mM EDTA, 0.5 % (v/v) NP-40, 
0.2 % (v/v) protease inhibitor cocktail) for denaturing immunoprécipitation, or RIPA 
buffer for non-denaturing immunoprécipitation. Selected aliquots were supplemented 
with 0.4 mL IX PBS or a crude lysate from Keapl-His -expressing BL21 (DE3) E. coli. 
The bacterial lysate was prepared by pelleting a 10 mL culture (induced with 1 mM 
IPTG for 4 h at 37 °C, 250 rpm) at 5000 g for 5 min. The pellet was washed in 10 mL 
IX PBS and centrifuged at 5000 g for 5 min. The pellet was resuspended in 1 mL IX 
PBS and disrupted by sonication (10 sec, followed by 10 sec recovery, x 4 repeats). 
Disrupted bacteria were centrifuged at 5000 g for 5 min, and the supernatant retained as 
a crude lysate. Aliquots were pre-cleared with 20 pL protein-G agarose beads via 
incubation on a mechanical roller at 4 °C for 1 h. The beads were pelleted by 
centrifugation at 5000 g for 1 min. The supernatants were transferred to a new tube and 
supplemented with 5 pg monoclonal mouse anti-Keapl or polyclonal goat anti-Keapl 
antisera. Immunoprécipitation was performed overnight at 4 °C, on a mechanical roller. 
Antibody conjugates were captured via the addition of 50 pL protein-G agarose beads, 
and incubation at 4 °C, on a mechanical roller, for 2 h. The beads were pelleted, by 
centrifugation at 5000 g for 1 min, and washed three times with 0.2 mL IX PBS. In 
order to elute immunoprecipitated proteins, the beads were resuspended in an equal 
volume of NuPAGE loading buffer, heated at 80 °C for 5 min, and centrifuged at 5000 g 
for 5 min. The supernatants were loaded onto pre-cast 4-12 % NuPAGE Novex bis-tris 
polyacrylamide gels. Western blot analysis was performed essentially as described in 
section 2.2.6. For samples in which the monoclonal mouse anti-Keapl antibody had 
been used for immunoprécipitation, membranes were probed with the goat anti-Keapl 
primary and rabbit anti-goat HRP-conjugated IgG secondary antibodies. For samples in 
which the polyclonal goat anti-Keapl antibody had been used for immunoprécipitation, 
membranes were probed with the monoclonal mouse anti-Keapl primary (1:1000 in
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TBS-Tween containing 2 % (w/v) BSA) and rabbit anti-mouse HRP-conjugated 
secondary (1:10,000 in TBS-Tween containing 2 % (w/v) BSA) antibodies.
5.2.3 Preparation of mouse K ea p l coding sequence DNA template
The DNA template for mouse Keapl was prepared as described in section 3.2.2.
5.2.4 Polymerase chain reaction
The purified vector, containing the mouse Keapl cDNA clone, was used as a template 
for hot-start PCR amplification of the mouse Keapl coding sequence. A forward primer 
(5’-ATGCAGCCCGAACCCAAG-3’) and two reverse primers (‘STOP’ 5’-TCAGCAG 
GTACAGTTTTG-3 ’ and ‘V5-HIS’ 5’-GCAGGTACAGTTTTGTTGAT-3’) were 
designed to enable the amplification of Keapl with (‘STOP’) or without (‘V5-HIS’) the 
stop codon (TGA). Hot-start PCR was performed as described in section 3.2.3. The PCR 
products were resolved by electrophoresis on a 1 % agarose gel, supplemented with 0.5 
pg/mL ethidium bromide, and purified using a Perfectprep gel cleanup kit, in accordance 
with the manufacturer’s instructions. The gel-purified PCR products were 3’ A-tailed 
using Taq DNA polymerase. Reactions (10 pL) contained 8 pL gel-purified PCR 
product, IX Taq DNA polymerase buffer containing 1.5 mM MgCl2, 5 pM 
deoxyadenosine triphosphate (dATP) and 2.5 U Taq DNA polymerase. A-tailing was 
performed at 72 °C for 8 min.
5.2.5 Sub-cloning of K ea p l into pcDNA3.1/V5-His-TOPO
The A-tailed Keapl PCR products were ligated into the T-overhangs of the TOPO 
cloning site of pcDNA3.1/V5-His-TOPO, in accordance with the manufacturer’s 
instructions. XL10-Gold ultracompetent E. coli were immediately transformed with the
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ligated constructs (3 pL per 30 pL bacteria), via a 30 sec heat-shock at 42 °C, and 
incubated in 0.25 mL SOC media for 1 h, at 37 °C, 250 rpm. The bacteria were streaked 
onto a sterile LB-agar plate, containing 50 pg/mL ampicillin, and incubated at 37 °C 
overnight. Antibiotic-resistant colonies were picked from the plate and used to inoculate 
2 mL LB broth containing 50 pg/mL ampicillin; these cultures were incubated for 24 h 
at 37 °C, 250 rpm. The constructs were purified by mini-prep. Diagnostic restriction 
digests were performed with Baml/Eco47U\ (5 pL PCR product, 10 U Baml, 10 U 
Eco47lll, IX buffer D, 37 °C, 1 h) and EcoRN/Eco47lll (5 pL PCR product, 10 U 
EcoRW, 10 U Eco47l\\, IX buffer SB, 37 °C, 1 h). Glycerol stocks of a 
pcDNA3.1/Keapl-transformed XL10 Gold colony were made by supplementing a mid­
log phase culture with 15 % (v/v) glycerol; these stocks were stored at -80 °C until 
required. For transfections, pcDNA3.1/Keapl was purified from a 0.6 L culture of XL 10 
Gold E. coli, in LB broth supplemented with 50 pg/mL ampicillin, using a QIAfilter 
Plasmid Midi Kit. pcDNA3.1/Keapl was eluted into IX TE buffer, and the DNA 
concentration and purity were assessed as described for RNA in section 2.2.13, with the 
following exception (given that an absorbance of 1 at 260 nm equates to 50 pg/mL 
DNA):
Absorbance at 260 nm x 100 (to correct fo r  dilution) x  50 = DNA concentration (pg/mL)
5.2.6 DNA two-strand sequencing
XL10 Gold E. coli transformed with pcDNA3.1/Keapl, along with primers (3.2 pM), 
were sent to Geneservice for two-strand sequencing of pcDNA3.1/Keapl. The T7 
forward (5’-TAATACGACTCACTATAGGG-3’) and BGH reverse (5’-CCTCGACTG 
TGCCTTCTA-3’) priming sites were designated as the external sequencing sites. The 
internal sequencing primers were custom-synthesised by Sigma-Genosys, in accordance 
with the requirements of Geneservice; internal forward 5’-CCACCCTAAGGTCATGG 
AAA-3’, internal reverse 5’-GCTAGTTATTGCTCAG CGG-3’. Sequencing results 
were analysed using ChromasPro software; no mutations were identified.
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5.2.7 Cell culture
Hepa-lclc7 were maintained as described in section 2.2.2. The human embryonic 
kidney cell line, HEK293T, was maintained in ‘growth media’ (DMEM supplemented 
with 584 mg/L L-glutamine, 10 % FBS, 100 U/mL penicillin and 100 pg/mL 
streptomycin) and cultured as described for Hepa-lclc7 in section 2.2.2. HEK293T are 
transformed with the large T antigen of Simian virus 40 (SV40), and this enables 
episomal replication of transfected vectors that contain the SV40 origin of replication, 
effectively amplifying the expression of the transfected gene product (DuBridge et al., 
1987).
5.2.8 Transfection of cells with Keapl-V5-His
Hepa-lclc7 or HEK293T cells were seeded onto 56.7 cm2 Nunclon A culture dishes, at 
5 x 106 cells/dish, 24 h prior to transfection,. At around 80 % confluency, cells were 
transfected with pcDNA3.1/Keapl-V5-His using Lipofectamine 2000, with slight 
modifications to the manufacturer’s instructions. For each dish of cells, 1 mL DMEM 
was combined with 16 pg pcDNA3.1/Keapl-V5-His in a sterile 25 mL tube. In a 
separate 25 mL tube, 1 mL DMEM was combined with 40 pL Lipofectamine 2000. The 
contents of each tube were combined, mixed gently, and incubated at room temperature 
for 20 min. The entire mixture was added, dropwise, to the dish of cells. Cells were 
returned to a humidified incubator, at 37 °C in a 5 % CO2 atmosphere, for 24 h. The 
cells from three dishes were combined and lysed, by repeated vigorous pipetting, in 1 
mL RIPA buffer. The lysate was clarified by centrifugation at 5000 g for 1 min.
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5.2.9 Western blot analysis of whole cell lysates
Whole cell lysates (20 jug) were analysed by Western blot as described in section 2.2.6. 
Recombinant mouse Keapl-His was loaded as a standard to confirm antibody 
specificity.
5.2.10 Purification of Keapl-V5-His from cell lysates
The whole cell lysate (1 mL) prepared in section 5.2.8 was aliquoted into two 1.5 mL 
microcentrifuge tubes (0.5 mL each). The lysates were incubated with 60 pL HIS-Select 
or anti-V5 agarose beads, on a mechanical roller, for 2 h at 4 °C. The beads were 
collected by centrifugation at 5000 g for 1 min, and washed three times with 0.5 mL IX 
PBS.
5.2.11 Western blot analysis of purified Keapl-V5-His
Keapl-V5-His purification was confirmed by Western blot analysis, essentially as 
described in section 2.2.6. Proteins were eluted from HIS-Select or anti-V5 agarose 
beads by resuspending in an equal volume of NuPAGE loading buffer. The slurry was 
heated at 80 °C for 5 min, the beads were pelleted by centrifugation at 5000 g for 5 min, 
and the supernatant loaded onto a pre-cast 4-12 % NuPAGE Novex bis-tris 
polyacrylamide gel.
5.2.12 Coomassie Brilliant Blue staining and in-gel tryptic digestion
Following electrophoresis, as described in section 2.2.6, the gel was fixed for 1 h in 40 
% (v/v) methanol containing 7 % (v/v) glacial acetic acid. Coomassie staining solution 
was prepared by mixing 4 part Coomassie stain (0.1 % (w/v) Coomassie Brilliant Blue
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G-250 in 2 % (w/v) phosphoric acid, 16 % (w/v) ammonium sulphate) with 1 part 
methanol. The gel was stained with Coomassie solution for 1 h, with gentle agitation. 
The gel was destained, with 25 % (v/v) methanol containing 10 % (v/v) glacial acetic 
acid, for 1 min. The gel was rinsed with, and then stored at 4 °C in, 25 % (v/v) methanol. 
The stained gel was placed on top of a light box and bands of interest were carefully 
excised using a scalpel. The gel pieces were individually destained, in 0.1 mL of 50 mM 
ammonium bicarbonate in 50 % (v/v) ACN, for 15 min at room temperature, with 
occasional agitation. The destaining solution was removed and the gel pieces were dried 
in a Concentrator 5301 over 15 min. The gel pieces were rehydrated in 10 pL of 50 mM 
ammonium bicarbonate containing 5 ng/pL sequencing-grade modified trypsin, and 
incubated at 37 °C overnight. Following the addition of 30 pL of 60 % (v/v) ACN, 1 % 
(v/v) TFA, the samples were placed in a sonicating water bath for 5 min, at room 
temperature. The gel pieces were pelleted by centrifugation, at 1000 g for 30 sec, and the 
supernatant transferred to a new tube. A further 30 pL of 60 % (v/v) ACN, 1 % (v/v) 
TFA was added to the gel pieces, and the samples were placed in a sonicating water bath 
for 5 min, at room temperature. The gel pieces were pelleted by centrifugation, at 1000 g 
for 30 sec, and the supernatant combined with that from the previous centrifugation step. 
The sample was dried in a Concentrator 5301 over lh, and the solute reconstituted in 10 
pL of 5 % (v/v) ACN, 0.05 % (v/v) TFA.
5.2.13 Preparation of Keapl-V5-His for mass spectrometry
Keapl-V5-His, bound to anti-V5 agarose beads, was reduced by resuspending the beads 
(50 pL dry volume) in 0.148 mL phosphate buffer and 2 pL of 0.1 M DTT. The slurry 
was incubated on a mechanical roller at 4 °C for 15 min. The beads were washed three 
times in 0.5 mL phosphate buffer to remove residual DTT. To cap unmodified cysteines, 
the beads were resuspended in 0.13 mL phosphate buffer and 20 pL of 0.55 M 
iodoacetamide, and incubated on a mechanical roller at 4 °C for 15 min. The beads were 
washed three times in 0.5 mL phosphate buffer to remove residual iodoacetamide. 
Tryptic digestion was performed as described in section 3.2.10. For LC-ESI-MS/MS
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analysis, the beads were pelleted by centrifugation at 5000 g for 30 sec. The supernatant, 
containing tryptic peptides, was transferred to a new tube and dried in a Concentrator 
5301 over 45 min. The solute was reconstituted in 65 pL of 5 % (v/v) ACN, 0.05 % 
(v/v) TFA.
5.2.14 MALDI-TOF mass spectrometry
Samples were analysed as described in section 3.2.11.
5.2.15 LC-ESI-MS/MS mass spectrometry
The reconstituted solute (60 pL) from section 5.2.13 was loaded using a 0.1 mL loop. 
Samples were analysed essentially as described in section 3.2.12. LC conditions were as 
follows: 15 min at 5 % (v/v) ACN, 0.05 % (v/v) TFA, a gradient of 5-48 % (v/v) ACN, 
0.05 % (v/v) TFA over 60 min, 10 min at 99 % (v/v) ACN, 0.05 % (v/v) TFA and 10 
min at 5 % (v/v) ACN, 0.05 % (v/v) TFA, with a flow rate of 0.35 pL/min throughout.
5.2.16 Treatment of Keapl-V5 -expressing cells with electrophiles
Keapl-V5 -expressing HEK293T cells were treated essentially as described for Hepa- 
lclc7  cells in section 2.2.3. Three dishes of cells were simultaneously exposed to each 
electrophile. The cells from these three dishes were combined and lysed, by repeated 
vigorous pipetting, in 1 mL RIPA buffer. The lysate was clarified by centrifugation at 
5000 g for 1 min.
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5.2.17 Preparation of nuclear fractions
Nuclear fractions were prepared from HEK293T cells as described for Hepa-lclc7 cells 
in section 2.2.4.
5.2.18 Determination of protein content
The total protein content of subcellular fractions was determined as described in section 
2.2.5.
5.2.19 Western blot analysis of nuclear fractions
Nuclear fractions (20 pg) were resolved by denaturing electrophoresis and transferred to 
nitrocellulose membranes, which were then blocked, as described in section 2.2.6. 
Blocked membranes were probed for 1 h with a monoclonal mouse anti-human Nrf2 
antiserum (1:1000 in TBS-Tween containing 2 % (w/v) BSA). Following several washes 
in TBS-Tween, membranes were probed for 1 h with rabbit anti-mouse HRP-conjugated 
anti-IgG (1:10,000 in TBS-Tween containing 2 % (w/v) BSA). Recombinant human 
Nrf2-His was loaded as a standard to confirm antibody specificity.
5.2.20 Immunopurification of Keapl-V5-His
Keapl-V5-His was immunopurified from the whole cell lysate prepared in section 5.2.4.
1 mL lysate was incubated with 80 pL anti-V5 agarose beads, on a mechanical roller, for
2 h at 4 °C. The beads were collected by centrifugation at 5000 g for 1 min, and washed 
three times with 0.5 mL IX PBS.
181
Chapter 5
5.2.21 Western blot analysis of immunopurified Keapl-V5-His
Keapl-V5-His immunopurification was confirmed by Western blot analysis, as 
described in section 5.2.11. To probe for DNCB adducts, a rabbit anti-DNP primary 
antibody was used (1:20,000 in TBS-Tween containing 2 % (w/v) BSA). To enable 
additional probing, membranes were stripped by shaking in 0.1 M glycine (pH 3.0), for 
2 h, at room temperature.
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5.3 RESULTS
5.3.1 Immunoprécipitation of endogenous Keapl
In an effort to examine the modification of Keapl by Nrf2-activating electrophiles under 
physiologically relevant cellular conditions, attempts were made to immunoprecipitate 
endogenous Keapl from Hepa-lclc7 cells and analyse the protein by mass 
spectrometry. At the time at which these investigations were carried out, two 
commercial anti-Keapl primary antibodies were available. The first was a monoclonal 
antibody, produced from a hybridoma resulting from the fusion of a mouse myeloma 
with B cells obtained from a mouse immunised with a purified recombinant fragment 
(amino acids 90-250) of human Keapl (R&D Systems). The fragment of human Keapl 
used as the immunogen shares 98 % sequence homology with the equivalent fragment of 
mouse Keapl. Furthermore, this antibody can detect the mouse protein by Western blot 
(Fig. 5.1a). The second anti-Keapl antibody was a polyclonal antibody, raised in goat 
against a purified recombinant fragment (amino acids 10-60) of human Keapl (Santa 
Cruz Biotechnology). The fragment of human Keapl used as the immunogen for this 
antibody shares 84 % sequence homology with the equivalent fragment of mouse Keapl. 
This antibody can also detect the mouse protein by Western blot (Fig. 5.1b).
Monoclonal 
anti-Keapl IgG
B mKeap1-His
Keapl ►
Polyclonal 
anti-Keapl IgG
Fig. 5.1 - Detection of mouse Keapl by monoclonal and polyclonal anti-Keapl 
antibodies. Recombinant mouse Keapl-His was purified using Ni2+ -charged agarose 
beads and various amounts were resolved by denaturing electrophoresis. Keapl was 
detected by Western blot, using a monoclonal (A) or polyclonal (B) anti-Keapl 
antibody. This result demonstrates that each antibody can detect mouse Keapl by 
Western blot. Note, the amounts of protein loaded onto each gel are not identical, thus it 
is not possible to differentiate between the sensitivities of the antibodies from these gels.
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Ideally, it would be possible to immunoprecipitate endogenous Keapl under non­
denaturing conditions, so as not to disrupt the structural integrity of the protein and 
affect the putative modification of Keapl by Nrf2-activating electrophiles. However, the 
ability of both anti-Keapl antibodies to detect mouse Keapl by Western blot had only 
been confirmed under denaturing conditions, and hence immunoprécipitations were 
attempted separately under non-denaturing and denaturing conditions. Protein G 
sepharose was used to immunopurify antibody conjugates, as both Keapl antibodies 
were of the IgG class, which shows high affinity for streptococcal Protein G (Bjorck et 
a l, 1984).
A series of controls demonstrated that the polyclonal anti-Keapl antibody reacted 
strongly with Protein G, and non-specifically with some cellular proteins in both non- 
denatured and denatured lysates (Fig. 5.2). Although endogenous Keapl was detected in 
the input and flow-through fractions of the cell lysates, particularly in the non-denatured 
lysate, immunoprécipitation with the monoclonal anti-Keap 1 antibody only resulted in a 
noticeable recovery of Keapl when the cell lysates were supplemented with recombinant 
mouse Keapl-His protein (Fig. 5.3). Even less endogenous Keapl protein was recovered 
following immunoprécipitation with the polyclonal anti-Keapl antibody (Fig. 5.4). 
Therefore, under the experimental conditions employed, the two available commercial 
anti-Keapl antibodies are not suitable for the immunoprécipitation of endogenous 
Keapl from Hepa-lclc7 cells. Although extensive optimisation may enhance the 
recovery of Keapl from cells, it is anticipated that the material yielded may still not be 
sufficient for effective analysis by mass spectrometry.
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Fig. 5.2 - Non-specific reactivity of polyclonal anti-Keapl antibody with cellular 
proteins and Protein G. Hepa-lclc7 cells were lysed under denaturing (TSD) or non­
denaturing (RIPA) conditions. Each lysate (0.2 mg protein) was incubated with Protein 
G sepharose beads for 1 h at 4 °C. Lysates (20 pg) were resolved, by denaturing 
electrophoresis, alongside the proteins eluted from the respective Protein G sepharose 
beads and a crude lysate from Keapl-His -expressing BL21 (DE3) E. coli. Proteins 
reacting with the polyclonal anti-Keapl antibody were detected by Western blot. IB; 
immunoblot.
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IP: Monoclonal anti-Keap1 / IB: Polyclonal anti-Keap1
Fig. 5.3 - Attempted immunoprécipitation of Keapl from Hepa-lclc7 cells using a 
monoclonal anti-Keapl antibody. Hepa-lclc7 cells were lysed under denaturing 
(TSD) or non-denaturing (RIPA) conditions. Lysates (1 mg protein) were not 
supplemented (- recomb.), or supplemented (+ recomb.) with a crude lysate from Keapl- 
His -expressing BL21 (DE3) E. coli, and pre-cleared with Protein G sepharose beads for 
1 h at 4 °C. Cleared lysates were incubated at 4 °C, overnight, with 5 fig monoclonal 
anti-Keapl antibody, and antibody conjugates were captured via incubation with Protein 
G sepharose beads for 2 h at 4 °C. Fractions of the lysates pre- (input) and post- (flow­
through) immunoprécipitation were resolved by denaturing electrophoresis, alongside 
the proteins eluted from the respective Protein G sepharose beads and appropriate 
controls. Keapl was detected by Western blot, with a polyclonal anti-Keapl antibody. 
IP; immunoprécipitation. IB; immunoblot.
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Antibody ►
Protein G ►
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Fig. 5.4 - Attempted immunoprécipitation of Keapl from Hepa-lclc7 cells using a 
polyclonal anti-Keapl antibody. Hepa-lclc7 cells were lysed under denaturing (TSD) 
or non-denaturing (RIPA) conditions. Lysates (1 mg protein) were not supplemented (- 
recomb.), or supplemented (+ recomb.) with a crude lysate from Keapl-His -expressing 
BL21 (DE3) E. coli, and pre-cleared with Protein G sepharose beads for 1 h at 4 °C. 
Cleared lysates were incubated at 4 °C, overnight, with 5 pg polyclonal anti-Keapl 
antibody, and antibody conjugates were captured via incubation with Protein G 
sepharose beads for 2 h at 4 °C. Fractions of the lysates pre- (input) and post- (flow­
through) immunoprécipitation were resolved by denaturing electrophoresis, alongside 
the proteins eluted from the respective Protein G sepharose beads and appropriate 
controls. Keapl was detected by Western blot, with a monoclonal anti-Keapl antibody. 
IP; immunoprécipitation. IB; immunoblot.
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5.3.2 PCR amplification of mouse K ea p l coding sequence
In light of the unsuccessful attempts to immunoprecipitate endogenous Keapl from 
Hepa-lclc7 cells, the ectopic expression of epitope-tagged Keapl was pursued as an 
alternative method of detecting in-cell modification of Keapl by mass spectrometry. The 
mouse Keapl coding sequence (1875 bp) was amplified by PCR. Primers were designed 
to enable to amplification of the coding sequence with or without the TGA stop codon, 
to facilitate the eventual translation of a wild-type (‘STOP’) or V5-His -tagged Keapl 
protein, respectively. Both PCR products were 3’ A-tailed (Fig. 5.5) in order to enable 
ligation into the TOPO cloning site of pcDNA3.1/V5-His-TOPO (Fig. 5.6).
Fig. 5.5 - Schematic diagram showing 3’ A-tailing of the mouse K ea p l coding 
sequence (CDS) and its ligation into pcDNA3.1/V5-His-TOPO, via the T-overhangs 
of the TOPO cloning site. The nucleotides immediately flanking the TOPO cloning site 
of pcDNA3.1/V5-His-TOPO are represented as solid lines.
Fig. 5.6 - pcDNA3.1/V5-His-TOPO vector map. The A-tailed Keapl coding sequence 
was ligated into the T-overhangs of pcDNA3. l/V5-His-TOPO. Image taken from the 
Invitrogen on-line catalogue (http://www.invitrogen.eom/content/sfs/vectors/pcdna3.l 
v5histopo_map .pdf).
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5.3.3 Ligation of mouse Keapl coding sequence into pcDNA3.1/V5-His-TOPO
The A-tailed Keapl PCR products were ligated into pcDNA3.l/V5-His-TOPO, and 
XL10-Gold ultracompetent E. coli were transformed with one of the two ligated 
constructs. Successful transformation was confirmed by diagnostic restriction digests of 
construct DNA purified from selected bacterial colonies (Fig. 5.7). Specifically, 
fragments of the expected size(s) were visualised following digestion with BamHl and 
Eco47\\\ (BamHl cuts at -34 of Keapl, Eco47\\\ cuts at 1606 of Keapl; 1640 bp 
fragment) and Eco47lll and EcoRV (Eco47lll cuts at 1606 of Keapl, EcoKV cuts at 
1891 of Keapl \ 285 bp fragment).
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Fig. 5.7 - Diagnostic restriction digests of pcDNA3.1/Keapl ‘STOP’ and ‘V5-His’ 
variants from putative transformed XL10-Gold E. coli. Each pcDNA3.1/Keapl 
construct was purified from three selected bacterial colonies (#1-3 and #A-C) by mini- 
prep. The constructs were digested with BamHl and Eco47lll (BamHl cuts at -34, 
Eco47lll cuts at 1606; 1640 bp fragment) and Eco47lll and EcoKV (Eco47lll cuts at 
1606, EcoRV cuts at 1891; 285 bp fragment). The restriction fragments, the undigested 
constructs, and a 100 bp DNA ladder were resolved by electrophoresis on a 1 % (w/v) 
agarose gel, containing 0.5 pg/mL ethidium bromide. DNA fragments were visualised 
under UV illumination. Constructs yielding restriction fragments of expected size, i.e. 
those from colonies #2, #3, #B and #C, are labeled *.
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These diagnostic restriction digests demonstrate that the Keapl coding sequences ligated 
into pcDNA3. l/V5-His-TOPO successfully, and in the correct orientation. In order to 
confirm that the PCR amplification process had not introduced mutations into the Keapl 
coding sequence, the pcDNA3.1/Keapl constructs were verified by two-strand 
sequencing. This process confirmed that no non-synonymous mutations, i.e. those that 
result in the translation of a different amino acid, were present in either 
pcDNA3.1 /Keap 1 construct.
5.3.4 Expression and purification of pcDNA3.1/Keapl
HEK293T, a human embryonic kidney cell line that is widely used as a model for the 
ectopic expression of proteins, and Hepa-lclc7, the mouse hepatoma cell line used for 
investigations into the molecular regulation of the Nrf2-ARE pathway in chapter 2, were 
transiently transfected with Keapl -STOP (i.e. wild-type protein) or -V5-His (Keapl 
protein proceeded by a 45 amino acid sequence, which contains the V5 epitope and 
polyhistidine region, but does not contain any cysteines). Both Keapl variants were 
expressed in both cell lines, however the level of expression was markedly higher in 
HEK293T cells (Fig. 5.8). In light of the relatively weak expression of Keapl -STOP 
and -V5-His in Hepa-lclc7 cells, and given that only Keapl-V5-His could be affinity- 
or immuno-purified from cell lysates, all subsequent experiments were undertaken using 
HEK293T cells transiently expressing Keap 1-V5-His only.
Theoretically, it should be possible to purify Keapl-V5-His by both Ni2+ affinity and 
anti-V5 immunoaffinity, as the protein bears both a V5 epitope and a polyhistidine tag. 
In order to compare the recovery of Keapl-V5-His achieved with each purification 
method, cell lysates prepared from Keap 1-V5-His -expressing HEK293T cells were 
incubated with Ni -charged agarose beads or anti-V5 agarose beads.
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Fig. 5.8 - Transient expression of Keapl-STOP and Keapl-V5-His in HEK293T 
and Hepa-lclc7 cells. HEK293T or Hepa-lclc7 cells were mock transfected or 
transfected for 24 h with pcDNA3.1/Keapl -STOP or -V5-His. Whole cell lysates were 
prepared and resolved by denaturing electrophoresis. Keapl and P-actin were detected 
by Western blot. Recombinant mouse Keapl-His was loaded onto the gel as a standard 
(Std).
Although Ni2+ affinity purification did yield a large amount of Keapl, as assessed by 
Western blot, a substantial number of other proteins were co-purified, as demonstrated 
by Ponceau Red stain of the pull-down fraction (Fig. 5.9). Such was the abundance of 
contaminating proteins within the sample, it was not possible to identify Keapl-V5-His 
by MALDI-TOF MS analysis. Anti-V5 immunopurification yielded a greater amount of 
Keapl, in a much purer form, than Ni2+ affinity purification (Fig. 5.9). In fact, only three 
prominent protein bands were visible on the Ponceau Red stain of the pull-down fraction 
(Fig. 5.9). The major constituents of these bands were identified, by LC-ESI-MS/MS 
analysis of Coomassie Brilliant Blue G-250 -stained, trypsin-digested polyacrylamide 
gel sections, to be mouse Keapl and the heavy (gamma) and light (kappa) chains of 
mouse IgG (Fig. 5.10); the latter were the fragments of anti-V5 IgG released from the 
anti-V5 agarose beads, along with Keapl-V5-His, during the elution process. MALDI- 
TOF MS analysis of the total protein fraction bound to the anti-V5 agarose beads, 
following incubation with Keapl-V5-His -expressing HEK293T cell lysate, identified 
mouse Keapl as the major constituent protein (Fig. 5.11 and Fig. 5.12).
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Fig. 5.9 - Purification of Keapl-V5-His from HEK293T cells. HEK293T cells were 
mock transfected or transfected for 24 h with pcDNA3.1/Keapl-V5-His. Whole cell 
lysates were prepared and incubated with Ni2+-charged agarose beads or anti-V5 agarose 
beads for 2 h at 4 °C. The crude lysates, the proteins that eluted from the respective 
agarose beads (pull-down) and the lysates that remained following the pull-downs (flow­
through) were resolved by denaturing electrophoresis, alongside protein molecular 
weight markers. Resolved proteins were transferred to nitrocellulose and total protein 
was visualised by Ponceau Red stain (A). Keapl was detected on the same membrane by 
Western blot (B).
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Kelch-like ECH-associated protein 1
(mouse)
Immunoglobulin heavy (gamma) chain
(mouse)
Immunoglobulin light (kappa) chain
(mouse)
Fig. 5.10 - Identification of prominent proteins eluted from anti-V5 agarose beads.
HEK293T cells were mock transfected or transfected for 24 h with pcDNA3.1/Keapl- 
V5-His and whole cell lysates were prepared. The lysates were incubated with Ni2+- 
charged agarose beads or anti-V5 agarose beads and all fractions were resolved by 
denaturing electrophoresis. The Ponceau Red stain of the proteins, following transfer to 
nitrocellulose, is shown. The equivalent polyacrylamide gel was stained with Coomassie 
Brilliant Blue G-250 and the bands were excised. The protein(s) present within the 
bands were digested with trypsin, and the resulting peptide mixtures were analysed by 
LC-ESI-MS/MS. The data obtained from the MS/MS spectra were used in a ProteinPilot 
database search to identify the major protein constituent(s) for each band. The protein 
identified with the highest degree of confidence for each band is shown.
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1583.8325 1862.9440
Fig. 5.11 - MALDI-TOF mass spectrum of the tryptic digest of protein(s) purified 
by anti-V5 immunoaffinity from Keapl-V5-His -expressing HEK23T cells.
HEK293T cells were transfected for 24 h with pcDNA3.1/Keapl-V5-His, whole cell 
lysates were prepared and incubated with anti-V5 agarose beads. Bead-bound protein(s) 
were reduced with 1 mM DTT, alkylated with 55 mM iodoacetamide, and digested 
overnight with 240 ng trypsin. The resulting peptide mixture was visualised on a 
Voyager DE Pro MALDI-TOF Biospectrometry Workstation, in linear positive ion 
mode.
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Accession Mass Score Description
1. gi [7710044 69508 101 kelch-like ECH-associated protein 1 [Mus musculus]
2. gi |74181739 69492 101 unnamed protein product [Mus musculus]
3. gi ¡26337871 69478 94 unnamed protein product [Mus musculus]
4. gi j 74212473 69482 93 unnamed protein product [Mus musculus]
5. gi ¡37359786 71015 88 mKIAA0132 protein [Mus imusculus]
Match to: gi|7710044 Kelch-like ECH-associated protein 1 [Mus musculus]
Sequence Coverage: 47%
1 MQPEPKLSGA PRSSQFLPLW SKCPEGAGDA VMYASTECKA EVTPSQDGNR 
51 TFSYTLEDHT KQAFGVMNEL RLSQQLCDVT LQVKYEDIPA AQFMAHKW L
101 ASSSPVFKAM FTNGLREQGM EWSIEGIHP KVMERLIEFA YTASISVGEK 
151 CVLHVMNGAV MYQIDSWRA CSDFLVQQLD PSNAIGIANF AEQIGCTELH 
201 QRAREYIYMH FGEVAKQEEF FNLSHCQLAT LISRDDLNVR CESEVFHACI 
251 DWVKYDCPQR RFYVQALLRA VRCHALTPRF LQTQLQKCEI LQADARCKDY 
301 LVQIFQELTL HKPTQAVPCR APKVGRLIYT AGGYFRQSLS YLEAYNPSNG 
351 SWLRLADLQV PRSGLAGCW GGLLYAVGGR NNSPDGNTDS SALDCYNPMT 
401 NQWSPCASMS VPRNRIGVGV IDGHIYAVGG SHGCIHHSSV ERYEPERDEW 
451 HLVAPMLTRR IGVGVAVLNR LLYAVGGFDG TNRLNSAECY YPERNEWRMI 
501 TPMNTIRSGA GVCVLHNCIY AAGGYDGQDQ LNSVERYDVE TETWTFVAPM 
551 RHHRSALGIT VHQGKIYVLG GYDGHTFLDS VECYDPDSDT WSEVTRMTSG 
601 RSGVGVAVTM EPCRKQIDQQ NCTC
Fig. 5.12 - MASCOT protein database search result for peptide mass fingerprint 
obtained from the MALDI-TOF MS analysis of protein(s) purified by anti-V5 
immunoaffinity from Keapl-V5-His -expressing HEK293T cells. The peptide mass 
fingerprint shown in Fig. 5.11 was used in a MASCOT protein database search 
(http://www.matrixscience.com), which identified mouse Keapl as the major constituent 
protein in the tryptic digest. The five proteins identified with the highest degree of 
confidence are shown (all are variant database entries for mouse Keapl). The amino acid 
sequence coverage for mouse Keapl was 47 %. The specific amino acids covered by the 
MALDI-TOF MS analysis are underlined and in bold.
5.3.5 Validation of Keapl-V5 -expressing HEK293T cells as a model for 
investigating the modification of Keapl by Nrf2-activating electrophiles in cells
As the results presented in section 5.3.4 demonstrate that the most efficient method of 
purifying Keapl-V5-His from HEK293T cells was via the V5 epitope, the construct will 
subsequently be referred to simply as Keapl-V5. HEK293T cells were transiently 
transfected with Keapl-V5 and exposed to 100 pM DNCB for 1 h. These conditions 
were shown to induce the nuclear accumulation of Nrf2 in Hepa-lclc7 in chapter 2, and 
here (Fig. 5.13a). In response to DNCB exposure, Nrf2 accumulated within the nuclei of 
both mock transfected HEK293T cells and cells expressing epitope-tagged Keapl (Fig.
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5.13b), findings that are consistent with recent studies by Liebler and colleagues (Hong 
et a l,  2005a; Hong et a l, 2005b). Furthermore, Keapl-V5 immunopurified from 
HEK293T cells was shown to be associated with endogenous Nrf2, and this association 
was enhanced following exposure of cells to DNCB, in agreement with recent 
independent observations (He et a l, 2006; Kobayashi et a l,  2006) (Fig. 5.14). The in­
cell modification of Keapl-V5 by DNCB was demonstrated by the reaction of an anti- 
DNP antibody with Keapl-V5, following its immunoprécipitation from DNCB-exposed, 
but not vehicle-exposed, cells (Fig. 5.14). Therefore, Keapl-V5 -expressing HEK293T 
cells represent a functionally valid model system for investigating the modification of 
Keapl by Nrf2-activating molecules, and the associated biological effects, in a cellular 
context.
A
Hepa-
1c1c7
B
HEK293T
Mock +V5
Fig. 5.13 - Ectopic expression of Keapl-V5 in HEK293T cells does not compromise 
the responsiveness of Nrf2 to DNCB. Hepa-lclc7 cells or HEK293T cells that were 
mock transfected or transfected with Keapl-V5 were exposed to 0.5 % (v/v) DMSO (-) 
or 100 pM DNCB (+) for 1 h. Nuclear fractions were prepared and the Nrf2 protein level 
was assessed in Hepa-lclc7 (A) or HEK293T cells (B) by Western blot analysis with an 
anti-mouse or anti-human Nrf2 antibody, respectively. Recombinant mouse (Hepa- 
lclc7) or human (HEK293T) Nrf2-His was loaded onto the appropriate gel as a standard 
(Std). Non-specific proteins that cross-react with the antibody are labeled *.
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DNCB: -  +
Keapl ►
Nrf2 ►
DNP ►
IP (V5)
Fig. 5.14 - Association of Keapl-V5 with endogenous Nrf2 and modification by 
DNCB in HEK293T cells. HEK293T cells expressing Keapl-V5 were exposed to 0.5 
% (v/v) DMSO (-) or 100 pM DNCB (+) for 1 h. Keapl-V5 was immunopurified using 
anti-V5 agarose beads. The proteins eluted from the beads were resolved by denaturing 
electrophoresis. Keapl-V5, its association with endogenous Nrf2, and its modification 
by DNCB were assessed by Western blot analysis with anti-Keapl, anti-human Nrf2 and 
anti-dinitrophenyl (DNP) antibodies, respectively.
5.3.6 Mass spectrometric analysis of Keapl-V5 modification by Nrf2-activating 
electrophiles in cells
Keapl-V5 -expressing HEK239T cells were exposed to NAPQI, DNCB (both 100 pM) 
or 15d-PGJ2 (10 pM) for 1 h, conditions that stimulated the nuclear accumulation of 
Nrf2 in Hepa-lclc7 cells in chapter 2. LC-ESI-MS/MS analysis revealed that NAPQI 
modified Cys-226 (2/2 experiments), -288 (2/2) and -434 (2/2), DNCB modified Cys- 
257 (2/2), and 15d-PGJ2 modified Cys-257 (2/2) and -273 (2/2) of Keapl-V5 in 
HEK293T cells (Fig. 5.15). Careful examination of the MS/MS spectrum indicating 
modification of Cys-273 by 15d-PGJ2 revealed that, by coincidence, the unfragmented 
peptide ion [M+2H]2+ (557.3 amu) masked both y5 (557.4 amu) and *b2 (557.28) 
fragment ions, resulting in a relatively high intensity peak at this m/z (Fig. 5.15f-g). 
Overall, although there is residue selectivity amongst this panel of Nrf2-activating 
molecules, a common theme is apparent, in that the modification of cysteines within the 
IVR domain of Keapl (Fig. 5.16) is associated with the activation of Nrf2 by 
electrophiles in cells. Despite recent suggestions that Keapl is ubiquitinated under 
certain conditions of chemical/oxidative (Hong et a l, 2005b; Zhang et a l, 2005), there 
was no evidence for the ubiquitination of Keapl-V5 in the experiments reported here.
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Fig. 5.15 - MS/MS spectrum indicating modification of Keapl-V5 (A) Cys-226 and 
(B) Cys-288 by NAPQI in HEK293T cells, y- and b-ions are labelled where present. * 
denotes ions for which a mass shift of +149.1 amu indicates modification by NAPQI. 
Immonium ions are labelled with the one-letter code for their corresponding amino acid.
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Fig. 5.15 - MS/MS spectrum indicating modification of Keapl-V5 (C) Cys-434 by 
NAPQI and (D) Cys-257 by DNCB in HEK293T cells. y- and b-ions are labelled 
where present. * denotes ions for which a mass shift of C) +149.1 amu indicates 
modification by NAPQI and D) +166.0 amu indicates modifications by DNCB. 
Immonium ions are labelled with the one-letter code for their corresponding amino acid.
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F ig . 5 .1 5  -  M S /M S  sp e c tr u m  in d ica tin g  m o d if ica t io n  o f  K e a p l-V 5  (E ) C y s-2 5 7  an d  
(F ) C y s-2 7 3  b y  1 5 d -P G J 2 in  H E K 2 9 3 T  c e lls , y- and b-ions are labelled where present. 
It should be noted that adduction of Keapl cysteines by 15d-PGJ2 may occur via either 
o f the electrophilic «,/i-unsaturated carbonyl moieties (labelled #). * denotes ions for 
which a mass shift of +316.2 amu indicates modification by 15d-PGJ2. Immonium ions 
are labelled with the one-letter code for their corresponding amino acid.
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Fig. 5.15 - Magnified view of [M+2H]2+ from MS/MS spectrum indicating 
modification of Keap-V5 (G) Cys-273 by 15d-PGJ2 in HEK293T cells. The
unfragmented peptide ion [M+2H]2+ (557.3 amu) masks both the y5 (557.4 amu) and *b2 
(557.28) fragment ions in Fig. 5.15f.
1
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C434
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15d-PGJ2 H i  1 t  t t  1 I 1 1 1  I I  I 1---------- H— I H - - H --------- H  t  t I 1 1 1 ----------h  f t  I I I  I  I
!VR domain
Fig. 5.16 - Summary of Keapl-V5 cysteine adduct patterns for NAPQI, DNCB and 
15d-PGJ2 in HEK293T cells. Modification maps for cysteine-containing Keapl-V5 
peptides were generated using a software package described previously by Beynon 
(2005). The horizontal lines represent the full-length Keapl protein (amino acids 1-624), 
the vertical lines represent the boundaries between sequential tryptic peptides. Filled 
boxes represent cysteine-containing peptides found to be modified by NAPQI (■), 
DNCB (■) or 15d-PGJ2 (D).The specific cysteines modified are noted at the top of the 
figure. The IVR domain of Keapl (amino acids 180-314) is highlighted.
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5.3.7 Mass spectrométrie analysis of putative Keapl-V5 -interacting proteins
Although the primary aim of the experiments described in this chapter was to identify 
the specific Keapl cysteine targets of Nrf2-activating electrophiles within a cellular 
context, the techniques used also enabled the characterisation of other proteins that were 
immunopurified from HEK293T cells with Keapl-V5. Due to a lack of time at the end 
of the project, it was not possible to differentiate between proteins that had an intrinsic 
affinity for the anti-V5 agarose beads and those that were immunopurified in a complex 
with Keapl-V5. Nevertheless, a subset of nuclear and cytosolic proteins was 
consistently identified in the immunopurified fractions by LC-ESI-MS/MS (Table 5.1). 
Four proteins were detected in the immunopurified fraction only when HEK293T cells 
had been exposed to an Nrf2-activating electrophile, and not vehicle control (Table 5.2). 
These proteins were identified as dipeptidyl-peptidase 3 (DPP3), eukaryotic peptide 
chain release factor subunit 1, heat shock protein 90p (HSP-90P), and peroxiredoxin 1 
(PRX1).
Protein Function
40S ribosomal protein S12 Structural constituents of the ribosome60S ribosomal protein L12
Actin, cytoplasmic 1 Structural constituent of the cytoskeleton
ATP-dependent RNA 
helicase A
Transcriptional activator; unwinds double-stranded 
DNA and RNA
ATP synthase subunit alpha, 
mitochondrial precursor
Produces ATP from ADP in the presence of a proton 
gradient across the mitochondrial membrane.
DNA-binding protein A Translational repressor
Elongation factor 1-alpha 1 Promotes GTP-dependent binding of aminoacyl-tRNA to the A-site of ribosomes during protein biosynthesis
Table 5.1 - Proteins immunopurified alongside Keapl-V5 from HEK293T cells 
exposed to vehicle or Nrf2 activators. HEK293T cells expressing Keapl-V5 were 
exposed to vehicle (0.5 % (v/v) DMSO) or Nrf2 activators (100 pM DNCB, 100 pM 
NAPQI or 10 pM 15d-PGJ2) for 1 h. Keapl-V5 was immunopurified using anti-V5 
agarose beads. Proteins eluted from the beads were analysed by LC-ESI-MS/MS. 
Proteins identified in at least two samples from cells exposed to vehicle or Nrf2 
activators are presented. Protein function descriptions are taken directly from the NCBI 
Entrez Protein database (http://www.ncbi.nlm.nih.gov/sites/entrez?db=protein).
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Heat shock 70 kDa protein 1 Molecular chaperone; stabilises proteins against 
aggregation and mediates folding of newly translated 
polypeptides
Heterogeneous nuclear 
ribonucleoprotein A/B Binds single-stranded RNA
Histone HID Enable condensation of nucleosome chains into higher 
order structures.Histone H2BHistone H4
Ig gamma-1 chain C region 
secreted form Fragments o f anti-V5 antibody, covalently attached to agarose beadsIg heavy chain V region H8
Interleukin enhancer-binding 
factor 3
May facilitate double-stranded RNA-regulated gene 
expression at the level of post-transcription
KH domain-containing, 
RNA-binding, signal 
transduction-associated 
protein 1
Adapter protein in signal transduction cascades; 
represses CBP-dependent transcriptional activation by 
binding to CBP; mediates mRNA nuclear export
Non-POU domain- 
containing octamer-binding 
protein
DNA- and RNA binding protein; involved in several 
nuclear processes
Nuclease sensitive element­
binding protein 1
Binds to splice sites in pre-mRNA and regulates splice 
site selection; binds and stabilizes cytoplasmic mRNA
Nucleolysin TIAR
RNA-binding protein; possesses nucleolytic activity 
against cytotoxic lymphocyte target cells; may be 
involved in apoptosis
Nucleophosmin
Associated with nucleolar ribonucleoprotein 
structures; binds single-stranded nucleic acids; may 
function in the assembly and/or transport of the 
ribosome
Phosphoglycerate mutase 
family member 5 precursor
Catalyzes the conversion of 3-phosphoglycerate to 2- 
phosphoglycerate in the glycolytic cycle
Probable ATP-dependent 
RNA helicase DDX17
Involved in ATP-dependent RNA unwinding; required 
in a variety of cellular processes including splicing, 
ribosome biogenesis and RNA degradation
Protein TFG
Putative component of the NF-kB pathway that 
interacts with NEMO and TANK, and activates NF-kB 
in cooperation with other proteins.
Putative Xaa-Pro 
aminopeptidase 3
Releases any N-terminal amino acid that is linked to 
proline
RNA-binding protein EWS Translational repressor
Table 5.1 contd. - Proteins immunopurifled alongside Keapl-V5 from HEK293T 
cells exposed to vehicle or Nrf2 activators.
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RNA-binding protein FUS Promotes ATP-independent annealing of 
complementary single-stranded DNAs and D-loop 
formation in superhelical double-stranded DNA
Serine/arginine repetitive 
matrix protein 2
Component of the active spliceosome; involved in pre- 
mRNA splicing
Sequestosome-1
Scaffold protein; may regulate the activation of NF-kB 
by TNF-a, nerve growth factor and IL-1; may regulate 
signaling cascades through ubiquitination
Splicing factor 3B subunit 1 Involved in RNA splicing
TATA-binding protein- 
associated factor 2N
RNA and DNA -binding protein; belongs to the RNA 
polymerase II (Pol II) transcriptional multiprotein 
complex
Tubulin alpha-1A chain Structural constituents of microtubulesTubulin beta-2A chain
Y-box-binding protein 2
Major constituent of messenger ribonucleoprotein 
particles (mRNPs); involved in regulating the stability 
and/or translation of germ cell mRNAs.
Zinc finger protein 503 Transcriptional repressor
Table 5.1 contd. - Proteins immunopurified alongside Keapl-V5 from HEK293T 
cells exposed to vehicle or Nrf2 activators.
Protein Function
Dipeptidyl-peptidase 3 Cleaves N-terminal Arg-Arg-p-naphthylamide from a peptide comprising four or more residues
Eukaryotic peptide chain 
release
factor subunit 1
Directs the termination of nascent peptide synthesis in 
response to the stop codons UAA, UAG and UGA.
Heat shock protein 90p
Molecular chaperone; stabilises proteins against 
aggregation and mediates folding of newly translated 
polypeptides
Peroxiredoxin 1 Reduces peroxides; involved in redox regulation of the cell
Table 5.2 - Proteins immunopurified alongside Keapl-V5 from HEK293T cells 
exposed to Nrf2 activators only. HEK293T cells expressing Keapl-V5 were exposed 
to vehicle (0.5 % (v/v) DMSO) or Nrf2 activators (100 pM DNCB, 100 pM NAPQI or 
10 pM 15d-PGJ2) for 1 h. Keapl-V5 was immunopurified using anti-V5 agarose beads. 
Proteins eluted from the beads were analysed by LC-ESI-MS/MS. Proteins identified in 
at least two samples from cells exposed to Nrf2 activators, but not vehicle, are presented. 
Protein function descriptions are taken directly from the NCBI Entrez Protein database 
(http://www.ncbi.nlm.nih.gov/sites/entrez?db=protein).
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5.4 DISCUSSION
The Nrf2-ARE pathway protects mammalian cells against chemical/oxidative stress, via 
the inducible expression of cytoprotective enzymes and proteins (for a review, see 
Kensler et a l, 2007). The elucidation of the precise molecular mechanisms that underlie 
the capacity of the Nrf2-ARE pathway to ‘sense’ and respond to stress is vital to our 
understanding of the biochemical pathways that regulate Nrf2-dependent cell defence. It 
has been proposed that chemical inducers activate the Nrf2-ARE pathway through the 
direct modification of critical cysteine residues within Keapl, the cytosolic repressor of 
Nrf2 (Dinkova-Kostova et a l, 2002). Although the results presented in chapter 4 and a 
number of recent studies (Dietz et a l, 2005; Dinkova-Kostova et a l, 2002; Eggler et a l, 
2005; Hong et a l, 2005a; Hong et a l, 2005b; Liu et a l, 2005; Luo et a l,  2007) have 
provided compelling evidence for the modification of recombinant Keapl protein by 
Nrf2-activating molecules in vitro, very little is known regarding the residue-selectivity 
o f Keapl modification in a cellular context. Therefore, the aim of the work presented in 
this chapter was to develop a cell-based method to enable the characterisation, by 
MS/MS, of Keapl modification within a more biologically-relevant cellular setting, in 
order to explore the hypothesis that modification of Keapl is associated with activation 
o f Nrf2 in cells.
Initial attempts to characterise Keapl modification in cells focused on the 
immunoprécipitation of the endogenous protein from Hepa-lclc7 cells. As a general 
strategy to look at post-translational modification of proteins, immunoprécipitation 
coupled to mass spectrometry is still in its infancy (for some examples, see Abraham et 
a l,  2000; Walgren et a l, 2003; Yang et a l, 2006). Unfortunately, it was not possible to 
immunoprecipitate enough Keapl for MS/MS analysis, despite employing two different 
anti-Keapl antibodies under non-denaturing and denaturing conditions. Further 
optimisation may enhance the yield of this procedure, but it may be that the low cellular 
abundance of Keapl, as has recently been reported by McMahon et a l (2006), is below 
the present detection limits of MS/MS analysis, particularly when considering that the 
non-specific binding of other proteins may mask the Keapl signal.
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In light of the unsuccessful attempts at immunoprécipitation of endogenous Keapl, a 
cell-based model was developed, in which Keapl-V5 was ectopically expressed in 
HEK293T cells. Efforts to purify Keapl-V5 from cells using a secondary affinity tag, 
the polyhistidine epitope that has a high affinity for Ni2+, were not successful, due to the 
large number of contaminating proteins that co-precipitated with Keapl-V5. However, 
this can be rationalised in light of the observation that proteins with as little as two 
adjacent histidines show affinity for the Ni2+ nitrilotriacetic acid adsorbent that is 
typically used for purification of polyhistidine-tagged proteins (Hochuli et a l, 1988). A 
BLAST protein database search reveals at least 91 human proteins that contain four or 
five adjacent histidines. A much higher number of matches would be anticipated for 
proteins with two or three adjacent histidines. Conversely, no human proteins contain 
the complete 14 amino acid V5 epitope (GKPIPNPLLGLDST), which probably 
accounts for the relatively low complexity of the anti-V5 agarose bead eluate in section 
5.3.4. Therefore, use of the polyhistidine tag alone is not sufficient for the highly 
stringent purification of Keapl-V5 from cells.
The functional validity of Keapl-V5 -expressing HEK293T cells as a model for 
studying the biochemical regulation of the Nrf2-ARE pathway was confirmed by the 
following observations; a) Nrf2 nuclear accumulation was detected following exposure 
of mock-transfected and Keapl-V5 -expressing cells to DNCB, b) Keapl-V5 interacted 
with endogenous Nrf2, and this interaction was enhanced following exposure of cells to 
DNCB, and c) Keapl-V5 was modified by DNCB in cells, as shown by its 
immunoreactivity towards an anti-DNP antibody. It is plausible that the over-expression 
of Keapl-V5 may alter the dose-response relationship for Nrf2 activation by chemical 
inducers, through the increased repression of the transcription factor under basal 
conditions. However, at least at the single concentration of DNCB used to validate this 
model system in section 5.3.5, this did not appear to be the case, a finding that is 
consistent with previous studies whereby epitope-tagged Keapl has been over-expressed 
in cells (Dhakshinamoorthy et a l, 2001; Hong et al., 2005a; Hong et a l, 2005b; Zhang 
et a l, 2004). It could be suggested that ectopically-expressed Keapl-V5 may simply be 
compartmentalised within the cell at some distance from the native site(s) of interaction
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with Nrf2. However, this cannot be the case entirely, as endogenous Nrf2 has clearly 
been shown to associate with Keapl-V5 in section 5.3.5. Thus, although it would appear 
that over-expression of Keapl-V5 does not compromise the functionality of the Nrf2- 
ARE pathway, in terms of its ability to respond to chemical inducers, further work is 
required to fully characterise the nature of the interaction between Keapl-V5 and 
endogenous Nrf2 under basal conditions and in the presence of chemical/oxidative 
stress. For example, it would be of interest to examine the effect of Keapl-V5 
expression, perhaps with or without co-expression of Nr£2, on the activity of an ARE- 
driven luciferase reporter transgene, such as that described in section 2.2.8.
Using the functional HEK293T cell model in which modification of Keapl could be 
detected concomitantly with activation of Nrf2, residue-selective adduction of Keap 1 by 
NAPQI, DNCB and 15d-PGJ2 was observed. NAPQI modified Cys-226, -288 and -434, 
DNCB modified Cys-257, and 15d-PGJ2 modified Cys-257 and -273 of Keapl-V5. Of 
these residues, Cys-257, -273 and -288 of mouse Keapl have previously been shown to 
be highly reactive towards dex-mes in vitro (Dinkova-Kostova et al., 2002). In addition, 
it has been demonstrated that site-directed mutagenesis of Cys-273 and/or -288 of 
human and mouse Keap 1 causes an increase in the basal activity of Nrf2 (Kobayashi et 
al., 2006; Levonen et al., 2004; Wakabayashi et al., 2004; Zhang et al., 2003). On the 
other hand, the single mutation of Cys-257 of human and mouse Keapl (Levonen et al., 
2004; Zhang et al., 2003) or the compound mutation of Cys-226 along with Cys-241 and 
-249 of mouse Keapl (Wakabayashi et al., 2004) have no apparent effect on the basal 
and/or inducible activity of Nr£2.
There are no reports on the functional effect of mutating Cys-434, the one residue 
outside of the IVR domain that was found to be adducted (by NAPQI) in this study. 
However, it is notable that this residue lies at the end of strand p2 blade III of the 0- 
propeller structure that is formed by the DGR domain of Keapl (Padmanabhan et al., 
2006). A hydrogen bond between the neighbouring Ser-431 and Asn-414 of Keapl 
stabilises the position of Arg-415, which allows it to interact with residues located 
within the ETGE and DLG motifs of the Neh2 domain of Nrf2 (Padmanabhan et al.,
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2006). It is possible, therefore, that the modification of Cys-434 may provoke a local 
conformational change that may disrupt the molecular contacts between Keapl and 
Nrf2, leading to a loss of repression of the transcription factor. Hence, further 
investigations are required to define the biological significance o f the direct modification 
of Cys-434, and the other Keapl target residues identified here. For instance, there may 
be value in examining the effect of mutating Cys-434 to a bulky amino acid such as 
tryptophan or tyrosine, as a means of assessing the likely effect on Nrf2 activity of a 
substantial chemical modification at Cys-434 of Keapl.
Although no single residue in Keapl-V5 was targeted by all three molecules in cells, the 
common theme established in chapter 4, i.e. the modification of one or more cysteines 
within the IVR domain of Keapl, was again apparent. Indeed, the only previous report 
of residue-selective Keapl adduction in cells also identified IVR residues (Cys-241, - 
257 and -273) as targets of BIA (Hong et a l, 2005b). Recent work has also shown that 
binding of biotinylated 15d-PGJ2 (Hosoya et a l, 2005) to Keapl is attenuated by 
compound mutation of cysteine residues within this IVR domain, including Cys-257 and 
-273, which have been shown to be modified by 15d-PGJ2 in cells in this study. In this 
regard, it would be interesting to investigate whether the mutation of single or multiple 
residues that are targets of the panel of electrophiles used here completely abolishes the 
modification of Keapl and prevents the activation ofNrf2.
It was notable that, although all three Nrf2-activating molecules did modify cysteine 
residues within the IVR domain of Keapl-V5 in cells and Keapl-His in vitro (chapter 
4), the overall pattern of adducts associated with each molecule was more random in the 
in vitro experiments. There are several plausible explanations for this discrepancy. 
Firstly, the redox states of the numerous cysteines in Keapl have yet to be determined, 
with the exception of the eight residues located within the DGR domain of the human 
protein; these cysteines do not appear to participate in disulphide bonds, at least in the 
absence of chemical/oxidative stress (Li et a l, 2004). Therefore, a recombinant Keapl - 
His protein in which all cysteines are free for adduction, as used in chapter 4, may not be 
representative of the physiological state of the protein in cells. It is therefore imperative
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that the redox states of the cysteine residues outside of the DGR domain of Keapl are 
determined. Secondly, the relative reactivities of Keapl cysteines in the recombinant 
protein may differ significantly from the situation in cells, due to protein folding, post- 
translational modification(s), and/or the interaction with protein partners. These factors 
may cause some potential binding sites that are free for adduction in vitro to be obscured 
on the protein in cells. Thirdly, in order to modify Keapl within a cell, an electrophile 
must bypass various intracellular antioxidants and reductants, such as GSH, as well as 
other cellular proteins. These obstacles may hinder the modification of some cysteines in 
Keapl that may not be as reactive as those which were found to be adducted in cells 
here. For these reasons, one should be cautious when attempting to extrapolate data 
obtained from in vitro analyses to a cellular or in vivo context.
Despite the discrepancies between the two methods, a degree of overlap was observed 
between some of the target residues identified in cells and those that were found to be 
the most reactive in recombinant Keapl-His in vitro. This suggests that, whilst in vitro 
systems are not fully representative of the physiological conditions within cells, 
determining the reactivity of cysteines in recombinant Keapl in vitro towards inducers 
of the Nrf2-ARE pathway is useful. The different reactivities of Keapl residues in the 
two model systems used in this thesis may be informative of various cellular factors, 
such as protein folding, that may influence the nature of the trigger for Nrf2 activation. 
Future work should focus on utilising the model cell system described here to examine 
the site-selectivity of Keapl modification by other electrophiles, in order to further 
characterise the critical target residues o f Nrf2-activating molecules within cells. 
Furthermore, this system may prove useful in defining the role of Keapl modifications 
other than alkylation in triggering Nrf2-dependent cell defence.
HEK293T cells (DuBridge et al., 1987) have been used as a model in many studies 
whereby the ectopic expression of a protein has been exploited to gain an insight into its 
biological role. A particularly noteworthy example is the recent work by Macpherson et 
al. (2007), who used mass spectrometry to demonstrate that thiol-reactive, noxious 
electrophiles activate the transient receptor potential ankyrin 1 ion channel, which is
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present in nociceptive neurons, via the covalent modification of reactive cysteine 
residues. Indeed, HEK293T were used as the cellular expression vehicle in the only 
previous examination of Keapl modification by an Nrf2-activating molecule in cells 
(Hong et al., 2005b). Although HEK293T cells are a suitable model, it would be 
desirable to examine Keapl modification in Hepa-lclc7 cells, to enable a better 
correlation with the biochemical analyses performed in chapter 2. To this end, transient 
expression of Keapl-V5 was attempted in Hepa-lclc7 cells, but, as demonstrated in 
section 5.3.4, the level of expression was considerably lower than that in HEK293T 
cells. Indeed, this is not unexpected, given that HEK293T cells, but not Hepa-lclc7 
cells, are transformed with the large T antigen of SV40 (DuBridge et al., 1987), enabling 
episomal replication of pcDNA3.1/Keapl and thus effectively increasing the expression 
of Keapl-V5. In addition, attempts were made to generate Hepa-lclc7 clones stably- 
transfected with pcDNA3.1/Keapl, but these attempts were unsuccessful. This may be 
rationalised in terms of continual over-expression of Keapl causing a relentless over­
repression of Nrf2, lowering cytoprotective barriers, and thus resulting in transfected 
cells being highly susceptible to background levels of oxidative stress. Therefore, the 
constant over-expression of Keapl may be toxic to cells. In keeping with this, there are 
no reports in the literature in which stably-transfected Keapl-expressing cell lines have 
been developed. Hence, there may be value in pursuing the generation of stably- 
transfected Hepa-lclc7 cells using an inducible expression system, such as the 
doxycycline-responsive Tet-On system (Gossen et al., 1995). The expression of 
transgenes through the Tet-On system can be tightly regulated in response to varying 
concentrations of doxycycline (Gossen et al., 1995), such that it may be possible to 
express Keapl-V5 at levels equivalent to endogenous Keapl, reducing the confounding 
effects of protein over-expression, whilst still enabling immunopurification and mass 
spectrometric analysis.
Whilst a comprehensive analysis was not possible within the timeframe of this thesis, it 
was noted that some proteins were consistently immunopurified along with Keapl-V5 
from HEK293T cells. Interestingly, both cytosolic and nuclear proteins were identified, 
despite the recent confirmation that endogenous Keapl is predominantly a cytosolic
210
Chapter 5
protein (Watai et al., 2007). O f course, the disruption of subcellular compartments 
following cell lysis may expose some proteins that would not normally be accessible to 
Keapl under physiological conditions. Therefore, future work should examine the 
cellular localisation of Keapl-V5 and ensure that appropriate subcellular fractions are 
isolated prior to its immunopurification. Noteworthy proteins that were identified as 
putative Keapl-interacting partners include the cytoskeletal protein actin, which is 
known to associate with Keapl in the cytosol (Kang et al., 2004), KH domain- 
containing, RNA-binding, signal transduction-associated protein 1, which is known to 
repress transcriptional activation through binding to the Nrf2-interacting protein CBP 
(Babic et al., 2004; Hong et al., 2002; Katoh et al., 2001; Zhu et al., 2001), and 
phosphoglycerate mutase family member 5, which has recently been shown to be a 
substrate for Keapl-mediated ubiquitination and proteasomal degradation (Lo et al., 
2006). Although the physiological significance of these and other putative interactions 
with Keapl warrant further exploration, these particular observations may be important 
in terms of validating this method for identifying Keapl-interacting proteins. However, 
perhaps surprisingly, Nrf2 was not identified alongside Keapl-V5 in any of the 
immunopurified fractions. This conflict may represent the relative low cellular 
abundance of Nrf2, which may be below the limit of detection of current MS/MS 
analysis.
Four proteins were consistently identified in the immunopurified fraction only following 
exposure of HEK293T cells to an Nrf2-activating molecule. One of these proteins, DPP3 
is a cytosolic enzyme that cleaves N-terminal Arg-Arg-P-naphthylamide and, to a lesser 
extent, other dipeptide motifs (Ellis et al., 1967). Such peptidase activity is important in 
regulating the disposition of enkephalins and angiotensins (Ellis et al., 1967; Lee et al., 
1982). Although DPP3 has not previously been shown to associate with Nrf2 or Keapl 
directly, the ectopic expression of DPP3 has recently been shown to promote Nrf2 
nuclear accumulation and induce Nrf2-dependent cell defence in IMR-32 human 
neuroblastoma cells (Liu et al., 2007), via a mechanism that is sensitive to inhibition of 
the PI3K and PKC phosphorylation pathways (Liu et al., 2007). It is notable that, similar 
to Keapl (Dinkova-Kostova et al., 2005), DPP3 is a zinc-binding protein, and its activity
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is inhibited by thiol-reactive molecules (Fukasawa et al., 1998; Lee et al., 1982). 
However, it appears unlikely that Nrf2 or Keapl are substrates of DPP3, as neither 
protein contains the N-terminal Arg-Arg-P-naphthylamide motif that is favoured by the 
enzyme. Alternatively, DPP3 may directly associate with Keapl by some other means 
under conditions of chemical/oxidative stress and disrupt the interaction with Nrf2, 
triggering an adaptive defence response. A second protein that was identified as a novel 
activator of Nrf2 in the study by Liu et al. (2007) was the scaffold protein sequestosome 
1. This ubiquitin-binding protein, which may have a regulatory role in the NF-kB 
pathway (Moscat et al., 2007) was shown here, by mass spectrometry, to immunopurify 
along with Keapl-V5 in cells exposed to either vehicle or Nrf2 inducers. Therefore, the 
biochemical mechanisms by which DPP3 and sequestosome 1 activate the Nrf2-ARE 
pathway require further examination.
Of the other proteins that were shown to immunopurify alongside Keapl-V5 from 
HEK293T cells only following exposure to Nrf2-activating molecules, eukaryotic 
peptide chain release factor subunit 1 directs the termination of protein translation via 
recognition of a stop codon and the hydrolysis of the ester bond linking the polypeptide 
chain with the peptidyl site tRNA (for a review, see Nakamura et al., 1998). Another 
identified protein, HSP-90P is a molecular chaperone that acts to maintain correct 
protein folding and regulate the activity of several signaling proteins, including steroid 
hormone receptors and protein kinases (Pearl et al., 2006; Zhao et al., 2005). PRX1, 
which catalyses the reduction of peroxides (Ishii et al., 2007; Wood et al., 2003), was 
also immunopurified alongside Keapl-V5 only from HEK293T cells exposed to Nrf2- 
activating molecules. In light of the important antioxidant role of the PRX family (Ishii 
et al., 2007; Wood et al., 2003), it is possible that the putative interaction of PRX1 with 
Keapl signifies the involvement of oxidative stress, and more specifically a change in 
the redox state of Keapl cysteines, following exposure of cells to Nrf2-activating 
molecules. Although the 1-Cys PRX6 is known to interact with GSTP1-1, a process that 
reestablishes the catalytic activity of PRX6 (Manevich et al., 2004; Noguera-Mazon et 
al., 2006; Ralat et al., 2006), there are no reports documenting an interaction between 
the 2-Cys PRX1 and another protein. Hence, the identification of PRX1 as a possible
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interaction partner of Keapl is intriguing and, along with the other proteins discussed 
here, warrants further examination. O f course, in light of the absence of suitable 
controls, particularly anti-V5 immunopurifications from HEK293T cells that do not 
express Keapl-V5, it is not possible to differentiate between those proteins which 
genuinely interact with Keapl-V5 and those which simply have an affinity for the anti- 
V5 agarose beads. Once these controls are properly established, this model system may 
prove a valuable tool in identifying novel interaction partners of Keap 1 under different 
cellular conditions.
Although the work presented in this chapter represents the most comprehensive cellular 
analysis of Keapl modification by Nrf2-activating molecules to date, there remains a 
need to further characterise the residue-selectivities of different inducers, particularly 
those with distinct electrophilic chemistries, in order to gain further insight into the 
precise chemical nature of the redox switch that controls the activation of Nrf2- 
dependent cell defence. Mass spectrometry is increasingly being used to characterise the 
modification of endogenous protein(s) in cells and tissues (Ji et al., 2007; Koen et al., 
2006; Lemercier et al., 2004; Meier et al., 2007; Meier et al., 2005; Shin et al., 2007). 
Ultimately, experimental methods and bioanalytical techniques must evolve to enable 
the sensitive analysis of endogenous Keapl modification in vivo, in order to step closer 
to fully understanding the biochemical regulation of the Nrf2-ARE pathway under 
physiological conditions.
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Chapter 6
6.1 Introduction
Adverse drug reactions, such as DILI, constitute a major public heath concern. In order 
to improve patient wellbeing, and to address the issue of drug attrition within the 
pharmaceutical industry, it is important that the design and development of safer, more 
efficacious medicines is informed by continued advances in our understanding of the 
chemical, biochemical and molecular mechanisms that underlie specific adverse drug 
reactions. The process of drug metabolism can, in some cases, contribute to the onset of 
toxicity, through the generation of chemically reactive intermediates that can promote 
oxidative stress and/or inhibit the function of critical cellular macromolecules (for a 
review, see Park, 1986). Hence, the ability of an organism to withstand the potential 
toxic effect(s) of a given molecule is often determined by the balance between 
bioactivation and detoxification. In order to maintain a favourable balance between 
bioactivation and detoxification, mammalian cells have evolved a multi-faceted, highly 
regulated cell defence system that affords protection against the deleterious effects of 
endogenous and exogenous chemical species. The functionality of this defence system is 
regulated, in part, by the activity of certain transcription factors, particularly Nrf2 (for a 
review, see Jaiswal, 2004). An appreciation of the molecular mechanisms that underlie 
the adaptive response to cellular stress is vital to gain insights into the signalling events 
that determine the progression and outcome of adverse drug reactions, such as DILI. 
Therefore, the main aims of the studies presented in this thesis were to further our 
understanding of the means by which the Nrf2-ARE cell defence pathway is regulated, 
and to elucidate its role in the protection against DILL
6.2 Activation of Nrf2 by paracetamol -  Role of Keapl modification by NAPQI
The commonly-used analgesic and antipyretic paracetamol is often associated with 
DILI. Indeed, the hepatotoxicity associated with overdose of paracetamol is the single 
biggest cause of acute liver failure in both the UK (Davem et a l, 2006) and USA 
(Larson et a l, 2005). Research within this laboratory has provided evidence to suggest
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that the liver launches an adaptive defence response to paracetamol that is mediated by 
Nrf2 (Goldring et al., 2004), findings that have recently been confirmed by a separate 
research group (Aleksunes et al., 2008). Primed with the knowledge that Nrf2-activating 
molecules are chemically reactive and capable of modifying sulphydryl groups 
(Dinkova-Kostova et al., 2001), it was hypothesised that the underyling molecular 
mechanism by which paracetamol activates the Nrf2-ARE pathway was through the 
modification of Keapl by the metabolic intermediate NAPQI. Consistent with this 
hypothesis, the results presented in chapter 2 demonstrate that NAPQI can directly 
activate the Nrf2-ARE pathway and induce an adaptive defence response in a mouse 
liver cell line. Furthermore, the results presented in chapters 4 and 5 show that NAPQI 
can directly modify cysteine residues within Keapl, in a residue-selective manner, both 
in recombinant Keapl protein in vitro and in cells. Although further work is required, 
particularly using cells that possess the metabolic competence required to bioactivate 
paracetamol to NAPQI in situ, these findings support the notion that modification of 
Keapl by NAPQI underlies the ability of paracetamol to activate the Nrf2-ARE 
pathway. Through the analysis of Keapl modifications by the Nrf2-activating molecules 
DNCB and 15d-PGJ2, and by reference to several recent in vitro investigations of Keapl 
modification by structurally-distinct electrophiles (Dinkova-Kostova et al., 2002; Eggler 
et al., 2005; Hong et al., 2005a; Hong et al., 2005b; Luo et al., 2007), it has become 
clear that, although no single cysteine residue in Keapl is preferentially modified by all 
o f the molecules tested, the adduction of residues within the IVR domain represents a 
possible unifying theme. Indeed, cell-based models have been used to confirm that 
activation of Nrf2 by NAPQI, DNCB, 15d-PGJ2 (chapter 5 of this thesis) and BIA 
(Hong et al., 2005b) is associated with the selective modification of cysteines within the 
IVR domain of Keapl. Therefore, although further work is required to characterise the 
residue-selectivity of Keapl modification by other Nrf2-activating molecules in cells, 
and ultimately in vivo, it would appear that the modification of cysteine residues within 
the IVR domain is associated with the activation of Nrf2, and is therefore a possible 
triggering mechanism for the induction of Nrf2-dependent cell defence.
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6.3 The importance of Keapl modification in the activation of Nrf2
Although it is well-established that Nrf2-activating molecules can modify Keapl, it is 
important to consider the fate of Keapl following modification, and the means by which 
modification may contribute to the activation of Nrf2-dependent cell defence. The 
formation of high molecular weight forms of Keapl has been observed following 
exposure of cells to tBHQ (Zhang et a l, 2003) and ebselen (Sakurai et al., 2006), and 
this phenomenon is prevented through mutation of Cys-151 (Sakurai et al., 2006; Zhang 
et al., 2003), implying that Cys-151 plays an important role in ‘sensing’ molecules that 
promote the formation of high molecular weight Keapl complexes. It has been 
postulated that the incorporation of multiple ubiquitin molecules accounts for the 
increase in molecular weight of Keapl in response to tBHQ and ebselen. The 
ubiquitination and degradation of Keapl, via a proteasome-independent pathway, may 
contribute to the diminished repression of Nrf2 under certain conditions of 
chemical/oxidative stress (Hong et al., 2005b; Zhang et al., 2005). Molecular deletion of 
the IVR domain attenuates the ubiquitination of Keapl following exposure to tBHQ 
(Zhang et al., 2005), and MS/MS analysis has provided evidence for the ubiquitination 
of IVR residue Lys-298 (Hong et al., 2005b), further implicating the IVR domain as an 
important regulatory region of the Keapl protein. However, it appears that not all Nrf2- 
activating molecules induce the formation of high molecular weight forms of Keapl 
(Hong et al., 2005b; Sakurai et al., 2006; Zhang et al., 2005). Indeed, from the results 
presented in chapter 5, there was no evidence for the ubiquitination of Keapl-V5 in 
HEK293T cells following exposure to NAPQI, DNCB or 15d-PGJ2. Hence, the general 
importance of Keapl ubiquitination in the response to chemical/oxidative stress is yet to 
be fully determined.
When considering the biological consequence(s) of Keapl modification, it has yet to be 
demonstrated conclusively that direct modification of Keap 1 antagonises its interaction 
with the ETGE and/or DLG motifs of Nrf2. However, support for this concept has come 
from recent observations that the reaction of Nrf2-activating molecules with 
recombinant Keapl results in a conformational change in the protein, as demonstrated
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by alterations in its circular dichroism spectrum (Gao et al., 2007) and tryptophan 
fluorescence (Dinkova-Kostova et al., 2005b). Recently, Keapl has been shown to 
contain thiol-bound zinc, which is displaced following exposure of the protein to Nrf2- 
activating molecules, and Cys-273 and -288 of Keapl are important for zinc 
coordination (Dinkova-Kostova et al., 2005a). Amongst other E3 ubiquitin ligase 
complexes, MDM2, for example, requires integrity of its protein structure for its ligase 
activity towards the cell cycle regulator p53, via the coordination of zinc with cysteine 
residues (Fang et al., 2000). Hence, it is possible that chemical/oxidative stress may 
promote modification of critical cysteine residues within Keapl, resulting in the 
displacement of zinc and rendering Keapl unable to serve as an efficient substrate 
adaptor for Nrf2 ubiquitination. It has also been suggested that Nrf2-activating 
molecules can disrupt the ubiquitination of Nrf2 by attenuating the association between 
Keapl and CUL3, possibly through induction of conformational changes in the structure 
of Keapl (Gao et al., 2007). However, single/multiple mutations of cysteine residues 
within the IVR domain of Keapl do not affect its association with CUL3 (Kobayashi et 
al., 2004), and thus further evidence is required to support this notion.
The S-guanylation of Keapl by 8 -nitroguanosine 3',5'-cyclic monophosphate, a nitrated 
derivative of cyclic GMP, has recently been demonstrated in cultured cells (Sawa et al., 
2007), implying that putative endogenous ligands may interact with Keapl to activate 
Nrf2-dependent cell defence in response to oxidative/nitrosative stress. In addition to the 
concept of direct modification of Keapl by Nrf2-activating molecules, it has also been 
suggested that the oxidation of one or more cysteines may lead to the formation of a 
disulfide-linked Keapl homodimer, via the intermediate formation of a sulphenic acid 
(Wakabayashi et al., 2004). Should the oxidation of Keapl cysteines be confirmed as a 
mechanism of Nrf2 activation, it is possible that the induction of antioxidant defences 
(TRX, TRX-R, GR, GSH etc.) by Nrf2 may provide a means of regenerating functional 
Keapl, through the reduction of oxidised residues, and may therefore represent a 
feedback loop that limits the extent of Nrf2-ARE pathway activation over time.
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6.4 Activation of Nrf2 via mechanisms other than the modification of Keapl
It is important to consider that signaling events other than the modification of Keapl 
may contribute to the activation of the Nrf2-ARE pathway. Indeed, it is possible that 
multiple activation mechanisms have evolved to enable this cytoprotective pathway to 
respond to a variety of stimuli under diverse cellular conditions. The activation of Nrf2 
has been associated with the direct phosphorylation of the transcription factor by PKC 
(Bloom et al., 2003; Huang et al., 2002; Nguyen et al., 2000), ERK-1 (Papaiahgari et 
al., 2006) and PERK (Cullinan et al., 2003). Furthermore, the chemical inhibition of 
phosphatases, which serve to remove phosphate groups from the substrates of protein 
kinases (for a review, see Hunter, 1995), stimulates activation of the Nrf2-ARE pathway 
(Nguyen et al., 2003). Therefore, it is possible that the phosphorylation of Nrf2 enables 
it to evade Keapl-mediated repression. In this regard, Nrf2 may be regulated by a 
mechanism similar to that of the transcription factor p53 (Nguyen et al., 2004). Under 
physiological conditions, p53 is directed for ubiquitin-dependent proteasomal 
degradation via its association with the E3 ligase MDM2, but is phosphorylated in 
response to DNA damage, weakening its interaction with MDM2 and enabling its 
stabilisation (Chehab et al., 1999; Unger et al., 1999). Therefore, as with many other 
cellular processes, the activity of Nrf2 may be regulated by phosphorylation.
The pharmacological inhibition of protein kinase pathways has been used extensively to 
demonstrate a role for the PKC (Liby et al., 2005; Numazawa et al., 2003), MAPK 
(Papaiahgari et al., 2004; Yeh et al., 2006; Yuan et al., 2006; Zipper et al., 2003) and 
PI3K (Kang et al., 2007; Martin et al., 2004; Nakaso et al., 2003; Reichard et al., 2006; 
Wielandt et al., 2006) pathways in the activation of Nrf2 by specific inducers. It is 
important to consider that inhibition of a protein kinase pathway will undoubtedly have 
significant effects on multiple cell signaling processes, which themselves may have an 
impact upon the integrity of the Nrf2 system. Furthermore, the specificity of some o f the 
small-molecule inhibitors that are commonly used to dissect the involvement of certain 
protein kinases in a biological process has been questioned (Bain et al., 2003; Bain et 
al., 2007; Davies et al., 2000). The p38 MAPK inhibitor SB203580 (Alam et al., 2000;
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Balogun et al., 2003; Yeh et al., 2006), the ERK MAPK inhibitor PD98059 (Yao et a l, 
2007; Zipper et al., 2003; Zipper et a l, 2000), and the PI3K inhibitor LY294002 (Kang 
et a l,  2002; Lee et a l, 2001; Li et a l, 2006) have all been used to demonstrate the role 
of protein kinase cascades in the activation of Nrf2 by certain inducers, despite recent 
concerns regarding their specificity. Therefore, there are still some questions 
surrounding the importance of phosphorylation in the activation of Nrf2. What is clear is 
that no single protein kinase cascade is involved in the activation of Nrf2 by all inducers. 
Hence, in light of the conflicting evidence regarding the relative contributions of distinct 
protein kinases to the activation of Nrf2, the importance of phosphorylation in the 
stimulation of Nrf2 may be chemical, cell or species -dependent in nature. In any case, 
further work is required to fully define the role of phosphorylation in regulating the 
activation state of Nrf2. It is possible that the modification of cysteines within Keapl 
and the phosphorylation of Nrf2 represent cooperative mechanisms of triggering Nrf2- 
dependent cell defence. Certain protein kinases are known to be activated in response to 
oxidative stress, whereas cysteine-based phosphatases are inactivated under such 
conditions (for reviews, see Nakashima et a l,  2002; Salmeen et a l, 2005). Therefore, it 
is plausible that the onset of chemical/oxidative stress may trigger the activation of the 
Nrf2-ARE pathway via the modification of Keapl, the activation of Nrf2-targeting 
protein kinases, the inhibition of phosphatases, or indeed a combination of these 
mechanisms. It will be important to determine the relative contributions of these and 
other signals in driving the Nrf2 response.
Aside from the concept of post-translational modification, a novel mechanism of Nrf2 
activation has been proposed by Karapetian and colleagues (2005), who identified the 
nuclear protein prothymosin a  as a partner for Keapl, an interaction that may displace 
Nrf2 via competition for Keapl binding. Although predominantly documented as a 
cytoplasmic protein (Watai et a l, 2007), individual studies have described the nuclear 
translocation of Keapl in response to the nuclear export inhibitor leptomycin B and 
following the molecular mutation of a nuclear export signal (NES) found within the IVR 
domain of Keapl (Karapetian et a l, 2005; Nguyen et a l, 2005; Velichkova et a l, 2005). 
However, conflicting evidence exists regarding the nuclear accumulation of Keapl
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following exposure to chemical/oxidative stress (He et al., 2007; Nguyen et al., 2005; 
Velichkova et al., 2005). Notably, no nuclear localisation signal (NLS) has been 
identified in Keapl. Therefore, with the exception of experimental conditions under 
which the NES of Keapl is repressed, it is not clear under what physiological 
circumstances Keapl may localise to the nucleus, although it has been suggested that 
sub-cellular redistribution may be possible via association with Nrf2, which does 
possess at least two NLS (Velichkova et al., 2005). Hence, the likelihood of an 
interaction between Keapl and prothymosin a  requires clarification.
It is notable that investigations into the modification of the components of the Nrf2-ARE 
pathway by inducers have focused almost exclusively on Keapl, with apparently very 
little interest in the possibility that Nrf2 itself is directly modified by inducers. It is 
known that Nrf2 contains a redox-sensitive cysteine (Cys-506) in the Nehl DNA- 
binding domain (Bloom et al., 2002). Mutation or oxidation of this residue inhibits the 
ability of Nrf2 to drive ARE-regulated gene expression (Bloom et al., 2002). Hence, 
given that Nrf2-activating molecules clearly augment the transactivation of ARE-driven 
genes, it should be assumed that these molecules do not directly modify Cys-506 of 
Nrf2, at least under more physiological conditions. Further work is required to determine 
whether the modification of Cys-506 represents a toxic effect that perturbs the 
cytoprotective activity of Nrf2 following exposure of cells to very high levels of a 
xenobiotic. The human and mouse Keapl proteins contain 27 and 25 cysteines 
respectively, representing 4.3 and 4.0 % of the 624 total amino acids. In contrast, the 
human and mouse Nrf2 proteins contain six and seven cysteine residues, respectively, 
representing 1.0 % and 1.2 % of the 605 and 597 total amino acids. Given that the 
average cysteine content across all human and mouse proteins is 2.3 % (Miseta et al., 
2000), it is apparent that the cysteine content of Keapl is almost double, whereas that of 
Nrf2 is almost half, that of most proteins. Notwithstanding the many other cellular 
proteins that are cysteine-rich, it is possible that, within the confines of the Nrf2-ARE 
pathway, Keapl and Nrf2 have evolved with marked differences in cysteine content in 
order to provide a degree of selectivity for the modification of Keapl over that of Nrf2,
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such that cells can ‘sense’ and respond to chemical/oxidative stress without the 
disruption of Nrf2-DNA binding.
6.5 Contribution of the Nrf2-ARE pathway to the physiology of the liver
The Nrf2-ARE cell defence pathway appears to have an important role in the physiology 
and pathophysiology of the liver (for a review, see Aleksunes et al., 2007). For instance, 
studies on the effects of model hepatotoxins and hepatocarcinogens in Nrf2'A animals 
have shown that the integrity of the Nrf2-ARE pathway is vital to enable organisms to 
withstand exposure to paracetamol (Chan et al., 2001; Enomoto et a l, 2001; Okawa et 
al., 2006), 2-amino-3-methylimidazo[4,5-f]quinoline (Kitamura et al., 2007) and 
pentachlorophenol (Umemura et al., 2006). Furthermore, the liver appears to launch an 
adaptive, Nrf2-driven defence response following exposure to model hepatotoxins such 
as paracetamol and carbon tetrachloride (Fukushima et al., 2006; Goldring et al., 2004; 
Randle et al., 2008). Evidence has recently emerged to suggest that activation of the 
Nrf2-ARE pathway represents an early adaptive response to combat alcohol-induced 
liver injury, following the increase in oxidative stress that is associated with the 
induction of CYP2E1 by ethanol (Gong et al., 2006). Loss of Nrf2 is also associated 
with an increase in levels of lipid peroxidation and DNA damage in the liver, probably 
due to a compromised ability to nullify oxidative stress (Li et al., 2004). Therefore, the 
Nrf2-ARE pathway appears to serve a vital protective role against toxic insult in the 
liver, as indeed it does in many other tissues within the body.
For some drugs, including isoniazid, halothane and allyl alcohol, there is a well- 
established increase in the risk of DILI with age (Banks et al., 1995; Dalu et al., 1995; 
Maddrey, 2005; Mitchell et al., 1976; Mooney et al., 1985; Rikans, 1984; Schenker et 
al., 1994; Tarazi et al., 1993). The process of aging is also associated with a decline in 
the cytoprotective activity of Nrf2 (Shih et al., 2007; Suh et al., 2004; Zaman et al., 
2007). It is possible, therefore, that a gradual reduction in the protective capacity of the 
Nrf2-ARE pathway may contribute to the link between age and susceptibility to the
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DILI caused by some drugs. The age-related decline in Nrf2 activity may also be an 
important consideration in the transplantation of organs, as low levels of Nrf2 mRNA in 
the livers of older donors have been linked to reduced organ function following 
transplantation (Zaman et al., 2007). Nrf2 may serve an important role in the process of 
tissue repair, as liver regeneration is impaired, following partial hepatectomy, in mice 
lacking Nrf2 (Beyer et al., 2008). It appears that accumulation of ROS in the injured 
Nrf2-deficient liver reduces tyrosine phosphorylation of insulin receptor substrates 1 and 
2, preventing stimulation of insulin-like growth factor 1 receptor (Beyer et al., 2008). As 
a result, PI3K-mediated phosphorylation, and thus activation, of the protein kinase AKT 
and its downstream targets is reduced (Beyer et al., 2008), therefore inhibiting cell 
proliferation and survival (Lawlor et al., 2001). Hence, it would appear that the Nrf2- 
ARE pathway has several important roles in maintaining the physiological integrity of 
the liver, and in protecting it against deleterious toxic insults, such as those which may 
cause DILI. As such, the therapeutic targeting of the Nrf2-ARE pathway, either 
prophylactically or immediately following exposure to a hepatotoxin/carcinogen, may 
prove to be a worthwhile strategy for the prevention and/or treatment of DILI. 
Consistent with this notion, the synthetic triterpenoid CDDO-imidazolide, which is a 
potent inducer of the Nrf2-ARE pathway, has recently been shown to protect against 
aflatoxin-induced hepatocarcinogenesis in rats (Yates et al., 2006). Furthermore, 
pharmacological manipulation of Nrf2 by the isothiocyanate sulforaphane, a derivative 
of glucoraphanin, which is present at high concentrations in broccoli, Brussels sprouts 
and cabbage (Zhang et al., 1992), is currently being trialed as a means of preventing 
breast cancer (Comblatt et al., 2007; Dinkova-Kostova et al., 2007; Dinkova-Kostova et 
al., 2006; Shapiro et al., 2006).
6.6 Future directions
Since Nrf2 was first characterised by Moi et al. (1994), there have been huge advances 
in our understanding of the chemical, biochemical and molecular means by which the 
Nrf2-ARE pathway is regulated. This thesis has sought to further define the importance
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of direct modification of Keapl in the activation of Nr£2. Future research should 
consider the relative importance of different post-translational modifications (direct 
adduction, oxidation, phosphorylation) in triggering Nrf2 activation, and the precise 
means by which these modifications are translated into biological effect. However, 
before further studies are undertaken in this area, it is vital that the native redox states of 
the cysteine residues in Keapl are fully defined. In this regard, there may be value in 
developing a differential chemical capping approach, similar to that used in section 3.3.4 
o f this thesis, to define those cysteines that are free for modification and those that 
participate in disulphide bonds in the correctly-folded protein. The recombinant Keapl 
protein expressed and purified under non-denaturing conditions, described in section 
3.3.5, may be suitable for such an application. It will also be important to determine 
which cysteine residues are located on the solvent-accessible surfaces of Keapl, as it is 
these residues which are likely to be the most susceptible to modification. Of course, it 
should be considered that interactions with protein partners, including Nrf2, CUL3 and 
actin, may conceal otherwise accessible cysteines in Keapl. Therefore, it may be useful 
to create an in vitro reconstruction of the Nrf2-CUL3-Keapl-actin complex, and to 
identify the cysteine residues that are labelled. It is important that these experiments are 
performed promptly, so that a more representative in vitro test system can be designed, 
and so as to gain a better understanding of the value of extrapolating recent in vitro 
findings (Dinkova-Kostova et a l, 2002; Eggler et a l, 2005; Hong et a l, 2005a; Luo et 
a l,  2007) to a cellular and in vivo context.
Although there is strong evidence to suggest that Nrf2-activating molecules selectively 
modify cysteine residues in Keapl (Dinkova-Kostova et a l, 2002; Eggler et a l, 2005; 
Hong et a l, 2005a; Hong et a l, 2005b; Luo et a l, 2007), it has yet to be demonstrated 
unequivocally that modification of Keapl triggers the activation of Nrf2 in cells or in 
vivo. The major bioanalytical constraint that hampers the investigation of protein 
modification and function in parallel is that modifications are often substoichiometric in 
nature, with only as much as 1 -2  % of the total amount of a given protein modified 
under physiological conditions. This problem can be further compounded by the fact that 
modifications are often lost through the processes of protein turnover and repair
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(Schoneich et al., 2006). This makes it particularly difficult to detect a modified protein, 
and even more difficult to identify the site of modification, from a cell/tissue lysate 
containing thousands of proteins with different levels of abundance. In a recent review 
on this subject, Liebler (2008) likened this problem to “looking for dozens of needles in 
thousand of haystacks”. It is for this reason that many investigators seeking to define the 
impact of post-translational modification(s) on the activity of a given protein have opted 
initially to conduct experiments using recombinant protein, which can be expressed at 
relatively high levels and purified to near homogeneity via an incorporated epitope tag. 
Although useful for gaining a chemical insight into the modification of a protein in 
isolation, the in vitro reaction of a large amount of protein with a high concentration of 
electrophile is not indicative of the situation in cells and in vivo. Therefore, the 
enrichment of endogenous proteins is required in order to facilitate the reliable and 
sensitive analysis of relatively low-abundance post-translational modifications. Such 
enrichment strategies can be as simple as decreasing the overall complexity of the 
sample through biochemical purification of subcellular compartments and organelles. In 
addition, chemically-adapted model electrophiles, such as biotinylated analogues of 
iodoacetamide and N-ethylmaleimide (Dennehy et al., 2006; Shin et al., 2007), have 
been developed that enable affinity enrichment of modified proteins. However, such an 
approach may not be particularly valuable for investigations of protein modification by 
xenobiotics and intracellular signalling molecules, as these would also need to be 
chemically tagged. This may prove practically difficult, and it is not clear what effect the 
presence of such a tag has on the reactivity of an electrophile.
In light of the unsuitability of some pre-analytical enrichment strategies for examining 
the modification of native proteins in cells and tissues, advances have been made in the 
field of mass spectrometry that have effectively increased the specificity and the 
sensitivity of this already powerful analytical tool. One such advance is the process of 
multiple reaction monitoring (MRM), whereby predefined target ions, such as those that 
represent modified peptides, are selected and enriched within the mass spectrometer 
during the analytical run. Because only ions of a predefined mass-to-charge ratio are 
filtered into the collision cell of the mass spectrometer, and fragmented product ions can
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be trapped and ejected towards the mass detector at a given threshold, background 
signals are lowered significantly, and thus signal-to-noise ratios are increased, allowing 
more sensitive detection of modified peptides (Unwin et a l, 2005). In this regard, the 
prior characterisation of residue-specific modifications in vitro using recombinant 
proteins may better inform cellular and in vivo analyses, by identifying diagnostic data 
patterns that help to define specific ions to be selected during the MRM process. 
Research within our group has recently demonstrated the potential of MRM as a means 
o f detecting post-translational modifications in vivo, using mouse GSTP1-1 as a model 
protein (Jenkins et a l, 2008). Although the feasibility of using MRM to detect 
modification of proteins that are much lower in abundance than GSTP1-1, such as 
Keapl, is still unclear, advances in the sampling rate, sensitivity and resolution of mass 
spectrometers are now beginning to enable the characterisation of endogenous protein 
modification in cells and tissues (Ji et a l, 2007; Koen et a l, 2006; Lemercier et a l, 
2004; Meier et a l, 2007; Meier et a l, 2005; Shin et a l, 2007).
In addition to correlating the activation of Nrf2 with the occurrence of a particular 
modification per se, it will also be important to understand how the extent of 
modification influences the biological response. It is possible that Keapl functions as a 
redox rheostat, in that the modification of a single highly reactive ‘sensor’ cysteine 
within the IVR domain is sufficient to trigger the activation of Nrf2, with additional 
modifications of other cysteine residues augmenting this response. In this regard, it is 
vital to obtain quantitative measurements of the ratio of modified versus unmodified 
residues in Keapl, and to relate this to biological outcome. This may be possible through 
the use of stable isotope labelling of Keapl cysteines by isotope-coded affinity tagging 
(ICAT), in which heavy and light -tagged model electrophiles are applied to the protein 
or cell extract under different conditions (i.e. unmodified control sample = light-tagged, 
modified sample = heavy-tagged). Both samples are mixed and the mass differences 
resolved by mass spectrometry, in order to quantify their relative abundance 
(Sethuraman et a l, 2004a; Sethuraman et a l, 2004b). If a particular cysteine residue in 
Keapl is modified, it will not be available for ICAT labelling, and the abundance of the 
modified peptide ion will decrease relative to that of the unmodified ion.
227
Chapter 6
As discussed in section 6.4, it is important to consider that signaling events other than 
the direct modification of Keapl may contribute to the activation of the Nrf2-ARE 
pathway by some inducers. Recently, much attention has focused on the importance of 
reversible oxidation of thiols (to sulphenic acid; -SOH) as a signalling mechanism 
within cells (for a review, see Biswas et a l, 2006). In fact, there is evidence to suggest 
that pro-oxidants can activate Nrf2 (Gong et a l, 2006; Lee-Hilz et a l, 2006; Purdom- 
Dickinson et a l, 2007), and oxidation of protein thiols has been proposed as a means by 
which NAPQI induces hepatocellular dysfunction (for a review, see Jaeschke et a l, 
2003). Therefore, it is possible that both direct adduction and oxidation of Keapl are 
important in the activation of Nrf2 by NAPQI. The in vitro and cell-based assays 
developed during this thesis to study direct adduction of Keapl may be suitable tools for 
investigating the role of oxidation in the activation of Nrf2. Residue-specific oxidation 
can be detected by mass spectrometric measurement of the relevant mass shifts (+16 Da 
for -SOH, +32 Da for -S 0 2H, +48 Da for -SO3H), although the detection of reversible - 
SOH formation is complicated by the lability of this modification. However, -SOH 
trapping agents are available, such as 5,5-dimethyl-1,3-cyclohexanedione, which reacts 
with -SOH to form a stable thioether (Allison, 1976) that can be detected by mass 
spectrometry (+138 Da). In addition, -SOH can be detected following reaction with 
arsenite, which does not affect disulphides, but reduces -SOH back to -SH, which can 
then be labelled for detection (Torchinsky, 1981). These and other tools may facilitate 
investigations into the role of Keapl oxidation in the activation of Nrf2.
A switch in the ubiquitination of Nrf2 to that of Keapl has been suggested as a means by 
which some molecules antagonise Keapl-mediated repression of the transcription factor 
(Hong et a l, 2005b; Zhang et a l, 2005). However, the general importance of this 
mechanism is not yet clear. Ubiquitination can be detected by way of a Gly-Gly 
dipeptide tag (+114 Da) that remains attached to the modified lysine residue following 
tryptic digestion (Peng et a l, 2003). This principle of diagnostic mass shifts also enables 
the mass spectrometric detection of residue-specific phosphorylation (HPO3; +80 Da), 
and this is important because there is much ambiguity surrounding the importance of 
direct phosphorylation of Nrf2 in the activation of the transcription factor by some
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inducers. Therefore, much work remains to be done in defining the relative contributions 
o f these and other post-translational modifications in the activation of Nrf2. These 
important questions may be addressed, in order to advance our appreciation of the means 
by which the Nrf2-ARE pathway is regulated, once the relevant bioanalytical constraints 
are surmounted.
6.7 Concluding remarks
In summary, the main aims of the studies presented in this thesis were to further our 
understanding of the means by which the Nrf2-ARE pathway is regulated, and to 
elucidate its role in the protection against DILI. Specifically, investigations have been 
undertaken in an attempt to elucidate the molecular mechanisms by which paracetamol, 
which causes DILI in overdose, activates the Nrf2-ARE pathway in mouse liver. The 
results presented in this thesis have demonstrated that NAPQI, the hepatotoxic 
metabolite of paracetamol, can directly activate the Nrf2-ARE cell defence pathway in 
mouse liver cells, and selectively modifies cysteines residues within Keapl, both in the 
recombinant protein in vitro and in a cell-based model. In determining the residue- 
selectivity of Keapl modification in cells by NAPQI and other Nrf2-activating 
molecules, and taking into account the recent work of Hong et al. (2005b), a unifying 
theme has been observed, in that all of the molecules tested modify one or more 
cysteines within the IVR domain of Keapl. The identification of a universal triggering 
mechanism may better facilitate the targeting of the Nrf2-ARE pathway for the 
prevention and/or treatment of diseases, such as DILI, in the near future. Furthermore, a 
better understanding of the molecular mechanisms that govern the activity of the Nrf2- 
ARE pathway may facilitate its incorporation into pre-clinical screens for novel 
xenobiotics that are likely to cause chemical/oxidative stress and thus pose a risk of 
toxicity in patients.
In light of the important role of the Nrf2-ARE pathway in regulating inducible, and 
perhaps basal, cell defence, genetic variation in this pathway may have important
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consequences for human health. Research in this laboratory has identified several novel, 
albeit synonymous, polymorphisms in the genes encoding Nrf2 and Keapl, through the 
screening of a cohort of healthy human volunteers (Wang et al., 2006). Single nucleotide 
polymorphisms have been identified within the promoter region of the human (Arisawa 
et al., 2007; Marzec et al., 2007; Yamamoto et al., 2004) and mouse (Cho et al., 2002) 
Nrf2 genes, and these mutations are associated with an increase in susceptibility to 
certain diseases (Arisawa et al., 2007; Arisawa et al., 2008; Cho et al., 2002; Marzec et 
al., 2007). Furthermore, two non-synonymous mutations in Nrf2 have recently been 
identified in Japanese type II diabetes patients (Fukushima-Uesaka et al., 2007), and 
somatic loss-of-fimction mutations in Keapl have been identified in lung and breast 
carcinoma cell lines and in lung cancer patients (Nioi et al., 2007; Padmanabhan et al., 
2006; Singh et al., 2006). It will be important to determine whether there is variability in 
the competence of the Nrf2-ARE pathway amongst the general population, and whether 
such variability influences an individual’s susceptibility to an adverse drug reaction. The 
design of safe and effective treatment regimens is critically dependent on our 
understanding of the chemical, biochemical and molecular mechanisms that underlie 
physiological processes and the actions of specific drugs. Therefore, if future work does 
reveal a degree of inter-individual variability in the competence of the Nrf2-ARE 
pathway, the development of a diagnostic screen, perhaps based on the establishment of 
a biomarker for the functionality of the Nrf2-ARE pathway, may contribute to the 
advancement of ‘personalised medicine’, by allowing clinicians to identify susceptible 
patients before, and not after, the onset of an adverse drug reaction.
230
Appendix
APPENDIX
MS/MS spectra depicting modification of GSTP1-1 
Cys-47 by 15d-PGJ2, iodoacetamide, NAPQI and DNCB
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Appendix Fig. 1 - MS/MS spectrum indicating modification of G S T P 1 -1  Cys-47 by 
15d -P G J2 (A) or iodoacetamide (B ) in vitro, y- and b-ions are labelled where present. 
* denotes ions for which a mass shift of +316.2 amu indicates modification by 15d-PGJ2 
(A) or +57.1 amu indicates modification by iodoacetamide (B). Immonium ions are 
labelled with the one-letter code for their corresponding amino acid. Note: both the 
singly-charged 15d-PGJ2 ion (317.2 amu), characteristic of adduct cleavage during 
MS/MS peptide fragmentation, and the cysteine-15d-PGJ2 immonium ion (392.2 amu) 
are absent following incubation of GSTP1-1 with iodoacetamide alone.
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Appendix Fig. 1 - MS/MS spectrum indicating modification of GSTP1-1 Cys-47 by 
NAPQI (C) or DNCB (D) in vitro, y- and b-ions are labelled where present. * denotes 
ions for which a mass shift of +149.1 amu indicates modification by NAPQI (C) or 
+166.0 amu indicates modification by DNCB (D). Immonium ions are labelled with the 
one-letter code for their corresponding amino acid.
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